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 1 Introduction 
  
2 Hyaluronic acid 
1.1 Hyaluronic acid 
1.1.1 Structure and physicochemical properties 
Hyaluronic acid (hyaluronan) was discovered in the vitreous humor of the eye by Meyer and 
Palmer in 1934 and subsequently found in most parts of the body, including the synovial fluid 
of joints and the skin. The proposed name “hyaluronic acid” derives from hyaloid (vitreous) 
and the constituent uronic acid.1 The structure of hyaluronan was also determined by Meyer 
and coworkers, but not before the 1950s.2 Hyaluronan is a linear high molecular weight 
polysaccharide and belongs to the family of glycosaminoglycans (GAG). It consists of 
repeating disaccharides comprised of β-1,3 linked N-acetyl-D-glucosamine (GlcNAc) and 
glucuronic acid (GlcUA) which are connected by β-1,4 glycosidic bonds.3 The structure of 
hyaluronic acid is displayed in Figure 1.1. 
 
 
Figure 1.1 Chemical structure of hyaluronic acid (HA). 
 
Hyaluronan consists of 20-25,000 disaccharide units, corresponding to a polymer length of 2-
25 µm. The hyaluronic acid (HA) polymers are among the largest matrix molecules with 
molecular weights between 106 to 107 Da.4 The apparent size of hyaluronan is even greater 
because the polymer is able to incorporate a large volume of water into its solvent domain 
that is 1000 times greater than the original volume.5 In the body, hyaluronan occurs in salt 
form and of highly negative charge because the carboxylic groups of the glucuronic acid 
moieties are deprotonated under physiological conditions (pKa 3-4).6 Hence, this 
macromolecule is most frequently referred to as “hyaluronan”. 
 
X-ray diffraction and NMR experiments in dimethyl sulfoxide (DMSO) confirmed that the 
secondary structure of hyaluronan is a tape-like, two-fold helix.7-10 Recent NMR and 
computer modeling studies by Almondet al. suggest a dynamic local confirmation, which is 
on average a contracted 4-fold helix.11 In general, the backbone of the hyaluronan molecule 
is stiffened by a combination of the chemical structure of the disaccharide, internal hydrogen 
bonds, and interaction with the solvent.12 Therefore, in solution, the hyaluronan polymer 
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adopts the shape of an expanded, random coil with reversible formation and breakdown of 
interactions between the hyaluronan strains.6,13,14 
 
1.1.2 Hyaluronan metabolism and physiological functions 
Compared to other members of the glycosaminoglycan family, hyaluronan differs in several 
respects: it is the only GAG that is non-sulfated, it is synthesized at the cytoplasmic surface 
of the plasma membrane as a free linear polymer, not in the Golgi apparatus and, therefore, 
is not covalently linked to a protein core.3,4,15,16 Hyaluronan is synthesized at the inner face of 
the plasma membrane by one of the three membrane-bound hyaluronan synthases, namely 
HAS1, HAS2 or HAS3.17 The cytoplasmic product is extruded through the plasma membrane 
into the extracellular matrix (ECM) permitting unconstrained polymer growth.18,19 
 
Hyaluronic acid is a major constituent of the extracellular matrix (ECM) of most tissues. It is 
found at high concentrations in rooster comb and several soft connective tissues, including 
skin, umbilical cord, synovial fluid, and vitreous humor.3,20 Hyaluronan can form highly 
viscous solutions and, thereby, influence the properties of this matrix.21 It plays an important 
role in various physiological and pathophysiological processes, such as embryonic 
development and morphogenesis22, wound healing23-25, repair and regeneration, 
inflammation26-28 and tumorigenesis29-31. Moreover, hyaluronan interacts with cell-surface 
receptors, such as CD44 (cluster of differentiation 44) and RHAMM (receptor for hyaluronic-
acid-mediated motility) that are associated with signal transduction and may help with cell 
motility and adhesion.32,33 
 
1.2 Hyaluronidases 
1.2.1 Occurrence and classification 
Hyaluronidases are a group of enzymes that degrade hyaluronan. They were first discovered 
in an extract of mammalian testes and other tissues by Duran-Reynals at the beginning of 
the last century. This so called “spreading factor”, which facilitated the diffusion of dyes and 
antiviral vaccines, was later named hyaluronidase by Karl Meyer to denote enzymes that 
degrade hyaluronan.34,35 The hyaluronidases are widely distributed in the animal kingdom 
and can be found in mammals, invertebrate animals (crustaceans, leeches, and insects), 
4 Hyaluronidases 
animal venoms, bacteria (e.g. Streptomyces) and bacteriophages, and in pathogenic fungi 
(e.g. Candida).21,35 
 
Based on their catalytic mechanism, the hyaluronidases can be divided into three groups 
(Figure 1.2).36,37 
 
 
Figure 1.2 Classification of hyaluronidase according to Meyer.36 Adopted from Muckenschnabel.38 
 
The hyaluronidases from the first group (EC 3.2.1.35) are endo-β-N-acetyl-D-
hexosaminidases that cleave the β-1,4-glycosidic linkages in hyaluronan to yield tetra- and 
hexasaccharides as the major final products with N-acetylglucosamine at the reducing end. 
Enzymes of this class can be found in mammalian spermatozoa, lysosomes, and the venoms 
of snakes and hymenoptera.21,39,40 The second group (EC 3.2.1.36) includes the endo-β-
glucuronidases, which are present in leeches and in certain crustaceans.41,42 These enzymes 
cleave the β-1,3-glycosidic bond in hyaluronan and yield tetra- and hexasaccharides as the 
main end-products with glucuronic acid at the reducing end.35 The third group (EC 4.2.2.1) 
includes the microbial hyaluronidases, which act as endo-N-acetyl-D-hexosaminidases. 
These enzymes cleave the β-1,4-glycosidic linkage by a β-elimination resulting in 
unsaturated disaccharides as products of exhaustive degradation of hyaluronan. Based on 
their catalytic mechanism, these enzymes were also termed hyaluronate lyases. According to 
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their catalytic mechanism, the latter must be clearly distinguished from the other two 
groups.35,43-45 
 
1.2.2 Hyaluronidases from eukaryotes 
In humans, there are six hyaluronidase-like sequences, five of them encoding functionally 
active enzymes, the hyaluronidases Hyal-1, Hyal-2, Hyal-3, Hyal-4 and PH-20 (SPAM1), 
whereas the pseudogene hyalp1 is transcribed, but not translated.46,47 The sequence 
similarity between the six subtypes varies from 33 % to 42 %.37 Hyal-1 was detected in 
mammalian plasma and urine, as well as at high levels in the liver, kidney, spleen, and heart 
and is localized in the lysosomes.48 Hyal-2 is present in many tissues, except the adult brain. 
It is either localized in the lysosome or anchored to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) link.49 Hyal-1 and Hyal-2 are the major hyaluronidases and 
have a pronounced activity optimum at pH 4. 48,50,51 However, the expression of Hyal-2 is 
extremely low and difficult to purify.52 The GPI-anchored PH-20 protein (SPAM1 sperm 
adhesion molecule) is located on the surface of mammalian sperm to facilitate penetration of 
the sperm through the hyaluronan-rich matrix of the oocyte.53  
 
The major soluble hyaluronidase present in bull testes extract, the bovine testicular 
hyaluronidase (BTH), which has been therapeutically applied as a spreading factor in several 
medical fields for many years, has been shown to be a fragment of the membrane bound 
PH-20 enzyme.54,55 
 
Hyaluronidase activity has been detected in the venom of many animals, such as snakes56,57, 
stonefish58, scorpions59,60, spiders61, lizards,62 and caterpillars63, in which they predominantly 
serve as “spreading factor” but have no intrinsic toxic activity.45 By degrading the hyaluronan 
of the extracellular matrix of the prey, local tissue damage is caused, which facilitates the 
distribution of other venom constituents. The hyaluronidase from bee venom was the first to 
be characterized in detail.64 Hyaluronidases in snake venom have been recognized as 
possible targets for the treatment of snake bites. Therefore, the venoms from two different 
snake species will be characterized in chapter 7. 
 
6 Hyaluronidases 
1.2.3 Hyaluronidases from prokaryotes 
Hyaluronidases are produced by many different genera of bacteria. Proteins or enzymes 
found on the surface of gram-positive organisms significantly contribute to pathogenesis and 
might be involved in the disease process caused by these pathogens. Human infections 
caused by gram-positive bacteria are increasingly difficult to treat, predominantly due to the 
emergence of antibiotic-resistant strains not only against penicillin but also against novel 
antibiotics such as vancomycin.65,66 The HA lyases produced by gram-positive bacteria are 
considered to act as virulence factors facilitating the spread of pathogens or toxins by 
breaking down the components of the extracellular matrix of the host.67 The enhanced tissue-
permeability, caused by hyaluronidase-mediated degradation of HA, appears to play a role in 
many health problems such as gangrene, meningitis, synovitis, hyperplasia, nephritis, 
mycoplasmosis, periodontal disease, mastitis, pneumonia, septicemia, syphilis, toxic shock 
syndrome, and wound infections.68-72 
Gram-positive microorganisms capable of producing HA lyases include various species of 
Spreptococcus, Staphylococcus, Peptostreptococcus, Propionibacterium, Streptomyces, and 
Clostridium.73-77 The HA lyases produced by gram-negative bacteria are not excreted to the 
extracellular matrix and, therefore, are less likely to play a role in pathogenesis.35,67,78 
 
By reducing the spreading of the pathogen, the inhibition of the hyaluronate lyases could be 
an approach to the treatment of bacterial infections.79 In this context, the HA lyases from 
S. agalactiae strain 4755 (SagHyal4755) and S. pneumoniae (SpnHyl) are the best 
characterized among the microbial hyaluronidases.80-82 S. pneumoniae predominantly 
colonizes the upper respiratory tract of humans and is a major human pathogenic bacterium. 
It causes life-threatening diseases, examples of which are pneumonia, bacteremia, and 
meningitis, as well as less threatening diseases, such as otitis media and sinusitis. Young 
children and the elderly are particularly prone to these diseases.82 The currently licensed 
pneumococcal vaccine is only moderately effective and it is not prescribed for children 
younger than two years.65,83 The bacterium S. agalactiae (group B streptococcus, GBS) is 
part of the normal human flora but has been an important cause of infection in newborn and 
young infants.84,85 Human infections by this gram-positive bacterium are meningitis and 
septicemia, which result in considerable morbidity and mortality.86 In cultures of 
S. pneumoniae and S. agalactiae the HA lyase is found both in the culture and in cell-
associated fractions, which suggests that at least part of the enzyme is released by the 
pathogen to surrounding host tissues during infection in order to facilitate bacterial 
invasion.74,81  
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The native hyaluronidases from both S. agalactiae and S. pneumoniae have molecular 
masses of 111 kDa and 107 kDa, respectively, but undergo autocatalytic conversion to 
smaller enzymatically active 92 kDa and 82 kDa forms.81,87 X-ray crystallography revealed 
that the structures of the HA lyases from S. agalactiae and S. pneumoniae are similar 
regarding the architecture of the entire enzyme as well as the geometry of the active site, 
sharing a similarity in the range of 65 % to 80 %.37,44,65 The active site of the lyases are 
composed of two main parts, a catalytic group responsible for substrate degradation and an 
aromatic patch responsible for the selection of cleavage sites on the substrate chains.44 In 
the catalytic cleft three catalytic residues, Asn429, His476, and Tyr488 (SagHyal4755 
numbering88), are located, which degrade the substrate through a proton acceptance and 
donation (PAD) mechanism (Figure 1.3).44,71,82 
 
 
Figure 1.3 Mechanism of hyaluronan degradation by hyaluronate lyase from S. agalactiae (SagHyal4755); 
schematic presentation of hyaluronan with HA1, HA2 and HA3 as disaccharide units and the position of the side 
chains Tyr488, His479 and Asn429 relative to the substrate (modified from Li and Jedrzejas).71,82 
 
The degradation process includes five different steps: (1) enzyme binding to negatively 
charged hyaluronan; (2) cleaving of β-1,4-glycosidic bond; (3) hydrogen exchange between 
enzyme and microenvironment; (4) release of disaccharide product; (5) translocation of the 
remaining HA by one disaccharide unit towards the reducing end.65,89,90 The truncated 
polymeric hyaluronan stays in the cleft after the release of the disaccharide and undergoes a 
processive mode of action until the chain is fully degraded into disaccharides.91 However, 
Kühn et al. proposed a nonprocessive mode of action for SagHyal4755, based upon the 
observation that hyaluronan degradation by SagHyal4755 yields a mixture of oligosaccharides 
and hyaluronan fragments of different sizes.92 
 
  
8 Hyaluronidases 
1.2.4 Hyaluronidase inhibitors 
In general, the role of hyaluronan and hyaluronan degrading enzymes, the hyaluronidases, is 
far from being understood. Potent and selective inhibitors for the hyaluronidases are required 
as pharmacological tools to further characterize and understand the physiological and 
pathophysiological role of hyaluronidases. Furthermore, from a therapeutic point of view, 
inhibitors might be useful in developing anti-bacterial67, anti-venom/toxin35, anti-tumor93, anti-
allergic agents,93 or even as contraceptives.94 An overview of all previously reported putative 
inhibitors of hyaluronidases was given by Girish in 2009.77 Documented hyaluronidase 
inhibitors are of different chemical nature. The presence of proteins as hyaluronidase 
inhibitors in human serum was thought to be a defense mechanism against venoms and 
pathogenic bacteria.95-97 A purified high molecular mass, thermolabile magnesium dependent 
glycoprotein from mouse serum, probably belonging to the inter-α-inhibitor family, was 
reported to be an inhibitor of bovine, testicular, snake and bee venom hyaluronidase.98 The 
inhibitory activity of diverse metal ions, among them being iron, cadmium, copper, or zinc 
salts was reported long ago.99 Based on substrate similarity, several glycosaminoglycans 
(GAGs) and polysaccharides were identified as hyaluronidase inhibitors. Heparin and 
heparan sulfate were observed to inhibit hyaluronidase, but only at concentrations much 
higher than physiological levels and in a non-competitive manner.100-102 Other described 
structurally related compounds were oxygen-sulfated GAGs and oxygen-sulfated fragments 
of hyaluronan.103 Toida et al. discovered that the O-sulfated hyaluronan fragments showed 
stronger inhibition than other O-sulfated GAGs. Furthermore, not only did the inhibition 
increase with the chain length of the hyaluronan oligomer, but these compounds also 
showed both competitive and non-competitive inhibition, in contrast to heparin.104 Chitosan 
was also characterized as an inhibitor with direct correlation between molecular weight and 
inhibitory activity.105 Alginic acid, which is also structurally related to hyaluronan, consists of 
L-glucuronic and D-mannuronic acid and shows molecular weight dependent inhibition of 
hyaluronidase.106 The synthetic condensation polymer of mandelic acid is reported to inhibit 
hyaluronidase.94  
 
A lot of low molecular weight natural products, such as: alkaloids107,108, flavones and flavone-
analogs60,109-114, and terpenes115,116 have been investigated for hyaluronidase inhibition. Other 
substances reported to show weak inhibition of hyaluronidase activity are antioxidants79,117 
and polyphenols118, non-saturated fatty acids119, antibiotics120, and lanostanoids.121 Moreover, 
anti-allergic drugs (e.g. disodium cromoglycate, DSCG)111,122 and anti-inflammatory drugs 
(cf. chapter 3.1) are claimed to possess hyaluronidase inhibitory activities. The research in 
our laboratories has led to the discovery and validation of potent inhibitors of hyaluronidases. 
For example, lipophilic derivatives of L-ascorbic acid (vitamin C) were developed, which are 
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among the most potent inhibitors of the bacterial hyaluronidase SagHyal4755 known 
today.123-126 A variety of heterocycles, such as benzimidazoles, benzoxazoles, indoles, 
phenylindoles and gluconolactones have been identified as potent hyaluronidase 
inhibitors.127-136 The aforementioned compounds are not drug-like mainly due to very high 
plasma protein binding, high molecular weights (> 500 g/mol), low bioavailability, or 
bioincompatibility (e.g. heparin). Because of the important role of hyaluronan in biological 
systems, potent inhibitors of hyaluronidases are needed to further investigate the role of 
hyaluronan and hyaluronidases in physiological and pathophysiological processes. 
 
1.3 Methods for the determination of hyaluronidase 
activity 
Since the discovery of the hyaluronidases by Duran-Reynals in 1928137, various methods for 
the determination of the enzymatic activity have been described. In 1994 Hynes and 
Ferretti138 summarized previously described test systems and divided them into groups 
based upon the assay performed, namely spectrophotometric139,140, radiochemical141, 
fluorogenic142, enzymoimmunological143, plate (solid media)144, chemical145,146, 
physicochemical145,147,148, and zymographic137,149 methods. Although many different methods 
for the determination of hyaluronidase activity can be found in the literature, only few can be 
deployed for routine analyses. Many of the early developed assays lack sensitivity or the 
workup procedures are rather laborious and time-consuming. M. Stern and R. Stern150 
discussed the advantages and limitations of the conventional methods in an article about a 
new ELISA-like assay for hyaluronidase and hyaluronidase inhibitors. A lot of assay 
techniques are based upon changes in viscosity151 and turbidity152. In 1944 the turbidimetric 
assay was described by Kass and Seastone153, based upon the observation of Meyer and 
Palmer154 that hyaluronan forms insoluble complexes with acidified blood serum. It was 
further developed by Dorfman and Ott152, as well as Di Ferrante.148 In this thesis, a 
colorimetric assay, which was developed by Reissig et al.146, and the turbidimetric assay are 
routinely exploited to determine the inhibitory effect of the synthesized compounds. Inhibitory 
activity was determined for the bacterial hyaluronate lyases from S. agalactiae strain 4755 
(SagHyal4755), S. pneumoniae (SpnHyl), and the bovine testicular enzyme BTH (formerly an 
approved drug; e.g. under the trade name Neopermease®). Both assay systems are briefly 
explained in the following sections.  
 
10 Methods for the determination of hyaluronidase activity 
1.3.1 Morgan-Elson assay 
The Morgan-Elson assay is a colorimetric assay and has been classified as a chemical 
assay by Hynes and Ferretti.138 The reducing ends of N-acetylhexosamine moieties form a 
red colored product after reaction with p-(dimethylamino)benzaldehyde (Ehrlich’s reagent; 
DMAB), as described by Reissig146 and Gacessa.155 This so called Morgan-Elson reaction is 
often used to determine the activity of hyaluronidases that liberate hyaluronan fragments with 
N-acetyl-D-glucosamine at the reducing end. The photometrical detection of the red-colored 
product at a wavelength of 586 nm enables the determination of the enzymatic activity. The 
classes of hyaluronidases that can be assayed by the Morgan-Elson reaction are the 
hyaluronate-4-glycanohydrolases (EC 3.2.35) and hyaluronate lyases (EC 4.2.2.1), as 
described in section 1.2. 
 
The reaction, which was investigated and described in detail by Muckenschnabel et al.,140 is 
shown in Figure 1.4. After incubation of the hyaluronidase at 37 °C the cleaved hyaluronan is 
heated to 100 °C under basic conditions (pH 9). The furanose form of N-acetyl-D-
glucosamine residues is converted to the chromogens I (α-configuration) and II 
(β-configuration) after elimination of ROH (cf. Figure 1.4).156,157 Subsequent treatment with 
concentrated hydrochloric acid (HCl) and glacial acetic acid results in elimination of water 
yielding chromogen III. The final red colored product, mesomeric forms of N3-protonated 
3-acetylimino-2-(4-dimethylaminophenyl)-methylidene-5-(1,2-dihydroxyethyl)furane, is 
obtained after the chromogen III reacts with p-(dimethylamino)benzaldehyde (Ehrlich’s 
reagent).  
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Figure 1.4 Mechanism of the Morgan-Elson reaction resulting in a red colored product according to 
Muckenschnabel et al.140 
 
The Morgan-Elson assay represents a useful, widely applicable and well reproducible 
method for the determination of hyaluronidase activity in the presence of inhibitors. However, 
in some cases the Morgan-Elson assay cannot be operated. If the putative inhibitor is 
colored or undergoes side-reactions with DMAB the photometric detection produces 
false-negative results. Heterocycles, such as indoles or phenylindoles, which were identified 
to be potent inhibitors of SagHyal4755, often form colored products under assay conditions. 
Pindur and coworkers extensively investigated the reaction of 3-methyl-1H-indole with 
p-(dimethylamino)benzaldehyde. They were able to show that the reaction follows the 
mechanism proposed by van Urk, resulting in intensively colored products.136,158,159 The 
yellow-colored indole derivative indomethacin, which is a non-steroidal anti-inflammatory 
drug, is also known as an inhibitor of SagHyal4755. It undergoes the van Urk-reaction 
providing colored products, rendering the application of the Morgan-Elson assay impossible.  
 
The Morgan-Elson assay can be used to quantify hyaluronidase activity according to the 
definition of the International Union of Biochemistry by defining 1 unit (U) as the amount of 
enzyme that catalyzes the liberation of 1 µmol N-acetyl-D-glucosamine at the reducing ends 
of sugars per minute under specified conditions.160 
12 Influence of the pH value on enzymatic activity 
1.3.2 Turbidimetric assay 
According to the classification by Hynes and Ferretti138, the turbidimetric assay represents a 
physicochemical assay. This method, as described by Di Ferrante148, is based upon the 
formation of insoluble complexes between non-degraded, high-molecular hyaluronan 
(mw > 8 kDa) and cetrimonium bromide (cetyltrimethylammonium bromide, CTAB). In 
contrast, a solution of oligosaccharides and smaller hyaluronan fragments (mw < 6-8 kDa) 
remains clear under the same conditions. Since the formed turbidity is proportional to the 
amount of high molecular weight hyaluronan fragments, the enzymatic activity can be 
quantified by photometric detection at 580 nm and 600 nm by means of reference samples 
(Figure 1.5). 
 
 
Figure 1.5 Principle of the turbidimetric assay based on the method of Di Ferrante148. Figure adopted from 
Braun.131 
 
This assay is fast, highly reproducible, easy to perform in cuvettes or microtiter plates and 
can be considered as the standard method for the determination of hyaluronidase activity 
and enzyme inhibition of the synthesized compounds in this thesis. 
1.4 Influence of the pH value on enzymatic activity 
The activities of the different hyaluronidases are dependent on the pH value. Hoechstetter160 
and Hofinger161 studied the pH dependent activity profiles of BTH and SagHyal4755. It is not 
possible to find a pH value, where all investigated enzymes show high activity. The bacterial 
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hyaluronate lyase shows highest activity at pH 5.0. Jedrzejas87 reported a pH 6 as the 
optimum for SpnHyl. Figure 1.6 shows the pH dependent activity of SpnHyl as determined in 
the turbidimetric and Morgan-Elson assay.  
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Figure 1.6 pH dependent activity of bacterial hyaluronate lyase from Streptococcus pneumoniae (SpnHyl) as 
determined in the turbidimetric assay (red) and the Morgan-Elson assay (black). 
 
The results differ from those reported by Jedrzejas. The pH values between 4.5 and 5.0 were 
determined to be the optimum for hyaluronidase activity. To obtain comparable IC50 values 
on BTH and SpnHyl the inhibitors were investigated at pH 5.0 as these enzymes show 
considerably high activity under these conditions in the turbidimetric assay. Thus, the 
obtained IC50 values are comparable to previously gained data from our workgroup 
(cf. investigations by Binder126, Braun131, Salmen127, Spickenreither124, and Textor136). 
 
Hyaluronan and hyaluronan degrading enzymes, the hyaluronidases, are widespread in 
nature and were both described in the middle of the last century. However, the role of both is 
far from being understood and the academic research remains a challenging field.1,147 The 
hyaluronidases have been a group of less extensively studied glycosidases.21,77 Inhibitors of 
hyaluronidases are required as pharmacological tools to investigate their complex functions 
in hyaluronan metabolism. Moreover, such substances are of potential therapeutic value, 
e. g. for the treatment of bacterial infections or snake bites.79,108  
 
The research in our laboratory has led to the discovery of potent inhibitors with a preference 
for the bacterial enzymes. For example, lipophilic derivatives of L-ascorbic acid (vitamin C) 
were developed, which are among the most potent inhibitors of the bacterial hyaluronidase 
SagHyal4755 known today.123-126 Moreover, potent hyaluronidase inhibitors were identified 
among a variety of heterocycles (cf. section 0).127-136 Generally, the potency of hyaluronidase 
14 References 
inhibition correlates with the lipophilicity of the compounds, which strongly affects the drug-
like properties, due to very high plasma protein binding. Although (weak) inhibitors of the 
bacterial hyaluronidases have been discovered among natural products and synthetic 
molecules, small drug-like molecules with sufficient inhibitory potency are not available at 
present.77,162,163 To cope with this problem, the focus of this thesis was set on the design, 
synthesis and characterization of inhibitors for the bacterial hyaluronidase SagHyal4755 with 
drug-like properties. 
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Hyaluronidases can be ubiquitously found in animals and microorganisms. They play an 
important role as a spreading factor in animal venoms and are thought to act as virulence 
factors of pathogenic bacteria. Potent and selective inhibitors of hyaluronidases are required 
as pharmacological tools to study the physiological and pathophysiological role of hyaluronan 
and hyaluronidases in detail. Furthermore, such substances are of potential therapeutic 
value for the treatment of a variety of diseases, such as cancer, bacterial infections, or bites 
of venomous animals, for example snake bites. 
 
Hyaluronan has amphiphilic properties due to the axial hydrogen atoms that contribute to the 
hydrophobic patch and the negatively charged carboxylic groups of glucuronic acid, which 
form a hydrophilic face. Compounds bearing acidic functional groups and long, lipophilic alkyl 
residues have been identified among the most potent inhibitors of bacterial hyaluronidase 
from Streptococcus agalactiae (SagHyal4755) with IC50 values in the lower micromolar range 
(cf. vitamin C palmitate: IC50 = 4 µM). However, the high degree of lipophilicity, which is 
characteristic of these compounds, is unfavorable in terms of drug-like properties and with 
respect to in vivo investigations, for example due to a high degree of plasma protein binding.  
 
The aim of this thesis was the design, synthesis, and characterization of novel inhibitors for 
the bacterial hyaluronate lyase from Streptococcus agalactiae strain 4755 (SagHyal4755) with 
focus on drug-like properties of these substances. The search for inhibitors was extended on 
approved, commercially available, non-steroidal, anti-inflammatory drugs (NSAIDs), as 
several NSAIDs were purported to have some hyaluronidase inhibiting activities.  
 
Indoles, in particular N-alkylated and hydroxylated 2-phenylindoles, were previously identified 
as potent inhibitors of bacterial hyaluronidases in our laboratory (cf. 4-{[6,7-dichloro-2-(4-
hydroxyphenyl)-3-methyl-1H-indol-1-yl]methyl}benzoic acid (UR-CT619) IC50 = 9 µM). 
Therefore, the indole scaffold was further exploited for the development of novel inhibitors. In 
addition, the synthesis and the investigation of the inhibitory activity of a series of 
oxadiazol-2-yl- and 2-carboxy-substituted indoles were objectives of this thesis. 
Bioisosteric approaches represent fundamental strategies in medicinal chemistry for the 
design of new lead compounds. Based upon a computer-assisted prediction of indolizines as 
inhibitors of the bacterial hyaluronidase, another project of this thesis is focused on the 
synthesis and investigation of a small library of 2-phenylindolizines.  
 
Snake venom hyaluronidases represent a possible therapeutic target in the treatment of 
snake bites. Therefore, the final part of this thesis deals with the characterization of snake 
venom from two different snake species with regard to hyaluronidase activity. 
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3.1 Introduction 
Recently, Girish et al. (2009) published a comprehensive though uncritical review on the 
biological and therapeutic perspective of inhibitors of hyaluronidases.1 A comparison of the 
published data from various sources (percent inhibition and IC50 values) is difficult due to 
differences in the applied test systems and assay protocols (e.g. incubation conditions, 
enzymes, enzyme concentrations, and substrate concentrations). However, according to this 
survey, inhibitors of bacterial, mammalian, and snake venom hyaluronidases can be found 
among proteins, glycosaminoglycans, polysaccharides, fatty acids, lanostanoids, antibiotics, 
antinematodal, synthetic, organic, and plant derived bioactive compounds, such as alkaloids, 
antioxidants, polyphenols, flavonoids, terpenoids, and anti-inflammatory drugs 
(cf. chapter 1.2.4). In this context, in search for drug-like hyaluronidase inhibitors, 
commercially available non-steroidal anti-inflammatory drugs (NSAIDs) were selected and 
tested as potential inhibitors of SagHyal4755 and bovine testis hyaluronidase (BTH) under 
standardized conditions. The selection of the compounds was inspired by previous 
experiences with hyaluronidase inhibitors in our workgroup.2-8 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) are drugs that provide analgesic, antipyretic, 
and anti-inflammatory effects by inhibiting arachidonic acid metabolism and are used to treat 
inflammation, pain, and fever. They are among the most commonly prescribed drugs 
worldwide. Acidic NSAIDs, which carry a lipophilic and hydrophilic part in the molecule, are 
often used for the symptomatic relief of pain, fever, or rheumatic arthritis. NSAIDs are 
traditionally grouped according to their chemical structure and are classified into different 
groups, such as salicylates, acetic acid derivatives, propionic acid derivatives, anthranilic 
acid derivatives, oxicams, and coxibs.9,10 
 
The typical anti-rheumatic drug sodium salicylate was reported to inhibit hyaluronidases from 
bacterial origin and testicular extracts by reducing the spreading effect in connective tissues, 
when injected into the skin by Guerra.11,12 Several reports confirmed the observation that 
salicylate and its derivatives, e. g. gentisic acid, inhibit hyaluronidases in vivo.13-16 In 1975 the 
anti-inflammatory drug indomethacin was reported by Szarzy, et al., to be an inhibitor for the 
bacterial hyaluronidase SagHyal4755.17 Moreover, phenylbutazone and oxyphenbutazone 
were stated to be potent hyaluronidase inhibitors.18 Suleyman, et al., evaluated the inhibitory 
effect of selected COX-2 inhibitors, such as rofecoxib, celecoxib, and nimesulide, on 
hyaluronidases by determining the vascular permeability.19 
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All selected commercially available drugs were small molecules. The aim was to identify 
substances, which might serve as a basis for the development of inhibitors with drug-like 
properties in terms of enhanced water solubility and reduced plasma protein binding. 
Moreover, compounds that are considered drug-like have sufficient ADME properties. Hence, 
good absorption and permeability are more likely for compounds that fulfill Lipinski’s “rule of 
five” (0 ≤ logP ≥ 5, molecular weight ≤ 500 Da, number of H-bond donors ≤ 5, number of 
H-bond acceptors ≤ 10).20,21 The inhibitory activities of the selected compounds on the 
bacterial hyaluronidase SagHyal4755 and the bovine testis hyaluronidase (BTH) are described 
in this chapter. 
 
3.2 Materials and methods 
3.2.1 Materials and methods 
Hyaluronan (hyaluronic acid) from Streptococcus zooepidemicus was purchased from Aqua 
Biochem (Dessau, Germany). Bovine serum albumin (BSA) was obtained from Serva 
(Heidelberg, Germany). The investigated hyaluronidases were enzyme preparations from 
different sources. Stabilized lyophilized hyaluronate lyase, i.e. 200,000 units (according to 
the supplier; 0.572 mg of enzyme from S. agalactiae strain 4755 plus 2.2 mg of BSA and 
37 mg of tris/HCl per vial) was kindly provided by id-Pharma (Jena, Germany). Lyophilized 
hyaluronidase from bovine testis (Neopermease®) (200,000 units, according to the supplier; 
4 mg enzyme plus 25 mg of gelatin per vial) was a gift from Sanabo (Vienna, Austria). 
Ascorbic acid 6-palmitate (Vcpal), diclofenac, indomethacin, and p-(dimethylamino)-
benzaldehyde (DMAB) were purchased from Sigma-Aldrich (Munich, Germany). If not 
otherwise indicated, all chemicals were of analytical HPLC grade and obtained from Merck 
(Darmstadt, Germany). Water was purified by a Milli-Q system (Millipore, Eschborn, 
Germany). 
 
3.2.2 Morgan-Elson assay 
3.2.2.1 General procedures 
The following reagents and solutions were prepared immediately before usage. McIlvaine’s 
buffer was prepared from solution 1 (0.2 M Na2HPO4, 0.1 M NaCl) and solution 2 (0.1 M citric 
acid, 0.1 M NaCl) by mixing appropriate portions to adjust the required pH value (pH 5.0). 
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The alkaline borate solution was prepared from a borate carbonate solution (solution A: 
17.3 g H3BO4 and 7.8 g KOH in 100 mL water) and a potassium carbonate solution 
(solution B: 8.0 g K2CO3 in 10 mL water) by combining 10 volumes of solution A and 
1 volume of solution B. For the solution of Ehrlich’s reagent, 1 volume of concentrated 
solution (20.0 g p-(dimethylamino)benzaldehyde dissolved in 25 mL of concentrated HCl and 
75 mL of glacial acetic acid; storage conditions: 4 °C, light protection) was diluted with 
4 volumes of glacial acetic acid. Stock solutions containing 5 mg/mL hyaluronic acid in water 
and 0.2 mg/mL BSA in water were prepared and stored at 4 °C.  
 
For the incubation mixture test compounds, dissolved in 18 µL of DMSO (final DMSO 
concentration: 3.9 % (v/v)), were incubated at 37 °C in the assay mixture containing 200 µL 
of buffer, 50 µL of BSA solution (0.2 mg/mL in water), 50 µL of HA solution (5 mg/mL in 
water), 82 µL of H2O and 50 µL of enzyme solution. The enzymatic reaction was stopped 
after 60 min by addition of 110 µL of alkaline borate solution and subsequent for 4.5 min on a 
heating block (100 °C). After cooling on ice for at least 2 minutes, 1250 µL of Ehrlich’s 
reagent were added, and the mixture was incubated at 37 °C for 20 minutes. The samples 
were transferred to acryl cuvettes, and the absorbance of the colored product was measured 
photometrically at a wavelength of 586 nm using a Cary 100 UV-Vis spectrometer (Varian, 
Darmstadt, Germany). As reference for 100 % enzyme activity, the formation of the red 
colored product of a sample without inhibitor (replaced by 18 µL DMSO) was quantified. In 
the absence of both, enzyme and inhibitor, (replaced by 50 µL of BSA solution and 18 µL 
DMSO, respectively), a reference for 0 % enzyme activity was determined.  
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3.2.2.2 Calculation of enzyme inhibition and IC50 values 
The highest concentration of the test compounds was adjusted to 1 mM. Regularly, a dilution 
series, covering a concentration range from 0.5 µM to 1 mM, was used for the determination 
of IC50 values. The effect of the test compounds on the enzymatic activity was calculated 
according to Equation 3.1. 
 
  	
 % =   −   −    ∙  100 
Equation 3.1 
 
Esample: mean extinction of the incubation mixture containing inhibitor (containing enzyme) 
Eblank: mean extinction of the incubation mixture containing inhibitor (without enzyme) 
Emax: mean extinction of the incubation mixture without inhibitor (containing enzyme) 
Emin: mean extinction of the incubation mixture without inhibitor (without enzyme) 
 
3.2.3 Turbidimetric assay 
3.2.3.1 General procedures 
The following dilutions were prepared immediately before use. Measurements were 
performed in McIlvaine’s incubation buffer, unless otherwise indicated. For BTH, SagHyal4755 
and SpnHyl, the pH value was 5.0. The stopping reagent was prepared from a solution of 
2.5 % cetrimonium bromide (cetyltrimethylammonium bromide, CTAB) in 0.5 N NaOH (w/v). 
Stock solutions containing 2 mg/mL of hyaluronan in water and 0.2 mg/mL of BSA in water 
were prepared and stored at 4 °C. Table 3.1 summarizes the enzymatic activities, pH values, 
and incubation periods in the two different assay formats in cuvettes and 96-well plates, 
respectively. 
 
Table 3.1 Conditions the turbidimetric assay, depending on the format. Modified from Textor.4 
assay 
format enzyme 
enzyme 
solution 
prepared 
(mU/mL) 
enzyme solution 
added to incubation 
mixture (total volume) 
(µL) 
final enzymatic 
activity in the 
incubation mixture 
(mU) 
pH 
incubation 
time 
(min) 
cuvette BTH 9.0 30 µL (270 µL) 0.27 5.0 30 
cuvette SagHyal4755 3.3 30 µL (270 µL) 0.1 5.0 30 
96-well SpnHyl 10.0 10 µL (75 µL) 0.1 5.0 30 
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3.2.3.2 Cuvette assay 
The IC50 values for BTH (Neopermease®) and SagHyal4755 were generally determined in the 
turbidimetric assay performed in acryl cuvettes according to the following procedure.6 For the 
incubation mixture, 120 µL of incubation buffer, 30 µL of BSA solution (0.2 mg/mL in water), 
30 µL of HA (2 mg/mL in water), and 50 µL of H2O were dispensed to Eppendorf reaction 
vessels. Then, 10 µL of inhibitor solution (inhibitor dissolved in 100 % DMSO) were added. 
The final DMSO concentration in the incubation mixture was 4 %, an amount, which is well 
tolerated, as it had been previously demonstrated in our workgroup.7,8 After addition of 30 µL 
of enzyme solution, the mixture was immediately incubated at 37 °C for 30 minutes 
(cf. Table 3.1). The enzymatic reaction was stopped by addition of 700 µL of CTAB solution 
(2.5 % CTAB in 0.5 N NaOH (w/v)). Then, the mixture was incubated at room temperature for 
an additional 20 minutes to allow development of sufficiently high turbidity. Subsequently, the 
incubation mixture was transferred to acryl cuvettes. The turbidity, quantified as optical 
density (OD), was measured at a wavelength of 580 nm using a Cary 100 UV-Vis 
spectrometer (Varian, Darmstadt, Germany) or at a wavelength of 578 nm using a LP700 
spectrophotometer (Dr. Bruno Lange GmbH, Berlin, Germany). Samples without inhibitor 
(minimal signal) and without, both, inhibitor and enzyme (maximal signal), were measured as 
references. 
 
3.2.3.3 96-well microtiter plate assay 
The turbidimetric assay described by Di Ferrante22 was modified to allow a quantification in 
96-well microtiter plates as described by Hofinger.23 Incubation mixtures contained the 
following compounds: 31 µL of incubation buffer, 8 µL of BSA solution (0.2 mg/mL in water), 
13 µL of HA (2 mg/mL in water), and 13 µL of H2O. For the investigation of test compounds 
3 µL of inhibitor solution (inhibitor dissolved in 100 % DMSO) were added. Subsequently, 
10 µL of enzyme solution were added, and the samples were immediately incubated at 37 °C 
for 30 minutes (cf. Table 3.1). The enzymatic reaction was stopped by addition of 200 µL of 
alkaline CTAB solution (2.5 % CTAB in 0.5 N NaOH (w/v)). Afterwards, the plates were 
incubated at room temperature for 20 min to provide sufficient turbidity. The turbidity, 
quantified as optical density (OD), was measured at λ = 580 nm (absorbance mode) using a 
Tecan Genios Pro microtiter plate reader (Tecan Deutschland GmbH, Crailsheim, Germany) 
with an XFluor Genios Pro software (version 4.55). The plates were shaken in the reader for 
10 seconds. The OD was measured after 2 seconds of settling time by 10 flashes at the 
center of each well. Samples without inhibitor (minimal signal) and without, both, inhibitor and 
enzyme (maximal signal), were measured as references. 
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3.2.3.4 Compound solubility 
Poor solubility of the putative inhibitors may lead to false-positive results in the turbidimetric 
assay. The solubility was determined prior to the investigation of hyaluronidase inhibition, 
taking the concentration range from 0.5 µM to 1 mM into consideration. To assess the 
solubility of the test compounds, a sample containing 920 µL citrate phosphate buffer 
(pH 5.0), 120 µL BSA solution (0.2 mg/mL) and 40 µL of a solution of the respective test 
compound (compound dissolved in 100 % DMSO) was measured at a wavelength of 580 nm 
using a Cary 100 UV-Vis spectrometer (Varian, Darmstadt, Germany). A cuvette filled with 
920 µL of buffer, 120 µL of BSA solution, and 40 µL of DMSO served as reference. 
Precipitation of the compounds at the investigated concentrations (≤ 1 mM) with alkaline 
CTAB solution (2.5 % CTAB in 0.5 N NaOH (w/v)) was not observed and can be excluded. 
 
3.2.3.5 Calculation of enzyme inhibition and IC50 values 
The effect of the test compounds on the enzymatic activity was calculated according to 
Equation 3.2. 
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Equation 3.2 
 
Emax: mean extinction of the incubation mixture without inhibitor (without enzyme) 
Esample: mean extinction of the incubation mixture containing inhibitor (containing enzyme) 
Emin: mean extinction of the incubation mixture without inhibitor (containing enzyme) 
 
The highest final concentration of the test compounds in the different assay formats was 
adjusted to 1 mM. Regularly, a dilution series covering a concentration range from 0.5 µM to 
1 mM was used for the determination of IC50 values using cuvettes and 96-well assay format. 
The activities were plotted against the logarithm of the inhibitor concentration, and 
IC50 ± SEM values were calculated by curve fitting of the experimental data with Sigma Plot 
11.0 (SPSS Inc., Chicago, USA) from at least two independent experiments performed in 
duplicate. 
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3.2.3.6 Determination of turbidity in the incubation mixture the presence of 
plasma proteins 
To determine the turbidity in the incubation mixture of the turbidimetric assay, four different 
samples were prepared as follows (Table 3.2). The absorbance was measured at a 
wavelength of 600 nm.  
 
Table 3.2 Composition of incubation mixtures for the investigation of high turbidity in positive control. 
sample sample 
1a (centrifuged)a 2b (non-centrifuged) 2a (centrifuged)a 2b (non-centrifuged) 
120 µL McIlvaine’s buffer (pH 5.0) 
 50 µL H2O 
 35 µL human plasma 
 30 µL HA (2 mg/mL) 
 25 µL DMSO (instead of inhibitor solution) 
120 µL McIlvaine’s buffer (pH 5.0) 
 50 µL H2O 
 35 µL human plasma 
 30 µL H2O (instead of HA) 
 25 µL DMSO (instead of inhibitor solution) 
a
 sample 1a and 2a were centrifuged for 5 min at 10, 000 U/min, rt. 
 
3.3 Inhibitory activity of selected non-steroidal 
anti-inflammatory drugs  
3.3.1 Salicylates 
Because of the numerous reports on the inhibitory effect of salicylates, compounds derived 
from salicylic acid were selected. The structures of the analyzed compounds are shown in 
Figure 3.1. 
 
 
Figure 3.1 Structures of investigated salicylic acid derivatives (1-4). 
 
The hyaluronidase inhibitory activities and calculated logD5.0 values of compounds 1-4 are 
summarized in Table 3.3. 
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Table 3.3 Inhibitory activity on hyaluronidases and logD5.0 values of salicylic acid derivatives 1-4. 
compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
1 inactive inactive -0.7 
2 inactive inactive -0.1 
3 40 % at 1 mM inactive 0.7 
4 195 ± 35 30 % at 1 mM 0.9 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test compounds in 
the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); b calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of salicylic acid (1), 
acetylsalicylic acid (2), salsalat (3), and diflunisal (4) is depicted as concentration-response 
curve in Figure 3.2. 
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Figure 3.2 Enzymatic activity of SagHyal4755 in the presence of salicylic acid (1), acetylsalicylic acid (2), salsalat 
(3) and diflunisal (4). 
 
Except for diflunisal (4), the investigated substances were inactive or showed only weak 
inhibition of the investigated enzymes (turbidimetric assay, pH 5.0). As a result, salicylic acid 
and acetylsalicylic acid do neither inhibit the bacterial hyaluronidase from Streptococcus 
agalactiae strain 4755 nor the bovine testicular hyaluronidase (BTH), when tested in the 
turbidimetric assay. This is in contrast to the results published by Guerra, who reported 
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inhibitory activity for sodium salicylate against bacterial and testicular hyaluronidase in the 
spreading test.11 
 
3.3.2 Acetic acid derivatives 
Five derivatives of phenyl- and heteroarylacetic acid were selected to investigate inhibitory 
activity against both, SagHyal4755 and BTH. The structures of the analyzed compounds are 
shown in Figure 3.3. 
 
 
Figure 3.3 Structures of investigated phenyl- and heteroarylacetic acid derivatives. 
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The hyaluronidase inhibitory activities and calculated logD5.0 values of compounds 5-9 are 
summarized in Table 3.4. 
 
Table 3.4 Inhibitory activity on hyaluronidases and logD5.0 values of phenyl- and heteroarylacetic acid derivatives 
5-9. 
compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
d 
5 30 % at 500 µM inactive 2.5 
6 40 % at 1 mM inactive 1.8 
7 inactive inactive 2.7 
8 25 % at 1 mM inactive 1.9 
9 442 ± 50 inactive 1.7 
10 161 ± 11b > 1000b 3.7 
11 350c 540c 3.2 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test compounds in 
the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); b as determined by 
Spickenreither5; c as determined by Salmen8; d calculated with ACD-Labs (Advanced Chemistry Development 
Inc., Toronto, Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of felbinac (5), tolmetin (6), 
etodolac (7), ketorolac (8) and sulindac (9) is depicted as concentration-response curve in 
Figure 3.4. 
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Figure 3.4 Enzymatic activity of SagHyal4755 in the presence of felbinac (5), tolmetin (6), etodolac (7), ketorolac (8) 
and sulindac (9). 
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Diclofenac (10) and indomethacin (11) had been published before and were used as 
reference compounds throughout this thesis.5,8 The investigated compounds are more 
lipophilic than the selected salicylates (1-4). Sulindac (8) showed weak inhibition on 
SagHyal4755, but was inactive BTH (turbidimetric assay, pH 5.0). In conclusion, the selected 
acetic acid derivatives showed only minor or no inhibition on the investigated bacterial and 
bovine hyaluronidase.  
 
3.3.3 Propionic acid derivatives  
Seven drugs bearing a 2-arylpropionic acid motif were investigated with respect to inhibition 
of SagHyal4755 and BTH. The structures of the selected propionic acid derivatives are shown 
in Figure 3.5. 
 
 
Figure 3.5 Structures of investigated 2-arylpropionic acid derivatives (12-18). 
 
The hyaluronidase inhibitory activities and calculated logD5.0 values of compounds 12-18 are 
summarized in Table 3.5. 
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Table 3.5 Inhibitory activity on hyaluronidases and logD5.0 values of 2-arylpropionic acid derivatives 12-18. 
compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
12 80 % at 1 mM inactive 2.9 
13 30 % at 1 mM inactive 2.2 
14 335 ± 131 inactive 2.8 
15 70 % at 1 mM inactive 2.1 
16 794 ± 313 inactive 2.5 
17 396 ± 69 inactive 2.8 
18 40 % at 1 mM inactive 2.3 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test compounds in 
the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); b calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of fenoprofen (12), indoprofen (13), 
flurbiprofen (14), ketoprofen (15), naproxen (16), ibuprofen (17) and oxaprozin (18) is 
depicted as concentration-response curves in Figure 3.6. 
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Figure 3.6 Enzymatic activity of SagHyal4755 in the presence of fenoprofen (12), flurbiprofen (14), naproxen (16), 
ibuprofen (17) and oxaprozin (18). 
 
Fenoprofen (12) was reported as a hyaluronidase inhibitor before.24 All 2-arylpropionic acid 
derivatives showed only weak inhibition of SagHyal4755 and no inhibition of BTH. With logD5.0 
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values of 2.8, flurbiprofen (14, IC50 = 335 µM) and ibuprofen (17, IC50 = 396 µM) were the two 
most active compounds investigated in this series. 
 
3.3.4 N-Anthranilic acids and celecoxib 
Flufenamic acid (19) and niflumic acid (20) were selected as representatives of N-anthranilic 
acid derivatives. Moreover, celecoxib (21) was tested due to the reported hyaluronidase 
inhibition of coxibs by Suleyman, et al.19 All compounds were investigated for their inhibitory 
effect on the bacterial hyaluronidase SagHyal4755 and the bovine testis hyaluronidase. The 
structures of the compounds are displayed in Figure 3.7. 
 
 
Figure 3.7 Structures of investigated anthranilic acid derivatives (19, 20) and celecoxib (21). 
 
The hyaluronidase inhibitory activities and calculated logD5.0 values of compounds 19-21 are 
summarized in Table 3.6. 
 
Table 3.6 Inhibitory activity on hyaluronidases and logD5.0 values of N-anthranilic acid derivatives and celecoxib 
19-21. 
compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
19 151 ± 31 inactive 3.9 
20 206 ± 24 10 % at 1 mM 2.5 
21 inactive inactive 2.6 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test compounds in 
the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); b calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of flufenamic acid (19), niflumic acid 
(20), and oxaprozin (21) is depicted as concentration-response curves in Figure 3.8. 
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Figure 3.8 Enzymatic activity of SagHyal4755 in the presence of flufenamic acid (19), niflumic acid (20) and 
oxaprozin (21). 
 
The purported inhibitory effect of celecoxib by Suleyman et al. was not confirmed for the 
bacterial hyaluronidase SagHyal4755 and the bovine testis hyaluronidase. Unfortunately, 
Suleyman et al., did not state which hyaluronidase was used in their testing procedures.19 
The N-anthranilic acid derivatives showed IC50 values between 151 µM and 206 µM on 
SagHyal4755, but only very weak or no inhibition on BTH. Compared to the aforementioned 
substances, flufenamic acid (19) and niflumic acid (20) are the most lipophilic with logD5.0 
values of 3.9 and 2.5, respectively. 
 
3.3.5 Miscellaneous compounds 
To investigate additional small molecules, compounds 22-24 (Figure 3.9) were tested for 
hyaluronidase inhibitory activity.  
 
 
Figure 3.9 Structures of investigated compounds 22-24. 
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The hyaluronidase inhibitory activities and calculated logD5.0 values of compounds 22-24 are 
summarized in Table 3.7. 
 
Table 3.7 Inhibitory activity on hyaluronidases and logD5.0 values of coxibs and benzodiazepine 22-24. 
compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
22 70 % at 1 mM inactive 2.2 
23 650 inactive 2.9 
24 15 % at 100 µM inactive 5.8 
a
 mean values ± SEM (N = 2, experiments performed in duplicate), highest concentration of the test compounds in 
the assay was 1 mM; IC50 values determined at pH 5.0 in the turbidimetric assay (cuvettes); b calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of oxazepam (22) and phenylbutazone 
(23) is depicted as concentration-response curves in Figure 3.10. 
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Figure 3.10 Enzymatic activity of SagHyal4755 in the presence of oxazepam (22) and phenylbutazone (23). 
 
Phenylbutazone (23), which also belongs to the group of NSAIDs, was reported as an 
inhibitor previously.4 The other two compounds 22 and 24 show weak inhibition of 
SagHyal4755 and no inhibition of BTH. 
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3.4 Inhibitory activity of diflunisal in the presence of 
plasma proteins 
Plasma protein binding is a very important aspect in the development of new drugs because 
it affects the bioavailability of drugs. Human serum albumin (HSA) is the most abundant 
multifunctional non-glycosylated, negatively charged protein in blood plasma (over 50 % of 
total plasma protein content). It is a globular protein (Mr = 66 kDa, concentration 
0.52-0.75 mM ≈ 34-50 mg/mL), has multiple hydrophobic binding sites, and is capable of 
binding several endogenous ligands and drugs.25-27 Diflunisal (4) is reported to bind to 
plasma proteins > 98 %.10,28 
 
In the turbidimetric assay a standard bovine serum albumin (BSA) concentration of 
0.2 mg/mL is applied. Therefore, possible plasma protein binding of the tested compounds is 
considered negligible. To determine whether the inhibitory activity of diflunisal against 
SagHyal4755 is diminished by serum albumin binding, the BSA concentration was raised to 
10 mg/mL. Besides diflunisal (4), the reference compounds vitamin C palmitate (Vcpal), 
diclofenac, (10) and indomethacin (11) were tested, too. 
 
The turbidimetric assay was carried out in cuvettes f (270 µL per cuvette). The amount of 
BSA solution was 35 µL (cf. section 3.2.3). Inhibitory activity of the compounds was tested at 
one concentration. The final assay concentration of diflunisal (4), diclofenac (10), and 
indomethacin (11) was set to 1 mM, Vcpal was tested at a final concentration of 50 µM due 
to its high potency (IC50 = 4 µM5). Samples without inhibitor (minimal signal response) and 
without both inhibitor and enzyme (maximal signal response) were also measured as positive 
and negative controls under assay conditions. 
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The percent inhibition of all tested compounds in the presence of both, 0.2 mg/mL and 
10 mg/mL, BSA is summarized in Table 3.8. 
 
Table 3.8 Percentual inhibition of diflunisal, Vcpal, diclofenac and indomethacin of SagHyal4755 in the presence of 
different BSA concentrations. 
compound 
final assay 
concentration 
(mM) 
percent inhibition of SagHyal4755a 
c(BSA) = 0.2 mg/mLb c(BSA) = 10 mg/mLb 
diflunisal (4) 1 93 ± 4 88 ± 4 
Vcpal 0.05 95 ± 1 6 ± 2 
diclofenac (10) 1 93 ± 6 90 ± 4 
indomethacin (11) 1 93 ± 4 89 ± 1 
a
 percent inhibition was determined at pH 5.0 in the turbidimetric assay (cuvettes); b mean values ± SEM (N = 2, 
experiments performed in duplicates). 
 
When the BSA concentration was raised from 0.2 mg/mL to 10 mg/mL, in case of Vcpal, a 
significant drop of potency from 95 % to 6 % inhibition was observed. This can be explained 
by almost complete binding of vitamin C palmitate to bovine serum albumin. Studies by 
Spickenreither revealed that about five molecules of Vcpal can be bound per BSA molecule.5 
For the other three compounds, diflunisal (4), diclofenac (10), and indomethacin (11), the 
inhibitory activity of SagHyal4755 was not as much affected (3 %-5 %). This observation is 
contrary to reports in literature on the plasma protein binding of diflunisal (> 98 %10,28). 
Possibly, a BSA concentration of 10 mg/mL is too low for complete serum albumin. In 
addition to serum albumin, many other proteins (e.g. globulins) are present in plasma. 
Hence, the compounds 4, 10 and 11 may bind to other proteins.  
 
The inhibitory activity of diflunisal (4), Vcpal, diclofenac (10), and indomethacin (11) was also 
determined in the presence of human plasma and fetal calf serum (FCS, Biochrom AG, 
Berlin, Germany) in order to investigate inactivation due to protein binding. The turbidimetric 
assay was performed as described above (cf. section 3.2.3), the amount of plasma applied in 
the assay was 35 µL. 
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The percent inhibition of the compounds in the presence of BSA (0.2 mg/mL), fetal calf 
serum (FCS), and human plasma is summarized in Table 3.9. 
 
Table 3.9 Percentual inhibition of diflunisal, Vcpal, diclofenac and indomethacin of SagHyal4755 in the presence of 
BSA (0.2 mg/mL), FCS and human plasma. 
compound 
final 
concentration 
(mM) 
percent-inhibition of SagHyal4755a 
c(BSA) = 0.2 mg/mL fetal calf serum (FCS)b human plasma
c
 
diflunisal (4) 1 93 ± 4 81 ± 18 
could not be 
determined 
Vcpal 0.05 95 ± 1 0 
diclofenac (10) 1 93 ± 6 92 ± 6 
indomethacin (11) 1 93 ± 4 86 ± 7 
a
 Percentual inhibition was determined at pH 5.0 in the turbidimetric assay (cuvettes); mean values ± SEM (N = 2, 
experiments performed in duplicate); b protein concentration: 34.6 ± 1 mg/mL FCS (as determined in the Bradford 
assay);29 c albumin concentration in the blood serum of an average adult human is 31.8-45 mg/mL.30 
 
In case of Vcpal, the exchange of BSA (0.2 mg/mL) with fetal calf serum (FCS) in the 
turbidimetric assay led to an exceptional loss of inhibitory activity. Therefore, it can be 
concluded that Vcpal binds to plasma proteins completely. Compared to the assay conditions 
in the absence of FCS and human plasma, the inhibition of SagHyal4755 by diflunisal (4), 
diclofenac (10), and indomethacin (11) was reduced by 1-12 %. With regard to the inhibitory 
activity in the turbidimetric assay, the lowest protein binding in FCS can be observed for 
diclofenac (10) and indomethacin (11). 
 
When human plasma was added instead of BSA (0.2 mg/mL), in the turbidimetric assay, the 
inhibitory activity of the compounds could not be determined because the turbidity of the 
sample without inhibitor (minimal signal response – no turbidity) was as high as the turbidity 
of the sample without both inhibitor and enzyme (maximal signal response – high turbidity). 
To exclude the possibility, that the utilized human plasma was too old, the assay was 
repeated under the same conditions using mouse plasma and a freshly prepared human 
plasma. However, the turbidity in the negative control was again too high to determine the 
percent inhibition on SagHyal4755.  
 
To solve this problem several possibilities were taken into consideration. It is conceivable 
that the hyaluronan, which is added in the turbidimetric assay, forms an insoluble complex 
with some components in the plasma to cause the high turbidity. Several reports have been 
given about the precipitation of high molecular weight hyaluronan after the addition of 
acidified horse serum or serum from other sources.31-36 Therefore, the absorbance of 4 
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different incubation mixtures (1a/b, 2a/b; cf. Table 3.2 in Section 3.2.3.6) was measured at a 
wavelength of 600 nm. The different incubation mixtures were prepared both, with and 
without hyaluronan. Both, the centrifuged samples (1a and 2a) as well as the non-centrifuged 
samples (1b and 2b) did not show any turbidity. All absorbance values were very low 
(around 0.1). Therefore, an insoluble complex between hyaluronan and plasma components 
can be excluded. 
 
Turbidity might result from very high amounts of hyaluronan in the plasma, so that during the 
incubation period (30 min, 37 °C) complete degradation of hyaluronan by the streptococcal 
hyaluronidase SagHyal4755 does not occur. A hyaluronan Assay Kit37 (HA-ELISA, K-1200, 
Echelon Biosciences Inc., Salt Lake City, UT, USA) was used to determine the amount of 
hyaluronan in 5 different plasma and FCS samples as described by the manufacturer.38 
Hyaluronectin (HN) is an HA-binding glycoprotein found in the brain. It has been used to 
make ELISA-like assays for hyaluronan.38 The principle of this assay is that hyaluronectin 
binds to HA, which is adsorbed onto a plastic microtest plate. The binding of HN to the HA-
coated plate decreases when a solution containing HA (solution to be assayed) is added. 
The amount of bound HN is measured by ELISA using purified specific anti-HN antibodies 
conjugated with alkaline phosphatase.39,40 
The plasma from wild type mice (mouse plasma 1 and 2) and the plasma from Hyal-2 
KO-mice were obtained from Prof. Dr. B. Flamion (University of Namur, Belgium; preparation 
of plasma is not described in this thesis, for detailed information cf. Hamberger41). The 
plasma samples were used in the HA assay without further dilution. The results are 
summarized in Table 3.10. 
 
Table 3.10 Amount of hyaluronan in 5 different plasma and FCS samples as determined in the HA assay. 
plasma 
amount of hyaluronan 
(ng/mL)a 
mouse plasma 1 2590 
mouse plasma 2 241 
Hyal-2 KO-mouse plasma 7877 
human plasmab 456 
fetal calf serum (FCS) 8028 
a
 determined in the hyaluronan enzyme-linked assay-kit (N = 1, performed in triplicate); b from female test person. 
 
The level of hyaluronan in mouse plasma 1, the KO-mouse plasma, and the fetal calf serum 
was very high between 2, 590-8, 028 ng/mL, as expected. The amount of hyaluronan in the 
second mouse plasma (2) was about ten-fold lower compared to mouse plasma 1, which is 
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normal, because hyaluronan levels can vary depending on the species and age.42 Also the 
plasma of the female test person, , showed the expected concentration values of hyaluronan 
for human plasma of adults.43 The amount of hyaluronan in fetal serum was much higher 
compared to the adult serum. However, in case of FCS the percent inhibition of SagHyal4755 
could be determined. In case of the human plasma it was not possible due to high turbidity in 
the reference sample that should not show any turbidity at all. These results proved that the 
high turbidity in the minimal response signal sample is not caused by high levels of 
hyaluronan or an insoluble complex between hyaluronan and components of the plasma.  
 
Possibly, the turbidimetric assay is not suited for serum-shift assays to estimate plasma 
protein binding of the tested compounds and its effect on the inhibitory activity on 
SagHyal4755. Therefore, the assay system was changed to the colorimetric Morgan-Elson 
assay. The incubation mixtures were prepared as described in Section 3.2.2. The final assay 
concentration of diflunisal (4) and diclofenac (10) was set to 1 mM, Vcpal was tested in a 
final concentration of 50 µM. Samples without inhibitor (maximal signal response, maximal 
coloration) and without both inhibitor and enzyme (minimal signal response, minimal 
coloration) were, also, measured as positive and negative controls under assay conditions. 
The yellow colored compound indomethacin (11) was not tested in the Morgan-Elson assay 
because it undergoes a side reaction, which provides a colored product, leading to 
false-negative results.4 The percent inhibition of the tested compounds in the presence of 
BSA (0.2 mg/mL), fetal calf serum (FCS), and human plasma is summarized in Table 3.11. 
 
Table 3.11 Percentual inhibition of diflunisal, Vcpal and diclofenac of SagHyal4755 in the presence of BSA 
(0.2 mg/mL), FCS and human plasma. 
compound 
final 
concentration 
(mM) 
percent inhibition of SagHyal4755a 
c(BSA) = 0.2 mg/mL fetal calf serum (FCS)b human plasma
c 
diflunisal (4) 1 90 ± 6 84 ± 1 
could not be 
determined Vcpal 0.05 99 ± 1 0 
diclofenac (10) 1 88 ± 6 87 ± 2 
a
 Percent inhibition was determined at pH 5.0 in the Morgan-Elson assay (cuvettes); mean values ± SEM (N = 2, 
experiments performed in duplicates); b protein concentration of FCS: 34.6 ± 1 mg/mL (as determined in the 
Bradford assay);29 c the albumin concentration in the blood serum of an average adult human is 31.8-45 mg/mL.30 
 
As expected, all tested compounds show very good inhibition in the final assay concentration 
(cf. Table 3.11) between 88-99 % in the presence of BSA (0.2 mg/mL). Compared to the 
percent inhibition in the presence of BSA (0.2 mg/mL) determined in the turbidimetric assay, 
the three tested compounds show comparable results. Inhibitory activity was slightly 
diminished in case of diflunisal (6 %) and diclofenac (1 %), but completely lost in case of 
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vitamin C palmitate (Vcpal) due to its high plasma protein binding. However, inhibition could 
still not be determined in the presence of human plasma. The samples with minimal and 
maximal response signals show the same coloration and, therefore, the same absorbance 
values (λ = 586 nm). The problem as to why inhibitory activity cannot be measured in the 
presence of human plasma has yet to be solved. 
 
The presence of an endogenous inhibitor of hyaluronidase, which was characterized as a 
thermolabile, magnesium dependent glycoprotein, in human serum and tissues was reported 
in the middle of the last century (1946-1955).44-47 In 2000, Mio et al. identified the serum 
inhibitor as a member of the inter-α-inhibitor family.48 The results presented in this section 
might indicate the presence of a substance in the plasma that inhibits the bacterial 
hyaluronidase yielding high turbidity of the positive controls. 
 
3.5 Peak plasma concentrations of commercial drugs 
The pharmacokinetic parameter cmax (peak plasma concentration) is the maximum 
concentration (in µg/mL) of a drug after a single dose. The peak plasma concentrations of 
the investigated non-steroidal anti-inflammatory drugs were taken into consideration. 
 
The highest final concentration (f. c.) in the incubation mixture in the turbidimetric assay was 
1 mM, if not otherwise indicated, due to poor solubility of the drug in aqueous buffer. The 
concentration in µg/mL for each drug was calculated and compared with the literature values 
for the peak plasma concentration cmax in human plasma (Table 3.12). Moreover, in this 
context, the inhibitory activities of the investigated NSAIDs on the bacterial hyaluronidase 
SagHyal4755 and the bovine testicular hyaluronidase BTH were discussed. 
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Table 3.12 Peak plasma concentrations and concentration in incubation mixture and inhibitory activity of 
SagHyal4755 of NSAIDs. 
drugs in clinical 
use 
peak plasma concentration final assay 
concentration 
of 1 mM 
corresponding 
to µg/mL 
SagHyal4755 
IC50 (µM)g 
BTH 
IC50 (µM)g dose (mg)a cmax (µg/mL) 
salicylic acid (1) 
 150-30049 138.1 inactive inactive 
acetylsalicylic acid 
(2) 1000-2000 24 ± 410 180.1 inactive inactive 
diflunisal (4) 250 41 ± 1150 250.2 195 ± 35 30 % at 1 mM 
felbinac (5) 3000b 0.034 ± 0.02951 106.1 (500 µM) inactive inactive 
tolmetin (6) 400 4052 279.3 40 % at 1 mM inactive 
etodolac (7) 200 / 600 14 ± 4 / 37 ± 953 287.4 inactive inactive 
ketorolac (8) 10-30c 0.8-3.010 255.3 25 % at 1 mM inactive 
sulindac (9) 200 4.754 356.4 442 ± 50 inactive 
diclofenac (10) 50 / 100d 0.42-2.010 296.2 161 ± 115 > 10005 
indomethacin (11) 50e 2.410 357.8 3508 5408 
fenoprofen (12) 600 5055 242.3 80 % at 1 mM inactive 
indoprofen (13) 100 8.3 ± 1.656 281.3 30 % at 1 mM inactive 
flurbiprofen (14) 100 1257 244.3 335 ± 131 inactive 
ketoprofen (15) 4 x 50f 2.4 ± 158 254.3 70 % at 1 mM inactive 
naproxen (16) 10-30c 55 ± 1410 230.3 794 ± 313 inactive 
ibuprofen (17) 800 61 ± 5.510 206.3 396 ± 69 inactive 
oxaprozin (18) 1200 80 ± 659 293.2 40 % at 1 mM inactive 
flufenamic acid 
(19) 200 6-2060 112.5 (400 µM) 151 ± 31 inactive 
niflumic acid (20) 740 0.18061 282.2 206 ± 24 10 % at 1 mM 
celecoxib (21) 500 0.705 ± 0.28610 381.4 inactive inactive 
oxazepam (22) 1200 45062 286.7 70 % at 1 mM inactive 
phenylbutazone 
(23) 2 x 100 2063 307.4 6504 inactive 
a
 Following an oral dose, if not otherwise indicated; b following a topical application; c range of cmax from different 
studies following a single 30 mg IM or 10 mg-oral dose in healthy adults; d following a single 50 mg enteric-coated 
tablet (EC) or 100 mg-sustained-release tablet (SR) given to healthy adults; e effective at concentrations of 
0.3-3 µg/mL; f following 4 x 50 mg ketoprofen capsules in fasted and fed state; g mean values ± SEM (N = 2, 
experiments performed in duplicate), highest concentration of the test compounds in the assay was 1 mM; IC50 
values determined at pH 5.0 in the turbidimetric assay (cuvettes). 
 
For all but two drugs (salicylic acid and oxazepam), the final concentration in the assay is 
higher compared to the peak plasma concentration (cmax) value from literature. The peak 
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plasma concentration of felbinac after a topical application of 3 g is 34 ng/mL, which is 
approximately 3000-fold lower compared to the highest final concentration in the incubation 
mixture (f. c. = 500 µM corresponding to 106.1 µg/mL). The smallest difference between 
peak plasma concentration and highest assay concentration was found for ibuprofen 
(f. c. = 1 mM corresponding to 206 µg/mL; cmax = 61 µg/mL) and oxaprozin (f. c. = 1 mM 
corresponding to 293 µg/mL; cmax = 80 µg/mL) for which the highest assay concentration is 
about 3-4-fold higher compared to the peak plasma concentration cmax.  
 
Compared to the peak plasma concentrations after a single dose, very high concentrations 
between 112-381 µg/mL were used in vitro in the turbidimetric assay for inhibition of 
SagHyal4755 and BTH. Except for diflunisal (4), diclofenac (10), and flufenamic acid (19), 
which show IC50 values below 200 µM on SagHyal4755, all of the other compounds showed 
weak or no inhibition of both enzymes in vitro. These results and previous investigations in 
our workgroup allow the conclusion that the bacterial hyaluronidase is more sensitive 
compared to the mammalian hyaluronidases. Moreover, the hyaluronidases from prokaryotes 
(SagHyal4755) and mammals (BTH, human hyaluronidases) must be clearly distinguished, as 
these enzymes exhibit different catalytic mechanisms to degrade their substrate hyaluronan. 
BTH is orthologous to the human hyaluronidase PH-20. Hence, the investigation on BTH can 
be regarded as an approach to evaluate potential inhibitors of PH-20.  
 
Taken together, the concentrations that are applied in vitro in the turbidimetric assay are 
relatively high (dilution series from 1 mM to 10 µM) and, except for salicylic acid and 
oxazepam, at least 3-4-fold higher compared to the peak plasma concentration in vivo. 
However, since in case of the bovine testis hyaluronidase the compounds showed very weak 
or no inhibition, it is expected that none of the compounds will show any effect in vivo on 
human hyaluronidases. The non-steroidal anti-inflammatory drugs are very potent inhibitors 
of the COX-1 and COX-2 enzymes, but cannot be used as hyaluronidase inhibitors. 
 
3.6 Summary and conclusion 
Non-steroidal anti-inflammatory drugs, phenylbutazone and retinoic acid were investigated 
under standardized conditions in the presence of SagHyal4755 and BTH. Compounds bearing 
characteristic structural elements, i.e. lipophilic moieties combined with an acidic functional 
residue, were preferentially chosen. However, the high degree of lipophilicity of previously 
identified active inhibitors of SagHyal4755 usually resulted in very high plasma protein binding 
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and a high logD5.0 value as well as surfactant properties.5 Among commercially available 
drugs, diflunisal (4; IC50 = 195 µM) and flufenamic acid (19; IC50 = 108 µM) showed the best 
inhibition of the bacterial hyaluronidase SagHyal4755 under the present conditions. Diflunisal 
(4) additionally showed weak inhibition of the bovine testicular hyaluronidase (BTH). 
Moreover, out of the investigated compounds that showed IC50 values around 200 µM (4, 10, 
19, 20), diflunisal (4) had the lowest calculated logD5.0 value (calculated logD5.0 = 0.9). 
In other words, under the current conditions, only inhibitors of SagHyal4755 were identified. 
Only the compounds diflunisal (4, 30 % at 1 mM) and niflumic acid (20, 10 % at 1 mM) 
showed weak inhibition of BTH which, also, suggests inactivity of these compounds at the 
related human PH-20 hyaluronidase. 
 
Diflunisal (4, IC50 = 195 µM), was identified as a putative lead compound for the design and 
synthesis of chemically related inhibitors. Interestingly, diflunisal is devoid of a long lipophilic 
carbon chain. With respect to the calculated logD5.0 (logD5.0 = 0.9), this might also represent 
a privileged structural element to overcome high plasma protein binding and thus might 
provide access to a new class of potent inhibitors of SagHyal4755. 
 
Several attempts were undertaken to determine the plasma protein binding of diflunisal (4) 
and the three reference compounds vitamin C palmitate (Vcpal), diclofenac (10), and 
indomethacin (11) using the both the colorimetric and turbidimetric assay. The inhibitory 
activity of these compounds on the bacterial hyaluronidase SagHyal4755 was determined in 
presence of an enhanced BSA concentration (10 mg/mL), fetal calf serum (FCS) and human 
plasma. In case of Vcpal, a significant drop of inhibition was observed in both assays, 
possible due to very high plasma protein binding. The inhibitory effect of diclofenac (10), 
diflunisal (4) and indomethacin (11) was only slightly diminished in the presence of BSA 
(10 mg/mL) and FCS in both investigated assay systems. The human plasma caused a very 
high turbidity in the positive control, which could indicate the presence of an inhibitor in the 
human plasma that has been reported for a long time. However, this is a problem that has 
yet to be dealt with. 
 
The peak plasma concentration cmax of the tested NSAIDs were compared with the highest 
final assay concentration corresponding to µg/mL. From the in vitro inhibitory activity on the 
bovine testis hyaluronidase, it was possible to draw conclusions for the related human 
hyaluronidase PH-20. The NSAIDs were tested in relatively high concentrations (1 mM to 
10 µM dilution series) but no or only weak inhibition of BTH could be observed. Therefore, it 
is possible to conclude that none of the investigated drugs will the human hyaluronidase in 
vivo.  
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4.1 Introduction 
The inhibition of hyaluronidase by salicylates was reported in the years 1946 to 1950.1-4 
Aiming at drug-like molecules, a set of several commercially available drugs, mainly NSAIDs, 
purported to have hyaluronidase inhibiting activities, was investigated for inhibition of 
bacterial hyaluronidase from S. agalactiae (SagHyal4755) and bovine testis hyaluronidase 
(BTH; cf. chapter 3). The biarylic salicyclic acid analog diflunisal5 (Figure 4.1) was identified 
as an inhibitor with an IC50 value in the micromolar range on SagHyal4755 (IC50 = 195 µM). 
 
 
Figure 4.1 Chemical structure of diflunisal. 
 
Over the past decade, potent inhibitors of hyaluronidase with a preference for the bacterial 
enzymes were discovered in our laboratory.6-11 Characteristics of the most active inhibitors 
are acidic functional groups and a high degree of lipophilicity. The structural features of these 
compounds are reminiscent of the amphiphilic repetitive motives of hyaluronan. In general, 
the potency of the inhibitors correlates with the lipophilicity. Unfortunately, the drug-like 
properties of highly lipophilic substances are strongly affected due to high plasma protein 
binding. 
 
Aiming at inhibitors with improved drug-like properties, the focus was set on a series of 
compounds that are structurally related to diflunisal (Figure 4.2). For the synthesis of the 
diflunisal derivatives, the Suzuki-Miyaura cross-coupling reaction of aryl halides with 
organoboron compounds was applied. 
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Figure 4.2 Structural modifications of diflunisal 
 
The diflunisal core-structure was modified in the “eastern part” (variations in positions 2-4; 
Figure 4.2) and the “western part” (variations in positions 2’-6’; Figure 4.2) of the molecule. 
For the selection of the moieties to be introduced into the diflunisal scaffold, based on 
relevant experience from our laboratory, the contribution of the substructures to the 
physicochemical and drug-like properties of the hyaluronidase inhibitors as well as the 
commercial availability of educts were taken into consideration.  
 
The two fluorine substituents of diflunisal were exchanged by several residues 
(cf. modification I in Figure 4.2), such as chlorine, trifluoromethyl, cyclohexyl, propanoic and 
acrylic acid and methoxy groups. On the one hand, the 2’,4’-F2 substitution pattern of 
diflunisal was maintained, on the other hand it was changed to investigate the influence of 
different substituents at other positions (3’,5’; 2’,5’). Monosubstitution with chlorine (2’-Cl; 
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4’-Cl) or trifluoromethyl (3’-CF3) were performed. Moreover, a bioisosteric exchange of 
chlorine by trifluoromethyl groups was performed (3’,5’-Cl2; 3’,5’-(CF3)2).  
 
Compared to the diflunisal molecule, compounds bearing chlorine or trifluoromethyl groups 
are more lipophilic in terms of the logD5.0 value but suffer from limited solubility. Hence, to 
retain good solubility, an additional negatively charged carboxylic group was introduced into 
the western part. Both, a propanoic acid residue (4’-C2H4COOH) and an acrylic acid residue 
(4’-C2H3COOH) were introduced into the molecule. To create molecules that are sterically 
more demanding, a cyclohexane ring (4’-C6H11) or an additional phenyl ring (3’-Ph and 4’-Ph) 
were introduced into the western part. Additional structural modifications of the western part 
(cf. modification II in Figure 4.2) include various different substituents (3’-Cl, 5’-OMe; 2’-OMe, 
5’-C3H9; 3’-Cl,4’-F and 3’-Cl, 4’-CN) were combined. Other structural modifications of the 
western part (cf. modification III in Figure 4.2) were performed by an exchange of the 
substituted phenyl ring with heterocycles, such as 2-methoxynaphthalene, 
benzo[d][1,3]dioxole, 2-chlorothiophene and 3-chloropyridine. 
 
The eastern part of the diflunisal molecule contains a salicylic acid moiety. To vary the 
position of the carboxylic group (position 3 in diflunisal) and the hydroxyl group in position 4, 
the salicylic acid was replaced by 2-, 3- and 4-benzoic acid (cf. modification IV in Figure 4.2). 
 
In the present chapter, the synthesis of selected diflunisal derivatives and the correlated 
inhibitory activity towards the bacterial hyaluronidase are described. 
 
4.2 Chemistry 
Carbon-carbon coupling reactions based on transition-metal catalysts have evolved as 
powerful tools in organic synthesis. Among them, palladium-catalyzed cross-coupling 
reactions are most prominent.12 The palladium-mediated cross-coupling of organic 
electrophiles, such as aryl halides with organoboron compounds in the presence of an 
inorganic base is known as the Suzuki-Miyaura reaction and has become one of the most 
powerful and convenient synthetic tools for the preparation of biarylic compounds.13-16 
 
The synthesis of the diflunisal analogs were carried out utilizing iodobenzoic acid or 
iodosalicylic acid as building blocks for the eastern part and organoboronic acids for the 
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western part of the molecules (cf. Figure 4.2). The Suzuki-Miyaura cross-coupling was 
carried out as outlined in Scheme 4.1. 
 
 
Scheme 4.1 Synthesis of the 2-, 3- and 4-carboxylic acid analogs. Reagents and conditions: Pd(dppf)Cl2•CH2Cl2, 
K2CO3 (2 M), toluene, ethanol (1:1:1, v/v/v), microwave 140 °C, 20 min.  
 
The biaryl compounds were synthesized in one step, starting from commercially available 
aryl boronic acids and aryl iodides according to the procedure described by Chalker et al.17 
Microwave irradiation (140 °C, 20 min) in toluene and ethanol in the presence of potassium 
carbonate (2 M) was used for rapid coupling to afford compounds 4.24-4.46.  
 
The mechanism of the Suzuki-Miyaura reaction is described as a general catalytic cycle, 
which involves oxidative addition of the aryl halide, transmetalation of the boronic acid and 
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reductive elimination of the biaryl.18 These intermediates have been proven by isolation and 
spectroscopic analyses.19,20 Oxidative addition of the aryl iodide to the palladium(0) complex 
affords a sTable trans-σ-palladium(II) complex.21 Reductive elimination of organic partners 
from the palladium(II) complex reproduces the palladium(0) complex. Water and base were 
found necessary to activate the boronic acid.18,22 
  
The target compounds 4.24-4.46 were separated from starting materials and isolated by 
flash chromatography in accepTable yields. 
 
4.3 Pharmacological results and discussion 
4.3.1 General conditions 
All synthesized diflunisal derivatives were investigated for inhibition of the bacterial 
hyaluronan lyase SagHyal4755 and the bovine testicular enzyme BTH (Neopermease®) at 
pH 5.0 in a turbidimetric assay based on the method of Di Ferrante23 as described in 
chapter 1. In the following, inhibitory activities are expressed as IC50 values unless IC50 
values could not be determined, due to poor solubility in aqueous buffer. In such cases the 
percent inhibition of the enzyme at the highest possible concentration of the compound is 
given. 
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4.3.2 Inhibitory activities of biphenyl-2-carboxylic acid derivatives 
The IC50 values determined for the analogs of biphenyl-2-carboxylic acids are summarized in 
Table 4.1. 
 
Table 4.1 Inhibitory activitya and calculated logD5.0 valuesb of biphenyl-2-carboxylic acid derivatives 4.24a and 
4.26a. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
4.24a 443 ± 38 inactive 2.5 
4.26a 264 ± 81 inactive 2.4 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, 
Canada) product version 12.0. 
The enzymatic activity of SagHyal4755 in the presence of 4.24a and 4.26a is depicted as 
concentration-response curves in Figure 4.3.  
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Figure 4.3 Enzymatic activity of SagHyal4755 in the presence of 4.24a and 4.26a. 
 
Both compounds showed only weak inhibition of SagHyal4755 and no inhibition of BTH. 
Compared to diflunisal (IC50 = 195 µM), the inhibitory activity of these particular compounds 
was weaker. Therefore, the substitution pattern of compounds bearing the 
biphenyl-2-carboxylic acid motif was not further investigated.  
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4.3.3 Inhibitory activities of biphenyl-3-carboxylic acid derivatives 
IC50-values determined for the analogs of biphenyl-3-carboxylic acids are summarized in 
Table 4.2. 
 
Table 4.2 Inhibitory activity and calculated logD5.0 valuesb of biphenyl-3-carboxylic acid derivatives 4.24b-4.32b, 
4.34b-4.38b and 4.40b-4.44b. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
c 
4.24b 121 ± 33 inactive 3.2 
4.25b inactive inactive 3.7 
4.26b 279 ± 100 25 % at 500 µM 3.0 
4.27b 94 ± 1 inactive 2.5 
4.28b 133 ± 33 inactive 2.2 
4.29b 248 ± 185 inactive 2.5 
4.30b inactive inactive 3.0 
4.31b inactive inactive 2.9 
4.32b inactive inactive 4.5 
4.34b 20 % at 100 µMb inactive 3.9 
4.35b 40 % at 200 µMb inactive 2.8 
4.36b inactive inactive -0.4 
4.37b inactive inactive 4.0 
4.38b inactive inactive 2.1 
4.40b 20 % at 100 µMb inactive 0.7 
4.41b inactive inactive 1.5 
4.42b inactive inactive 4.9 
4.43b inactive inactive 2.5 
4.44b 20 % at 100 µMb inactive 2.3 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b % inhibition of SagHyal4755 at indicated inhibitor concentration; c calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0.  
 
The enzymatic activity of SagHyal4755 in presence of 4.24b and 4.26b-4.29b is depicted as 
concentration-response curves in Figure 4.4. 
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Figure 4.4 Enzymatic activity of SagHyal4755 in the presence of 4.24b-4.29b. 
 
As a result, three compounds (4.24b, 4.28b and 4.27b) analyzed in this section showed 
higher inhibitory potency on SagHyal4755 than diflunisal. Notably, compound 4.27b bears two 
trifluoromethyl groups instead of the fluorine substituents in positions 2’ and 4’ of the 
diflunisal molecule. Additionally, the hydroxyl group in position 4 in the eastern part is 
missing. With an IC50 value of 94 µM compound 4.27b was 2-fold more potent than diflunisal. 
Shifting the arrangement of the trifluoromethyl groups from 2’, 4’ to 3’, 5’ revealed both 
poorer solubility (50 µM compared to 400 µM) and complete loss of inhibitory activity. 
Substances 4.24b (IC50 = 121 µM), 4.26b (IC50 = 279 µM), 4.28b (IC50 = 133 µM) and 4.29b 
(IC50 = 248 µM) showed moderate, compounds 4.34b, 4.35b, 4.40b and 4.44b very weak 
inhibition of SagHyal4755. 
 
It is remarkable that compounds 4.24b and 4.26b were superior to compounds 4.24a, 4.26a 
as a consequence of the different position of the carboxylic acid group (position 2, 
cf. Figure 4.3) in the eastern part of the molecules.  
 
The dicarboxylic acid 4.36b, which is less lipophilic (logD5.0 = -0.4) than compounds bearing 
one carboxylic group, was found to be inactive on SagHyal4755. The calculated logD5.0 value 
of the dichloro-substituted compound 4.24b (logD5.0 = 3.2) is higher than that of the 
corresponding bis(trifluoromethyl)-substituted analog 4.27b (logD5.0 = 2.5). However, the IC50 
value of 4.27b is slightly lower than the IC50 value of 4.24b. Both substances are superior to 
diflunisal. The combination of the structural elements of 4.24b and 4.27b in compound 4.28b 
revealed a calculated logD5.0 and an IC50 value in the same range (logD5.0 = 3.3; 
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IC50 = 133 µM). Mono-substitution with chlorine in position 2’ (4.26b) and 3’ (4.29b) resulted 
in about the same inhibitory effect on SagHyal4755 with IC50 values of 279 µM and 248 µM, 
respectively, whereas the 4’-chloro-substituted analog 4.31b was inactive. 
Substances 4.25b, 4.32b, 4.34b, 4.37b and 4.42b bear lipophilicity-increasing moieties in the 
western part resulting in logD5.0 values ranging from 3.8-4.9. These compounds were inactive 
on SagHyal4755 except for 4.34b, which showed weak inhibition. The introduction of other 
substituents, such as 2-carboxyvinyl (4.40b), cyano (4.38b), methoxy (4.41b) and tert-butyl 
or replacing the substituted phenyl by 7-methoxy-2-naphthyl- (4.43b) or a 
benzo[d][1,3]dioxol-5-yl (4.44b) residues did not increase inhibitory activity. 
 
The mammalian enzyme BTH was only weakly inhibited by 4.26b (25 % at 500 µM) and not 
inhibited by all the other compounds included in this section. This is in accordance with 
previous reports for diflunisal, which showed only very weak inhibition of BTH (30 % at 1 mM, 
cf. chapter 3). 
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4.3.4 Inhibitory activities of biphenyl-4-carboxylic acid derivatives 
IC50 values determined for the analogs of biphenyl-4-carboxylic acids are summarized in 
Table 4.3. 
 
Table 4.3 Inhibitory activitya and calculated logD5.0 valuesb of biphenyl-4-carboxylic acid derivatives 4.24c-4.28c, 
4.30c-4.35c, 4.37c-4.39c, 4.41c, 4.42c and 4.44c. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
c 
4.24c inactive inactive 3.1 
4.25c 20 % at 100 µMb inactive 3.9 
4.26c 10 % at 50 µMb inactive 3.0 
4.27c 50 % at 300 µMb inactive 2.5 
4.28c 20 % at 100 µMb inactive 2.2 
4.30c 30 % at 200 µMb inactive 3.0 
4.31c inactive inactive 2.9 
4.32c 25 % at 200 µMb inactive 2.5 
4.33c 55 ± 6 inactive 3.4 
4.34c 31 ± 2 >400 µM 3.9 
4.35c inactive inactive 2.8 
4.37c inactive inactive 4.0 
4.38c 20 % at 200 µMb inactive 2.0 
4.39c inactive inactive 0.8 
4.41c inactive inactive 1.5 
4.42c inactive inactive 4.9 
4.44c 15 % at 100 µMb inactive 2.3 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b % inhibition of SagHyal4755 and BTH, respectively, at indicated inhibitor 
concentration; c calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product 
version 12.0. 
 
The enzymatic activity of SagHyal4755 in presence of 4.33c and 4.34c is depicted as 
concentration-response curves in Figure 4.5. 
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Figure 4.5 Enzymatic activity of SagHyal4755 in the presence of 4.33c and 4.34c. 
 
Compounds 4.33c (IC50 = 55 µM) and 4.34c (IC50 = 31 µM) were the most potent inhibitors of 
SagHyal4755 among the synthesized diflunisal analogs. Compared to diflunisal, 4.33c and 
4.34c possess more lipophilic moieties in the western part of the molecule (cf. Figure 4.5), 
resulting in calculated logD5.0 values between 3.4 and 3.9. Compound 4.34c possesses an 
additional phenyl ring in position 3’ of the western part, which makes the molecule more 
sterically demanding. Compound 4.25c, which only differs from 4.34c in the position of the 
phenyl ring, shows only 20 % inhibition at 100 µM. Compared to the chlorine residues, the 
additional phenyl ring in 4.34c is bulkier, which might be beneficial for the inhibition of 
SagHyal4755.  
 
Whereas compounds 4.24a and 4.24b showed weak inhibition of 400 µM and moderate 
inhibition (IC50 = 121 µM) on SagHyal4755, the respective compound 4.24c was inactive. The 
same applies for compounds 4.26a and 4.26b, which both showed weak inhibition with IC50 
values of 321 µM and 280 µM, respectively, whereas compound 4.26c only revealed 10 % 
inhibition at 50 µM due to poor solubility. Compound 4.27b (IC50 = 94 µM) was more potent 
than 4.27c, which showed 50 % inhibition at 300 µM; an IC50 value could not be determined, 
due to poor solubility. For compound 4.28c (20 % inhibition at 100 µM) an IC50 value could 
not be determined, whereas compound 4.28b (IC50 = 133 µM) was a moderate inhibitor. By 
contrast, compound 4.34c revealed an IC50 value of 31 µM, whereas the corresponding 
isomer 4.34b compound was inactive. Compounds 4.25b, 4.30b, 4.32b and 4.38b were 
inactive, whereas the isomers 4.25c, 4.30c, 4.32c and 4.38c showed weak inhibition 
(IC50 value not determined due to poor solubility). The reverse was true for the isomers 
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(40 % at 200 µM) and 4.35c (inactive). Compounds 4.31b/c, 4.37b/c and 4.41b/c were both 
inactive and poorly soluble.  
 
Changing the arrangement of the trifluoromethyl groups from 2’,4’- (4.27c) to 3’,5’-position 
(4.30c) had only minor influence on the inhibition of SagHyal4755. The combination of a 
chlorine and a trifluoromethyl group (4.28c) was not superior to attaching only one kind of 
substituent in the western part (cf. 4.24c, 4.27c, 4.30c). Mono-chlorinated compounds 
(4.26c, 4.31c) were inactive, and the introduction of different other substitution patterns in the 
western part of the molecule (cf. 4.32c, 4.35c, 4.37c, 4.38c, 4.39c, 4.41, 4.42c, 4.44c) did 
not lead to increased inhibition of SagHyal4755. 
 
Interestingly, compound 4.34c showed weak inhibition of > 400 µM of the bovine testicular 
hyaluronidase, whereas all other compounds were inactive on this mammalian enzyme. 
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4.3.5 Inhibitory activities of 4-hydroxybiphenyl-3-carboxylic acid 
analogs 
IC50 values determined for the analogs of biphenyl-3-carboxylic acids are summarized in 
Table 4.4. 
 
Table 4.4 Inhibitory activitya and calculated logD5.0 valuesb of biphenyl-4-carboxylic acid analogs 4.24d-4.26d, 
4.28d-4.30d, 4.32d-4.34d, 4.37d, 4.39d-4.41d and 4.43d-4.46d. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
c 
4.24d 68 ± 12 25 % at 1 mM 1.9 
4.25d 33 ± 6 inactive 2.9 
4.26d 148 ± 48 40 % at 1 mM 1.7 
4.28d 50 ± 18 10 % at 1 mM 1.0 
4.29d 154 ± 33 50 % at 1 mM 1.3 
4.30d 48 ± 8 inactive 1.8 
4.32d 171 ± 33 inactive 1.3 
4.33d inactive inactive 2.2 
4.34d inactive inactive 2.6 
4.37d 80 % at 100 µMb inactive 2.8 
4.39d 50 % at 100 µMb inactive -0.5 
4.40d 60 % at 100 µMb inactive -2.0 
4.41d 40 % at 100 µMb inactive 0.3 
4.43d 76 ± 36 inactive 1.3 
4.44d 40 % at 100 µMb inactive 1.0 
4.45d 90 ± 14 10 % at 200 µMb 1.5 
4.46d 181 ± 23 40 % at 1 mM 0.3 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b % inhibition of SagHyal4755 and BTH, respectively, at indicated inhibitor 
concentration; c calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product 
version 12.0. 
 
The enzymatic activity of SagHyal4755 in presence of 4.24d, 4.25d, 4.30d and 4.43d is 
depicted as concentration-response curves in Figure 4.6. 
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Figure 4.6 Enzymatic activity of SagHyal4755 in the presence of 4.24d, 4.25d, 4.28d, 4.30d and 4.43d. 
 
In this group of compounds the most potent hyaluronate lyase inhibitors related to diflunisal 
were identified. The structures were designed as salicylic acid derivatives. 4-hydroxy-
1,1’:4’,1’’-terphenyl-3-carboxylic acid (4.25d, IC50 = 33 µM), bearing a phenyl moiety in 
position 4’ in the western part, was 6-fold more potent than diflunisal and next to 4.34c one of 
the most active inhibitors of SagHyal4755 among the diflunisal analogs. By contrast, 
compounds 4.25b and 4.25c (20 % inhibition at 100 µM) were inactive or very weakly active, 
respectively. Five additional compounds among those listed in Table 4.4 showed IC50 values 
below 100 µM (4.24d, 4.28d, 4.30d, 4.43d), whereas the corresponding analogs included in 
sections 4.3.3 and 0 revealed weak or no inhibition of the bacterial hyaluronidase.  
 
Compared to diflunisal, in the four compounds 4.24a-d, the fluorine atoms in positions 2’ and 
4’ were replaced by chlorine atoms. Compound 4.24d with an IC50 value of 68 µM is a more 
active inhibitor than the respective 4.24a-c compounds, which showed weak (4.24a) or 
moderate (4.24b) inhibition or proved to be inactive (4.24c) on SagHyal4755. Taken together, 
the compounds 4.24b and 4.24d, which bear the carboxylic group in position 3, were 
superior to their structural isomer 4.24c and the compound with the salicylic acid motif 
(4.24d) was the most potent inhibitor.  
 
Among the four mono-chlorinated compounds 4.26a-d, 4.26d was most potent, though at a 
lower level compared to the dichlorinated analog. Likewise, the combination of a chlorine and 
a trifluoromethyl substituent in positions 2’and 4’, respectively, was most effective with the 
salicylic acid scaffold as demonstrated for compound 4.28d (IC50 = 50 µM) (cf. 4.28b/c in 
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sections 4.3.3 and 4.3.4). The same holds for compounds 4.30b and 4.30c in comparison 
with 4.30d: whereas 4.30b is inactive and 4.30c was too poorly soluble to determine an IC50 
value, 4.30d was the most potent inhibitor of SagHyal4755 with an IC50 value of 48 µM. 
Likewise, the salicylic acid moiety (4.32d) gave higher inhibitory activity when comparing 
compounds 4.32b-d. By contrast, compound 4.34d did not show any inhibition of 
SagHyal4755, whereas substance 4.34c (IC50 = 31 µM) was the most potent inhibitor among 
all synthesized diflunisal analogs. Compounds 4.29b and 4.29d showed moderate inhibition 
with IC50 values of 248 µM and 154 µM. The solubility of 4.40b and 4.40d was too low (100 
µM) to determine IC50 values. In contrast to 4.43b (inactive), compound 4.43d (IC50 = 76 µM) 
showed moderate inhibition of SagHyal4755, again suggesting that the hydroxyl group 
contributes to the inhibition of the enzyme. 
 
Substances 4.26d (IC50 = 148 µM) and 4.29d (IC50 = 154 µM) are mono-chlorinated in 
position 4’ or 2’, respectively. Their inhibitory activity on SagHyal4755 was lower than that of 
the dichlorinated analog4.24d (IC50 = 68 µM). Hyaluronidase inhibitory activity was lost, when 
the halogen atoms were attached to positions 3’ and 5’. All the other structural variations 
(cf. 4.32d, 4.37d, 4.39d, 4.41d and 4.44d) resulted in inactive compounds. In case of the 
salicylic acid derivatives, the replacement of the halogenated phenyl ring gave a 
hyaluronidase inhibitor with a 7-methoxy-2-naphthyl residue in the western part of the 
molecule (4.43d: IC50 = 76 µM). Compounds 4.45d and 4.46d bear heterocyclic residues (5-
chlorothiophen-2yl- and 5-chloropyridin-3-yl residues, respectively) in the western part. With 
regard to the logD5.0 value, the more lipophilic substance, thiophene 4.45d (logD5.0 = 1.5) 
showed higher inhibitory activity (IC50 = 90 µM) compared to 4.46d (logD5.0 = 0.3, 
IC50 = 181 µM).  
 
Compounds 4.26d, 4.28d, 4.29d, 4.30d, 4.45d and 4.46d showed weak inhibition of the 
mammalian enzyme from bovine testis (BTH). All other compounds included in this section 
were inactive. 
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4.4 Inhibitory activities of selected compounds on 
SpnHyl 
The compounds described in this chapter were designed as inhibitors of the hyaluronate 
lyase from S. agalactiae (SagHyal4755). To compare the results from SagHyal4755 with data 
from an additional bacterial enzyme, an ensemble of eight inhibitors was selected for 
investigations on hyaluronidase from S. pneumonia (SpnHyl). Under identical assay 
conditions (including the pH value) these substances showed only weak inhibition or were 
inactive (4.25d) on SpnHyl (Table 4.5). 
 
Table 4.5 Inhibitory activitya,b of selected biphenyl-carboxylic acid derivatives 4.27b, 4.33c, 4.34c, 4.24d, 4.25d, 
4.28d, 4.30d, 4.43d. 
Compound 
SagHyal4755 
IC50 (µM)a 
SpnHyl 
IC50 (µM)a,b 
4.27b 94 ± 1 9 % at 200 µMb,c 
4.33c 55 ± 6 10 % at 200 µMb,c 
4.34c 31 ± 2 70 % at 500 µMc 
4.24d 68 ± 12 80 % 
4.25d 33 ± 6 inactive 
4.28d 50 ± 18 397 ± 69 
4.30d 48 ± 8 50 % at 500 µMc 
4.43d 76 ± 36 18 % at 200 µMb,c 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b IC50 values determined at pH 5.0 in the turbidimetric assay (96-well plate); c % 
inhibition of SpnHyl at indicated inhibitor concentration. 
 
For compound 4.28d an IC50 value of 397 µM was determined on SpnHyl, which was 8-fold 
higher than for inhibition of SagHyal4755. Moreover, 4.25d was the only substance that was 
inactive on SpnHyl, suggesting preference for the enzyme SagHyal4755. 
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4.5 Inhibitory activities of vitamin C palmitate in the 
presence of palladium catalyst 
Metal ions have early been described to possess inhibitory activities of hyaluronidases. 
Meyer reported on the inhibitory activities of Fe3+, Fe2+, Cu2+ and Zn2+ for the testicular 
hyaluronidase in 1951.24 Cd2+ and Zn2+ are also supposed to inhibit the bacterial 
hyaluronidase from Streptococcus dysgalactiase and Streptococcus zooepidemicus.25 
Moreover, the existence of a highly potent endogenous inhibitors, characterized as a 
thermolabile, magnesium dependent glycoprotein, present in human serum and tissues was 
reported.26-28 
 
For the synthesis of the compounds described and analyzed in this chapter, the palladium 
catalyst [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium complex with dichloro-
methane (Pd(dppf)Cl2•CH2Cl2, cf. Figure 4.7) was used. 
 
 
Figure 4.7 Structure of [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium complex with dichloromethane 
(Pd(dppf)Cl2•CH2Cl2). 
 
After completion of the reaction, the catalyst was removed from the reaction mixture and the 
crude products were purified by flash column chromatography. Due to this work-up 
procedure, traces of catalyst should not be present in the inhibitor solutions that were used in 
the turbidimetric assay for the determination of hyaluronidase inhibition. However, since 
several metal ions and their salts have been reported for hyaluronidase inhibition, a potential 
contribution of Pd(dppf)Cl2•CH2Cl2 to false-negative results was taken into consideration. 
Therefore, the reference compound vitamin C palmitate (Vcpal; Figure 4.8), which is known 
as a potent inhibitor of the bacterial hyaluronidase SagHyal4755, was tested in the 
turbidimetric assay in the presence of different concentrations (1.2-4.9 mol percent) of 
Pd(dppf)Cl2•CH2Cl2.  
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Figure 4.8 Structure of vitamin C palmitate (Vcpal). 
 
The results are summarized in Table 4.6. 
 
Table 4.6 Inhibitory activities of vitamin C palmitate (Vcpal) in the presence of different concentrations of the 
palladium catalyst Pd(dppf)Cl2•CH2Cl2. 
Compound 
SagHyal4755  
IC50 (µM)a 
Control, without 
Pd(dppf)Cl2•CH2Cl2 
1.2 mol%b 
Pd(dppf)Cl2•CH2Cl2 
2.7 mol%b 
Pd(dppf)Cl2•CH2Cl2 
4.9 mol%b 
Pd(dppf)Cl2•CH2Cl2 
Vcpal 4.1 ± 0.1a 4.7 ± 1 5.9 ± 3 6.6 ± 3 
a
 As determined by Spickenreither9; b with regard to a 1.35 mM stock solution of Vcpal, final assay concentration 
of stock solution is 50 µM (dilution series: 50 µM to 2.5 µM). 
 
With regard to the IC50 values, no relevant differences became obvious for the inhibition of 
SagHyal4755 by Vcpal in the absence or presence of palladium catalyst. Compared to the IC50 
value of Vcpal (IC50 = 4.1 µM) determined by Spickenreither9, the determined IC50 values for 
Vcpal in the presence of Pd(dppf)Cl2•CH2Cl2 were in the range from 4.7 µM to 6.6 µM, 
corresponding to less than a 2-fold decrease in inhibitory potency. If Pd(dppf)Cl2•CH2Cl2 had 
an inhibitory effect on SagHyal4755, the inhibitory activity of Vcpal should be increased, 
resulting in IC50 values lower than 4.1 µM. As a result, traces of palladium catalyst, if present 
in the incubation mixture, do not affect the inhibitory effect of the synthesized compounds.  
 
4.6 Summary and conclusion 
Aiming at inhibitors of the bacterial hyaluronidase SagHyal4755, the scaffold of the NSAID 
diflunisal was selected as a lead compound for structural modifications. This approach, 
starting from an approved drug, was expected to harbor the potential of improving the drug-
like properties compared to previously identified, highly lipophilic hyaluronidase inhibitors, in 
particular regarding logD5.0 values and plasma protein binding. According to a Suzuki-
Miyaura cross-coupling procedure, a library of biarylic benzoic and salicylic acid analogs was 
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synthesized. These compounds revealed in part markedly lower lipophilicity than the 
reference compound (diflunisal) and IC50 values in the two-digit micromolar range. 
 
The diflunisal core structure was changed in the eastern part by varying the position of the 
carboxylic acid at the biphenyl scaffold. In a first attempt, the carboxylic acid was introduced 
in the molecule in position 2. This did not result in better inhibitory activity of SagHyal4755 
compared to diflunisal although the lipophilicity was increased by chlorine residues. 
When the carboxylic acid was shifted to position 3, three compounds exhibit lower IC50 
values on the bacterial hyaluronidase (4.24b, 4.27b, 4.28b) compared to the lead compound. 
Such molecules incorporated either chlorine residues (cf. 4.24b) or trifluoromethyl groups 
(cf. 4.27b) or the combination of both (cf. 4.28b). Hence, it can be concluded, that for the 
inhibition of SagHyal4755 position 3 is more favorable compared to position 2 for the 
carboxylic acid moiety (cf. 4.24a and 4.24b). By introducing the carboxylic acid in position 4 
at the biphenyl scaffold, the inhibitory effect was further enhanced in case of two compounds 
(4.33c and 4.34c) which showed about 4-fold lower IC50 values than diflunisal. The 
lipophilicity of those compounds was increased by the 3’,5’-dichloro substitution pattern and 
an additional phenyl ring, respectively. Although compound 4.34c with an IC50 value of 31 µM 
was the most active inhibitor out of the whole series, retaining the salicylic acid moiety in the 
eastern part also led to more potent inhibitors of SagHyal4755 compared to diflunisal. Again, 
the introduction of chlorine substituents (4.24d), trifluoromethyl groups (4.30d), the 
combination of both (4.28d) and an additional phenyl ring (4.25d) were most effective to 
achieve inhibitors with IC50 values in the two-digit micromolar range. Moreover, the 
incorporation of a 2 methoxy-2-naphthyl (4.43d) residue, replacing the substituted phenyl 
ring in diflunisal, led to an IC50 value of 76 µM.  
 
To sum up, the best results with regard to the IC50 values were achieved when the carboxylic 
acid was incorporated in position 4 and when the salicylic acid moiety was utilized as eastern 
part. Moreover, the two most potent inhibitors from the diflunisal series were compounds in 
which the western part was substituted with an additional phenyl ring (4.34c in position 3’, 
4.25d in position 4’). Regarding lipophilicity, these two compounds had the highest logD5.0 
values (4.34c logD5.0 = 3.9; 4.25d logD5.0 = 2.9) of all substances of the respective series. 
The logD5.0 value of 4.25d is lower compared to the value of 4.34c because of the additional 
hydroxyl group in position 4. As the two compounds were equipotent in terms of the IC50 
value, the hydroxyl group appears to have no positive influence on the inhibition. However, 
by not diminishing the inhibitory effect, the OH group had no negative influence either. This 
suggests that it is favorable to leave the hydroxyl group incorporated in the molecule, 
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because it increases the solubility of the respective compound in aqueous buffer and 
decreases the lipophilicity, which is important with respect to possible in vivo studies. 
 
So far, only inhibitors of the bacterial hyaluronidase SagHyal4755 were identified. The second 
bacterial hyaluronidase SpnHyl was only weakly inhibited by the biphenyl carboxylic acids. 
Compound 4.25d was inactive on SpnHyl and preferred SagHyal4755 (IC50 = 33 µM). The 
mammalian hyaluronidase BTH was not affected by the small molecule inhibitors, except for 
compound 4.34c (IC50 > 400 µM). This also suggests inactivity of these compounds at the 
human ortholog of BTH, the human PH-20 hyaluronidase. 
 
The inhibitory activity of vitamin C palmitate on SagHyal4755 was investigated in the 
turbidimetric assay in the presence of palladium catalyst to exclude a possible effect of 
traces of catalyst from the Suzuki-Miyaura cross-coupling reaction in the incubation mixture. 
No difference in inhibitory activity of Vcpal on SagHyal4755 was observed. 
 
In summary, the structural modifications of an approved drug was suiTable to obtain novel 
inhibitors of the bacterial hyaluronidase SagHyal4755 that showed significantly higher 
inhibitory potency than the reference compounds diflunisal. 
 
4.7 Experimental section 
4.7.1 General conditions 
Chemicals and solvents were purchased from Acros Organics (Geel, Belgium), Alfa Aesar 
GmbH & Co. KG (Karlsruhe, Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich 
Chemie GmbH (Munich, Germany) and used without further purification. Deuterated solvents 
for NMR spectroscopy were from Deutero GmbH (Kastellaun, Germany). All solvents were of 
analytical grade of distilled prior to use. If moisture-free conditions were required, reactions 
were performed in dried glassware under inert atmosphere (argon or nitrogen). DMF 
(H2O < 0.01 %) was purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany) and 
stored over 3 Å molecular sieves. Millipore water was used throughout for the preparation of 
buffers and HPLC eluents.  
 
Nuclear Magnetic Resonance spectra were recorded with Avance 300 (1H: 300 MHz, 13C: 
75.5 MHz), Avance 400 (1H: 400 MHz, 13C: 100.6 MHz) and Avance III 600 Kryo 
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spectrometer (1H: 600 MHz, 13C: 150.9 MHz) from Bruker BioSpin GmbH (Rheinstetten, 
Germany). Chemical shifts are given in δ (ppm) relative to external standards. Coupling 
constants (J) are reported in Hz. Multiplicities are specified with the following abbreviations: 
s (singlet), d (doublet), t (triplet), q (quartet), m (mutiplet), s br (broad singlet), as well as 
combinations thereof. The Avance 400 and Avance 600 Kryo NMR spectrometer were used 
to measure 2D-NMR techniques (HSQC, HMBC, COSY) to assign 1H and 13C chemical 
shifts.  
 
Flash chromatography was performed in glass columns on silica gel (Merck silica gel 60, 
particle size 0.040-0.063 mm). Automated flash chromatography was performed on a Varian 
IntelliFlash 310 using pre-packed Varian Superflash columns (Varian, Darmstadt, Germany). 
Reactions were routinely monitored by thin layer chromatography (TLC) on aluminum plates 
coated with silica gel (Merck silica gel 60 F254, thickness 0.2 mm). The spots were visualized 
with UV light at 254 nM and/or a solution of bromocresol green (0.04 %) in ethanol 
(carboxylic acids). Microwave assisted reactions were performed on an Initiator 2.0 
synthesizer (Biotage, Uppsala, Sweden). Lyophilisation was done on a Christ alpha 2-4 LD 
equipped with a vacuubrand RZ 6 rotary vane vacuum pump. Melting points (mp) were 
measured on a BÜCHI 530 electrically heated copper block apparatus (Büchi AG, Flawil, 
Switzerland) using open capillaries and are uncorrected. Compounds were dried under 
reduced pressure (0.1-1 Torr) at room temperature.  
 
Analytical RP-HPLC was performed with a Eurospher-100 C18 column (250 x 4 mm, 5 µm, 
Knauer, Berlin, Germany) on a Merck Hitachi system consisting of a L-6200-A pump, an AS-
2000A auto sampler, a L-4000A UV-VIS detector and a F-1050 fluorescence 
spectrophotometer. UV-detection was done at 220 nm. Mixtures of acetonitrile (A) and 
0.05 % aq. TFA (B) were used as mobile phase. Helium degassing was used throughout. 
Compound purities were calculated as percentage peak area of the analyzed compound by 
UV detection at 220 nm. The applied gradient was: 0 to 30 min (A/B): 20/80 to 80/20 (v/v). 
Purity of the compounds tested for hyaluronidase inhibition was > 95 %. Preparative HPLC 
was performed with a system from Knauer (Berlin, Germany) consisting of two K-1800 
pumps, a K-2001 detector and a RP-column (Nucleodur-100 C18, 250 x 21 mm, Macherey-
Nagel, Düren, Germany) at a flow rate of 16 mL/min. Mixtures of acetonitrile and 0.1 % aq 
TFA were used as mobile phase. Acetonitrile was removed from the eluates under reduced 
pressure prior to lyophilisation.
 
 
Mass spectra (MS) were recorded on a Finnigan MAT 95 (EI-MS 70 eV), Finnigan SSQ 710A 
(CI-MS (NH3)) or a Finnigan ThermoQuest TSQ 7000 (ES-MS). For high resolution mass 
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spectrometry an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent 
Technologies, Santa Clara, CA) equipped with an ESI source or a Finnigan MAT 95 with a 
liquid secondary ionization system (LSI-MS) was used. The peak intensity in percent relative 
to the strongest signals is indicated in parenthesis. 
4.7.2 Chemistry 
4.7.2.1 Preparation of compounds 4.24-4.46 
General procedure17 
The pertinent biphenyl carboxylic acid (1eq) and the pertinent boronic acid (1eq) were 
dissolved in a 1:1:1 mixture of toluene, ethanol and 2M potassium carbonate solution (v/v/v). 
Pd(dppf)Cl2•CH2Cl2 (5 mol%) were added. Subsequently, the reaction mixture was stirred 
under microwave irradiation at 120 °C for 10 min. After cooling to room temperature the 
reaction mixture was taken up in water and washed with ethyl acetate. The resulting water 
phase was acidified to pH 2 with 0.5 N HCl. The precipitated crude product was filtered off, 
dried in vacuo and purified with flash chromatography (DCM/MeOH 100/0-80/20 v/v). 
 
2’,4’-Dichlorobiphenyl-2-carboxylic acid29 (4.24a) 
The title compound was prepared from 2-iodobenzoic acid (248 mg, 1 mmol) and 
2,4-dichlorophenylboronic acid (4.1, 191 mg, 1 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (40 mg, 15 %); mp 160 °C. RP-HPLC (220 nm): 
95.0 % (tR = 25.8 min, k = 10.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.26 (m, 1H, Ph-
H-5‘), 7.31 (d, J 8.2 Hz, 1H, Ph-H-6‘), 7.46 (m, 1H, Ph-H-3‘), 7.54 (m, 1H, Ph-H-4), 7.61-7.69 
(m, 2H, Ph-H-5,6), 7.96 (m, 1H, Ph-H-3), 12.73 (br s, 1H, COOH). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 126.9, 128.1, 128.3, 129.9, 130.8, 130.9, 131.6, 131.8, 132.3, 132.8, 
138.4, 139.6, 167.4. MS (EI-MS, 70 eV) m/z (rel. int. in %) 231.0 ([M+•], 100). HRMS (EI-MS) 
m/z calculated for 265.9901 [M+•], found 265.9902 [M+•]. C13H8Cl2O2 (265.99). 
 
2’,4’-Dichlorobiphenyl-3-carboxylic acid29 (4.24b) 
The title compound was prepared from 3-iodobenzoic acid (248 mg, 1 mmol) and 
2,4-dichlorophenylboronic acid (4.1, 191 mg, 1 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (97.7 mg, 37 %); mp 194 °C. RP-HPLC 
(220 nm): 89.4 % (tR = 25.6 min, k = 10.0). 1H-NMR (300 MHz, [D6]DMSO) : δ (ppm) 7.49 (d, 
J 8.3 Hz, 1H, Ph-H), 7.54 (m, 1H, Ph-H), 7.62 (t, J 7.7 Hz, 1H, Ph-H), 7.69 (m, 1H, Ph-H), 
7.77 (d, J 1.9 Hz, 1H, Ph-H), 7.96 (t, J 1.5 Hz, 1H, Ph-H), 8.00 (m, 1H, Ph-H), 13.15 (br s, 
1H, COOH). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 127.7 (Ph-C), 128.8 (Ph-C), 129.2 (Ph-
C), 129.8 (Ph-C), 130.8 (Ph-C), 132.2 (Ph-C), 132.6 (Ph-C), 133.2 (Ph-C), 133.5 (Ph-C), 
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137.7 (Ph-C), 166.9 (COOH). MS (ES-MS) m/z (rel. int. in %) 310.9 ([M+HCOO-], 100). 
HRMS (ESI) m/z [M+H]+ calculated for C13H9Cl2O2+: 264.9829, found 264.9845. C13H8Cl2O2 
(265.99). 
 
2’,4’-Dichlorobiphenyl-4-carboxylic acid29 (4.24c) 
The title compound was prepared from 4-iodobenzoic acid (248 mg, 1 mmol) and 
2,4-dichlorophenylboronic acid (4.1, 191 mg, 1 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (110 mg, 41 %); mp >210 °C. RP-HPLC 
(220 nm): 100 % (tR = 26.7 min, k = 10.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.48 (d, 
J 8.3 Hz, 1H), 7.51-7.60 (m, 3H), 7.78 (d, J 2.0 Hz, 1H), 8.03 (d, J 8.4 Hz, 2H) 13.09 (br s, 
1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 127.7, 129.2, 129.3, 129.4, 130.2, 132.1, 132.5, 
133.4, 137.8, 141.7, 166.9. MS (EI-MS, 70 eV) m/z (rel. int. in %) 266.0 ([M+•], 100), 249.0 
([M-OH•], 35). HRMS (EI-MS) m/z [M+•] calculated for C13H8Cl2O2•+: 265.9901, found 
265.9898. C13H8Cl2O2 (265.99). 
 
2’,4’-Dichloro-4-hydroxybiphenyl-3-carboxylic acid29 (4.24d) 
The title compound was prepared from 5-iodosalicylic acid (264 mg, 1 mmol) and 
2,4-dichlorophenylboronic acid (4.1, 191 mg, 1 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (30 mg, 10 %); RP-HPLC (220 nm): 94.0 % 
(tR = 26.6 min, k = 10.4). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.05 (d, J 8.6 Hz, 1H, Ph-
H-5), 7.45 (d, J 8.3 Hz, 1H, Ph-H-6‘), 7.50 (m, 1H, Ph-H-5‘), 7.59 (m, 1H, Ph-H-6), 7.73 (d, 
J 2.0 Hz, 1H, Ph-H-3‘), 7.82 (d, J 2.3 Hz, 1H, Ph-H-2). 13C-NMR (75 MHz, [D6]DMSO): 
δ (ppm) 113.0 (Cquat, Ph-C-4), 117.2 (Ph-C-5), 127.8 (Ph-C-5’), 128.4 (Cquat, Ph-C-1), 129.3 
(Ph-C-3’), 130.8 (Ph-C-2), 132.4, (Cquat, Ph-C-2’), 132.7 (Ph-C-6’), 132.8 (Cquat, Ph-C-4’), 
136.4 (Ph-C-6), 137.6 (Cquat, Ph-C-1’), 160.8 (Cquat, Ph-C-3), 171.5 (COOH). MS (ES-MS) 
m/z (rel. int. in %) 564.9 ([2M-H+]-, 100), 326.8 ([M+HCOO-], 35), 280.8 ([M-H+]-, 20). HRMS 
(ESI) m/z [M+H]+ calculated for C13H9Cl2O3+: 280.9778, found 280.9792. C13H8Cl2O3 
(281.99). 
 
1,1’:4’,1’’-Terphenyl-3-carboxylic acid30 (4.25b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
biphenyl-4-boronic acid (4.2, 139 mg, 0.7 mmol) according to the general procedure. Flash 
chromatography yielded a yellow solid (139 mg, 42 %); mp > 210 °C. RP-HPLC (220 nm): 
100 % (tR = 27.7 min, k = 10.9). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.39 (t, J 7.3 Hz, 
1H), 7.49 (t, J 7.5 Hz, 2H), 7.62 (t, J 7.7 Hz, 1H), 7.73 (d, J 7.3 Hz, 2H), 7.80 (s, 4H), 7.92-
8.02 (m, 2H), 8.25 (s, 1H), 13.12 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 126.5, 
127.1, 127.2, 127.2, 127.5, 128.2, 128.9, 129.3, 130.9, 131.5, 138.1, 139.4, 139.5, 139.8, 
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167.1. MS (EI-MS, 70 eV) m/z (rel. int. in %) 274.2 ([M+•], 100). HRMS (EI-MS) m/z [M+•] 
calculated for C19H14O2+•: 274.0994, found 274.0989. C19H14O2 (274.10). 
 
1,1’:4’,1’’-Terphenyl-4-carboxylic acid31 (4.25c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
biphenyl-4-boronic acid (4.2, 139 mg, 0.7 mmol) according to the general procedure. Flash 
chromatography yielded a white solid (80 mg, 42 %); mp > 210 °C RP-HPLC (220 nm): 
96.0 % (tR = 19.0 min, k = 7.1), 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.40 (t, J 7.3 Hz, 1H, 
Ph-H),7.50 (t, J 7.5 Hz, 2H, Ph-H),7.74 (d, J 7.2 Hz, 2H, Ph-H), 7.78-7.91 (m, 6H, Ph-H), 
8.04 (d, J 8.4 Hz, 2H, Ph-H), 12.99 (br s, 1H, COOH). 13C-NMR (75 MHz, [D6]DMSO): δ 
(ppm) 126.5 (2C, Ph-C), 127.2 (2C, Ph-C), 127.4 (Ph-C), 127.6 (Ph-C), 128.9 (2C, Ph-C), 
129.9 (2C, Ph-C), 137.8 (Ph-C), 139.3 (Ph-C), 139.8 (Ph-C), 143.6 (Ph-C), 167.0 (COOH). 
MS (EI-MS, 70 eV) m/z (rel. int. in %) 274.1 ([M+•], 100). HRMS (EI-MS) m/z [M+H]+ 
calculated for C19H15O2+: 274.0994, found 274.0987. C19H14O2 (274.10). 
 
4-Hydroxy-1,1’:4’,1’’-terphenyl-3-carboxylic acid (4.25d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
biphenyl-4-boronic acid (4.2, 297 mg, 1.5 mmol) according to the general procedure. Flash 
chromatography yielded a white solid (44 mg, 10 %); RP-HPLC (220 nm): 100 % 
(tR = 28.5 min, k = 11.2). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.08 (d, J 8.6 Hz, 1H), 7.37 
(t, J 7.3 Hz, 1H), 7.48 (t, J 7.5 Hz, 2H), 7.66-7.79 (m, 6H), 7.89 (m, 1H), 8.10 (d, J 2.4 Hz, 
1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.3, 117.8, 126.4, 126.6, 127.1, 127.4, 127.7, 
128.9, 130.6, 133.7, 137.9, 138.7, 139.5, 160.6, 171.7. MS (ES-MS) m/z (rel. int. in %) 579.1 
([2M-H+]-, 25), 335.0 ([M+HCOO-], 100), 288.9 ([M-H+]-, 90). HRMS (ESI) m/z [M-H+]- 
calculated for C19H13O3-: 290.0947, found 289.0875. C19H14O3 (290.09). 
 
4’-Chlorobiphenyl-2-carboxylic acid32 (4.26a) 
The title compound was prepared from 2-iodobenzoic acid (174 mg, 0.7 mmol) and 
4-chlorophenylboronic acid (4.3, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (27 mg, 11 %); mp 142 °C (ref.:32 165.5-166 °C). 
RP-HPLC (220 nm): 100 % (tR = 23.7 min, k = 9.2). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.35 (t, J 10.7 Hz, 3H), 7.43-7.53 (m, 3H), 7.58 (t, J 7.8 Hz, 1H), 7.77 (d, J 7.4 Hz, 1H), 12.85 
(br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 127.6, 127.9, 129.3, 130.1, 130.3, 131.0, 
131.8, 132.0, 139.7, 139.8. MS (EI-MS, 70 eV) m/z (rel. int. in %) 232.1 ([M+•], 100), 215.0 
([M-OH•], 60). HRMS (ESI) m/z [M-H+]- calculated for C13H8ClO2-: 232.0252, found 232.0254. 
C13H9ClO2 (232.03). 
78 Experimental section 
 
4’-Chlorobiphenyl-3-carboxylic acid33 (4.26b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
4-chlorophenylboronic acid (4.3, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a yellow solid (28 mg, 18 %); mp 187-189 °C (ref.:33 248 °C). 
RP-HPLC (220 nm): 100 % (tR = 25.9 min, k = 10.1). 1H-NMR (300 MHz, [D6]DMSO): 
δ (ppm) 7.50-7.65 (m, 3H), 7.70-7.78 (m, 2H), 7.87-8.00 (m, 2H), 8.17 (t, J 1.7 Hz, 1H), 13.14 
(br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 127.2, 128.5, 128.5, 128.9, 129.3, 131.0, 
131.5, 132.7, 138.0, 139.1, 167.0. MS (ES-MS) m/z (rel. int. in %) 231.0223 ([M-H]-). HRMS 
(ESI) m/z [M-H+]- calculated for C13H8ClO2-: 231.0218, found 231.0223. C13H9ClO2 (232.03). 
 
4’-Chlorobiphenyl-4-carboxylic acid33 (4.26c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
4-chlorophenylboronic acid (4.3, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a yellow solid (46 mg, 28 %); mp > 210 °C (ref.:33 
290-291 °C). RP-HPLC (220 nm): 100 % (tR = 25.1 min, k = 9.8). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 7.55 (d, J 8.5 Hz, 2H), 7.79 (m, 4H), 8.02 (d, J 8.3 Hz, 2H), 13.02 (br s, 
1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 126.7, 128.7, 128.9, 129.8, 129.9, 133.1, 137.7, 
142.8, 166.9. MS (ES-MS) m/z (rel. int. in %) 231.0222 ([M-H]-). HRMS (ESI) m/z [M-H+]- 
calculated for C13H8ClO2-: 231.0218, found 231.0221. C13H9ClO2 (232.03). 
 
4’-Chloro-4-hydroxybiphenyl-3-carboxylic acid34 (4.26d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
4-chlorophenylboronic acid (4.3, 235 mg, 1.5 mmol) according to the general procedure. 
Flash chromatography yielded a yellow solid (75 mg, 20 %); mp 169 °C. RP-HPLC (220 nm): 
100 % (tR = 26.6 min, k = 10.4). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.06 (d, J 8.6 Hz, 
1H), 7.48 (d, J 8.6 Hz, 2H), 7.65 (d, J 8.6 Hz, 2H), 7.83 (m, 1H), 8.03 (d, J 2.4 Hz, 1H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.3, 117.8, 127.8, 128.8, 129.8, 131.8, 133.7, 
137.7, 160.7, 171.6. MS (ES-MS) m/z (rel. int. in %) 495.0 ([2M-H+]-, 100), 361.0 
([M+CF3COO-], 20) 292.9 ([M+HCOO-], 30), 246.9 ([M-H+]-, 15). HRMS (ESI) m/z [M-H+]- 
calculated for C13H8ClO3-: 248.0201, found 248.0206. C13H9ClO3 (248.02). 
 
2’,4’-Bis(trifluoromethyl)biphenyl-3-carboxylic acid (4.27b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
2,4-bis(trifluoromethyl)phenylboronic acid (4.4, 180 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (80 mg, 34 %); mp 170 °C. RP-
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HPLC (220 nm): 100 % (tR = 27.2 min, k = 10.7). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.63 (d, J 4.6 Hz, 2H, Ph-H-), 7.72 (d, J 7.8 Hz, 1H, Ph-H-), 7.90 (s, 1H, Ph-H-2), 8.01-8.09 
(m, 1H, Ph-H-4), 8.15 (d, J 8.9 Hz, 2H, Ph-H-) 13.20 (br s, 1H, COOH). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 122.4 (q, J 28.08 Hz, CF3), 123.2 (m, Ph-C-3‘), 124.2 (q, J 26.12 Hz, 
CF3), 128.0 (q, J 30.04 Hz, Cquat, Ph-C-CF3), 129.9 (q, J 33.46 Hz, Cquat, Ph-C-CF3), 128.6 
(Ph-C-5), 129.1 (Ph-C-2), 129.3 (2C, Ph-C-4,5‘), 130.6 (Cquat, Ph-C-3), 132.9 (Ph-C-6), 133.6 
(Ph-C-6‘), 138.0 (Cquat, Ph-C-1), 143.9 (Cquat, Ph-C-1‘), 166.8 (Cquat, COOH). MS (EI-MS, 
70 eV) m/z (rel. int. in %) 334.1 ([M+•], 100), 317.0 ([M-OH•], 50). HRMS (ESI) m/z [M-H+]- 
calculated for C15H7F6O2-: 333.0356, found 333.0353. C15H8F6O2 (334.04). 
 
2’,4’-Bis(trifluoromethyl)biphenyl-4-carboxylic acid (4.27c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
2,4-bis(trifluoromethyl)phenylboronic acid (4.4, 180 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (150 mg, 64 %); mp 175-178 °C. 
RP-HPLC (220 nm): 100 % (tR = 27.5 min, k = 10.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.50 (d, J 8.1 Hz, 2H), 7.71 (d, J 7.9 Hz, 2H), 8.04 (d, J 8.4 Hz, 1H), 8.16 (d, J 8.6 Hz, 2H) 
13.15 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 122.0, 123.6, 125.5, 125.6, 128.1, 
128.6, 129.4, 129.5 (2 interfering carbon signals), 129.8, 131.2, 133.8, 142.6, 144.4, 167.6. 
MS (EI-MS, 70 eV) m/z (rel. int. in %) 334.1 ([M+•], 100), 317.0 ([M-OH•], 75). HRMS (ESI) 
m/z [M-H+]- calculated for C15H7F6O2-: 333.0356, found 333.0360. C15H8F6O2 (334.04). 
 
2’-Chloro-4’-(trifluoromethyl)biphenyl-3-carboxylic acid (4.28b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 2-chloro-
4-(trifluoromethyl)phenylboronic acid (4.5, 157 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (98 mg, 57 %); mp 150 °C. 
RP-HPLC (220 nm): 100 % (tR = 27.2 min, k = 10.7). 1H-NMR (300 MHz, [D6]DMSO): 
δ (ppm) 7.65 (t, J 7.7 Hz, 1H), 7.70 (d, J 8.0 Hz, 1H), 7.72-7.76 (m, 1H), 7.82 (m, 1H), 7.98-
8.07 (m, 3H), 13.19 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 124.3, 126.6, 128.8, 
129.2, 129.6, 129.7, 130.0, 130.9, 132.2, 132.4, 133.4, 137.5, 142.9, 166.8. MS (EI-MS, 
70 eV) m/z (rel. int. in %) 300.1 ([M+•], 100). HRMS (ESI) m/z [M-H+]- calculated for 
C14H7ClF3O2-: 299.0092, found 299.0086. C14H8ClF3O2 (300.02). 
 
2’-Chloro-4’-(trifluoromethyl)biphenyl-4-carboxylic acid (4.28c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 2-chloro-
4-(trifluoromethyl)phenylboronic acid (4.5, 157 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (73 mg, 43 %); mp 210 °C. 
RP-HPLC (220 nm): 100 % (tR = 27.7 min, k = 10.9). 1H-NMR (300 MHz, [D6]DMSO): 
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δ (ppm) 7.61 (d, J 8.4 Hz, 2H), 7.69 (d, J 8.0 Hz, 1H), 7.83 (m, 1H), 7.99-8.10 (m, 3H), 13.13 
(br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 124.3, 126.7, 129.2, 129.4, 129.7, 130.2, 
130.6, 132.1, 132.3, 141.5, 142.9, 166.8. MS (EI-MS, 70 eV) m/z (rel. int. in %) 300.1 ([M+•], 
100). HRMS (ESI) m/z [M-H+]- calculated for C14H7ClF3O2-: 299.0092, found 299.0086. 
C14H8ClF3O2 (300.02). 
 
2’-Chloro-4-hydroxy-4’-(trifluoromethyl)biphenyl-3-carboxylic acid (4.28d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 2-chloro-
4-(trifluoromethyl)phenylboronic acid (4.5, 337 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (240 mg, 50 %); mp 185 °C. 
RP-HPLC (220 nm): 100 % (tR = 28.1 min, k = 11.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.09 (d, J 8.7 Hz, 1H, Ph-H-5), 7.64-7.67 (m, 2H, Ph-H-6,6’), 7.77-7.80 (m, 1H, Ph-H-5’), 
7.88 (d, J 2.4 Hz, 1H, Ph-H-2), 7.97 (d, J 1.2 Hz, 1H, Ph-H-3’), 11.52 (br s, 1H, COOH). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.0 (Cquat, Ph-C-3), 117.3 (Ph-C-5), 122.5 (CF3), 
124.4 (Ph-C-5’), 126.7 (Ph-C-3’), 128.1 (Cquat, Ph-C-1), 130.9 (Ph-C-2), 132.3 (Ph-C-6’), 
132.4 (Cquat, Ph-C-4’), 136.3 (Ph-C-6), 142.7 (Cquat, Ph-C-1’), 161.1 (Cquat, Ph-C-4), 171.4 
(COOH). MS (ES-MS) m/z (rel. int. in %) 630.9 ([2M-H]-, 100), 360.9 ([M+HCOO-], 15), 314.9 
([M-H]-, 25). HRMS (ESI) m/z [M-H+]- calculated for C14H7ClF3O3-: 315.0041, found 315.0047. 
C14H8ClF3O3 (316.01). 
 
2’-Chlorobiphenyl-3-carboxylic acid35 (4.29b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
2-chlorophenylboronic acid (4.6, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a yellow solid (121 mg, 61 %); mp 196 °C (ref.:35 185-187 °C). 
RP-HPLC (220 nm): 100 % (tR = 22.1 min, k = 8.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.38-7.48 (m, 3H), 7.55-7.65 (m, 2H), 7.69 (m, 1H), 7.93-8.03 (m, 2H), 13.12 (br s, 1H). 13C-
NMR (75 MHz, [D6]DMSO): δ (ppm) 127.6, 128.5, 128.6, 129.5, 129.8, 130.7, 131.1, 131.4, 
133.5, 138.7, 138.8, 166.9. MS (EI-MS, 70 eV) m/z (rel. int. in %) 232.1 ([M+•], 100). HRMS 
(ESI) m/z [M+H]+ calculated for C13H10ClO2+: 232.0291, found 233.0091. C13H9ClO2 (232.03). 
 
2’-Chloro-4-hydroxybiphenyl-3-carboxylic acid (4.29d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
2-chlorophenylboronic acid (4.6, 235 mg, 1.5 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (273 mg, 64 %); mp 188 °C. RP-HPLC (220 nm): 
100 % (tR = 25.2 min, k = 9.8). 1H-NMR (300 MHz, [D6]DMSO): δ(ppm) 7.05 (d, J 8.6 Hz, 
1H), 7.33-7.46 (m, 3H), 7.51-7.64 (m, 2H), 7.83 (d, J 2.1 Hz, 1H). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 112.7, 117.0, 127.5, 129.1, 129.5, 129.8, 130.7, 131.2, 131.3, 136.4, 
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138.4, 160.5, 171.5. MS (ES-MS) m/z (rel. int. in %) 247.0175 ([M-H]-). HRMS (ESI) m/z [M-
H+]- calculated for C13H8ClO3-: 248.0201, found 248.0206. C13H9ClO3 (248.02). 
 
3’,5’-Bis(trifluoromethyl)biphenyl-3-carboxylic acid36 (4.30b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
3,5-bis(trifluoromethyl)phenylboronic acid (4.7, 180 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (35 mg, 15 %); mp 198 °C 
(ref.:36 205-207 °C). RP-HPLC (220 nm): 100 % (tR = 27.9 min, k = 11.0). 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 7.64 (t, J 7.8 Hz, 1H), 7.90-8.02 (m, 2H), 8.11 (d, J 7.8 Hz, 1H), 8.21 (s, 
2H), 8.31 (br s, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 123.1, 126.7, 128.6, 129.4, 
130.7, 131.2, 132.8, 133.3, 133.7, 139.6, 144.1, 169.3. MS (EI-MS, 70 eV) m/z (rel. int. in %) 
334.0 ([M+•], 100), 317.0 (50), 289.1 (10), 269.0 (35), 220.1 (20), 201.0 (10), 170.1 (5), 149.1 
(10), 133.6 (5), 125.1 (10), 109.8 (5), 75.1 (5), 51.1 (5). HRMS (ESI) m/z [M-H+]- calculated 
for C15H7F6O2-: 334.0389, found 334.0385. C15H8F6O2 (334.04). 
 
3’,5’-Bis(trifluoromethyl)biphenyl-4-carboxylic acid37 (4.30c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
3,5-bis(trifluoromethyl)phenylboronic acid (4.7, 181 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (121 mg, 52 %); mp 204 °C. RP-
HPLC (220 nm): 98 % (tR = 27.0 min, k = 10.6). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 7.83 
(d, J 8.5 Hz, 2H), 8.00 (s, 1H), 8.16 (d, J 8.6 Hz, 2H), 8.24 (s, 2H). 13C-NMR (75 MHz, 
[D4]MeOH): δ (ppm) 122.6, 123.1, 126.7, 128.6, 128.8, 131.8, 132.4, 133.3, 143.5, 144.0, 
169.2. MS (EI-MS, 70 eV) m/z (rel. int. in %) 334.0 ([M+•], 100), 317.0 ([M-OH•], 60), 315.0 
([M-F•]+, 15). HRMS (ESI) m/z [M-H+]- calculated for C15H7F6O2-: 334.0389, found 334.0386. 
C15H8F6O2 (334.04). 
 
4-Hydroxy-3’,5’-bis(trifluoromethyl)biphenyl-3-carboxylic acid (4.30d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
3,5-bis(trifluoromethyl)phenylboronic acid (4.7, 386 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (204 mg, 39 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 29.2 min, k = 11.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.65 (t, J 1.9 Hz, 1H), 7.80 (d, J 1.9 Hz, 2H), 7.87 (d, J 8.5 Hz, 2H), 8.02 (d, J 8.5 Hz, 2H), 
13.08 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 125.6, 127.2, 127.5, 129.8, 130.5, 
134.7, 141.2, 142.4, 166.7. MS (EI-MS, 70 eV) m/z (rel. int. in %) 266.0 ([M+•], 100), 249.0 
([M-CH3•], 45). HRMS (ESI) m/z [M-H+]- calculated for C13H7Cl2O2-: 267.9834, found 
267.9835. C13H8Cl2O2 (265.99). 
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3’-Chlorobiphenyl-3-carboxylic acid35 (4.31b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
3-chlorophenylboronic acid (4.8, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (90 mg, 55 %); mp 185 °C (ref.:35 178-180 °C). 
RP-HPLC (220 nm): 100 % (tR = 25.6 min, k = 10.0). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.48 (m, 2H), 7.56-7.71 (m, 2H), 7.76 (t, J 1.7 Hz, 1H), 7.89-8.02 (m, 2H), 8.18 (t, J 1.6 Hz, 
1H), 13.16 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 125.5, 126.5, 127.4, 127.6, 
128.8, 129.3, 130.8, 131.2, 131.5, 133.8, 138.9, 141.3, 167.0. MS (EI-MS, 70 eV) m/z (rel. 
int. in %) 232.1 ([M+•], 100). HRMS (ESI) m/z [M-H+]- calculated for C13H8ClO2-: 232.0252, 
found 232.0254. C13H9ClO2 (232.03). 
 
3’-Chlorobiphenyl-4-carboxylic acid38 (4.31c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
3-chlorophenylboronic acid (4.8, 110 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (120 mg, 68 %); mp > 210 °C 
(ref.:38 249-250 °C). RP-HPLC (220 nm): 100 % (tR = 24.5 min, k = 9.5). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 7.42-7.58 (m, 2H), 7.71 (d, J 7.2 Hz, 1H), 7.75-7.88 (m, 3H), 8.02 (d, 
J 8.2 Hz, 2H), 13.06 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 125.6, 126.6, 126.9, 
128.0, 129.9, 130.1, 130.8, 133.8, 141.1, 142.6, 166.9. MS (EI-MS, 70 eV) m/z (rel. int. in %) 
232.0 ([M+•], 100). HRMS (ESI) m/z [M-H+]- calculated for C13H8ClO2-: 232.0252, found 
232.0247. C13H9ClO2 (232.03). 
 
3’-Chloro-5’-methoxybiphenyl-3-carboxylic acid (4.32b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 3-chloro-
5-methyoxyphenylboronic acid (4.9, 131 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (70 mg, 28 %); mp 191-193 °C. RP-HPLC 
(220 nm): 100 % (tR = 26.1 min, k = 10.2). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.07 (t, 
J 2.0 Hz, 1H), 7.16-7.22 (m, 1H), 7.31 (t, J 1.6 Hz, 1H), 7.60 (t, J 7.8 Hz, 1H), 7.96 (t, 
J 6.7 Hz, 2H), 8.16 (t, J 1.6 Hz, 1H), 13.15 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): 
δ (ppm) 55.7, 111.5, 113.4, 118.8, 127.4, 128.9, 129.3, 131.3, 131.4, 134.4, 138.9, 142.2, 
160.5, 167.0. MS (EI-MS, 70 eV) m/z (rel. int. in %) 262.0 ([M+•], 100). HRMS (ESI) m/z [M-
H+]- calculated for C14H10ClO3-: 262.0358, found 262.0356. C14H11ClO3 (262.04). 
 
  
 Diflunisal analogs as inhibitors of bacterial hyaluronidase 83 
3’-Chloro-5’-methoxybiphenyl-4-carboxylic acid (4.32c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 3-chloro-
5-methyoxyphenylboronic acid (4.9, 131 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white, crystalline solid (40 mg, 22 %); mp 194-197 °C. RP-
HPLC (220 nm): 100 % (tR = 26.6 min, k = 10.4). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.06-7.11 (m, 1H), 7.21-7.26 (m, 1H), 7.36 (t, J 1.7 Hz, 1H), 7.83 (d, J 8.5 Hz, 2H), 8.01 (d, 
J 8.5 Hz, 2H), 13.06 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 55.7, 111.6, 113.7, 
118.9, 127.0, 129.8, 130.2, 134.4, 141.8, 142.6, 160.5, 166.9. MS (EI-MS, 70 eV) m/z (rel. 
int. in %) 262.1 ([M+•], 100). HRMS (ESI) m/z [M-H+]- calculated for C14H10ClO3-: 262.0358, 
found 262.0354. C14H11ClO3 (262.04). 
 
3’-Chloro-4-hydroxy-5’-methoxybiphenyl-3-carboxylic acid (4.32d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 3-chloro-
5-methyoxyphenylboronic acid (4.9, 279 mg, 1.5 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (94 mg, 22 %); mp 206-207 °C. RP-HPLC 
(220 nm): 100 % (tR = 26.8 min, k = 10.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 3.83 (s, 
3H), 6.99 (t, J 2.0 Hz, 1H), 7.05 (d, J 8.6 Hz, 1H), 7.08-7.13 (m, 1H), 7.22 (t, J 1.6 Hz, 1H), 
7.85 (m, 1H), 8.02 (d, J 2.4 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 55.6, 110.8, 
112.5, 113.3, 117.7, 118.2, 128.2, 129.6, 134.0, 134.3, 141.9, 160.5, 161.0, 171.6. MS (ES-
MS) m/z (rel. int. in %) 555.0 ([2M-H+]-, 100), 390.9 ([M+CF3COO-], 20), 323.0 ([M+HCOO-], 
35), 276.9 ([M-H+]-, 20). HRMS (ESI) m/z [M-H+]- calculated for C14H10ClO4-: 278.0307, found 
278.0304. C14H11ClO4 (278.03). 
 
3’,5’-Dichlorobiphenyl-4-carboxylic acid (4.33c) 
The title compound was prepared from 4-iodobenzoic acid (129 mg, 0.52 mmol) and 
3,5-dichlorophenylboronic acid (4.10, 100 mg, 0.52 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (94 mg, 67 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 29.2 min, k = 11.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.66 (t, J 3.7 Hz, 1H, Ph-H-4’), 7.81 (d, J 1.8 Hz, 2H, Ph-H-2’,6’), 7.88 (d, J 8.7 Hz, 2H, Ph-H-
2,6), 8.02 (d, J 8.6 Hz, 2H, Ph-H-3,5), 13.08 (br s, 1H, COOH). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 125.6 (2C, Ph-C-2’,6’), 127.2 (2C, Ph-C-2,6), 127.5 (Ph-C-4’), 129.8 
(2C, Ph-C-3,5), 130.6 (Cquat, Ph-C-1’), 134.7 (2C, Cquat, Ph-C-3’,5’), 141.1 (Cquat, Ph-C-1), 
142.4 (Cquat, Ph-C-4), 166.7 (Cquat, COOH). MS (EI-MS, 70 eV) m/z (rel. int. in %) 266.0 
([M+•], 100), 249.0 ([M-CH3•], 45). HRMS (ESI) m/z [M-H+]- calculated for C13H7Cl2O2-: 
267.9834, found 267.9835. C13H8Cl2O2 (265.99). 
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3’,5’-Dichloro-4-hydroxybiphenyl-3-carboxylic acid29 (4.33d) 
The title compound was prepared from 5-iodosalicylic acid (347 mg, 1.3 mmol) and 
3,5-dichlorophenylboronic acid (4.10, 251 mg, 1.3 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (177 mg, 48 %); mp > 210 °C. RP-HPLC 
(220 nm): 100 % (tR = 29.3 min, k = 11.6). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.06 (d, 
J 8.7 Hz, 1H), 7.55 (t, J 1.8 Hz, 1H), 7.68 (d, J 1.9 Hz, 2H), 7.90 (m, 1H), 8.06 (d, J 2.5 Hz, 
1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.5, 117.9, 124.8, 126.3, 128.2, 128.5, 134.1, 
134.6, 142.5, 161.3, 171.5. MS (ES-MS) m/z (rel. int. in %) 564.9 ([2M-H+]-, 100), 394.9 
([M+CF3COO-], 10), 326.9 ([M+HCOO-], 20), 280.9 ([M-H+]-, 30). HRMS (ESI) m/z [M-H+]- 
calculated for C13H7Cl2O3-: 281.9812, found 281.9806. C13H8Cl2O3 (281.99). 
 
1,1’:3’,1’’-Terphenyl-3-carboxylic acid (4.34b) 
The title compound was prepared from 3-iodobenzoic acid (173 mg, 0.7 mmol) and 
biphenyl-3-boronic acid (4.11, 138 mg, 0.7 mmol) according to the general procedure. Flash 
chromatography yielded a white solid (137 mg, 71 %); mp 172-175 °C. RP-HPLC (220 nm): 
100 % (tR = 27.0 min, k = 10.6). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.39 (t, J 7.3 Hz, 
1H), 7.49 (t, J 7.4 Hz, 2H), 7.54-7.73 (m, 5H), 7.77 (d, J 7.3 Hz, 2H), 7.92 (s, 1H), 8.00 (m, 
2H), 8.26 (s, 1H), 13.14 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 125.1, 125.9, 
126.2, 126.9, 127.4, 127.5, 128.3, 128.9, 129.2, 129.6, 131.3, 131.4, 139.89, 139.93, 140.4, 
141.0, 167.2. MS (EI-MS, 70 eV) m/z (rel. int. in %) 274.3 ([M+•], 100), 257.2 ([M-OH•], 5). 
HRMS (EI-MS) m/z [M+•] calculated for C19H14O2+•: 274.0993, found 274.0991. C19H14O2 
(274.10). 
 
1,1’:3’,1’’-Terphenyl-4-carboxylic acid38,39 (4.34c) 
The title compound was prepared from 4-iodobenzoic acid (173 mg, 0.7 mmol) and 
biphenyl-3-boronic acid (4.11, 138 mg, 0.7 mmol) according to the general procedure. Flash 
chromatography yielded a white solid (37 mg, 19 %; mp ref.:39 221 °C). RP-HPLC (220 nm): 
96 % (tR = 27.5 min, k = 10.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.08 (d, J 8.6 Hz, 
1H), 7.34-7.66 (m, 7H), 7.75 (d, J 7.3 Hz, 2H), 7.84 (s, 1H), 7.94 (m, 1H), 8.11 (d, J 2.4 Hz, 
1H). 13C-NMR (75 MHz, DMSO): δ (ppm) 113.4, 117.7, 124.5, 125.3, 125.4, 126.9, 127.5, 
128.1, 128.8, 129.5, 131.1, 134.1, 139.7, 140.0, 140.9, 160.6, 171.7. HRMS (ESI) m/z [M-
H+]- calculated for C19H13O2-: 273.0916, found 273.0915. C19H14O2 (274.10). 
 
4-Hydroxy-1,1’:3’,1’’-terphenyl-3-carboxylic acid (4.34d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
biphenyl-3-boronic acid (4.11, 297 mg, 1.5 mmol) according to the general procedure. Flash 
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chromatography yielded a yellow solid (84 mg, 19 %); mp > 210 °C. RP-HPLC (220 nm): 
100 % (tR = 27.5 min, k = 10.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.40 (t, J 7.3 Hz, 
1H), 7.50 (t, J 7.4 Hz, 2H), 7.59 (t, J 7.7 Hz, 1H), 7.67-7.75 (m, 2H), 7.78 (d, J 7.3 Hz, 2H), 
7.91 (d, J 8.4 Hz, 2H), 7.97 (s, 1H), 8.05 (d, J 8.4 Hz, 2H), 13.01 (br s, 1H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 125.3, 126.0, 126.6, 126.9 (2 interfering carbon signals), 
127.0 (2 interfering carbon signals), 127.6, 128.9 (2 interfering carbon signals), 129.6, 129.7, 
129.8 (2 interfering carbon signals), 139.6, 139.8, 141.0, 144.2, 167.1. HRMS (ESI) m/z [M-
H+]- calculated for C19H13O3-: 289.0870, found 289.0871. C19H14O3 (290.09). 
 
3’-Chloro-4’-fluorobiphenyl-3-carboxylic acid (4.35b) 
The title compound was prepared from 3-iodobenzoic acid (173 mg, 0.7 mmol) and 3-chloro-
4-fluorophenylboronic acid (4.12, 122 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white, crystalline solid (57 mg, 32 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 25.9 min, k = 10.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.52 (t, J 9.0 Hz, 1H), 7.60 (t, J 7.7 Hz, 1H), 7.73 (m, 1H), 8.00-7.90 (m, 3H), 8.17 (s, 1H), 
13.15 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 117.2, 117.5, 120.0, 120.2, 127.4, 
127.5, 128.8, 129.3, 131.2, 131.5, 155.3, 158.6, 167.0. MS (ES-MS) m/z (rel. int. in %) 498.9 
([2M-H+]-, 30), 294.9 ([M+HCOO-], 100), 248.9 ([M-H+]-, 5). HRMS (ESI) m/z [M-H+]- 
calculated for C13H7ClFO2-: 250.0158, found 250.015. C13H8ClFO2 (250.02). 
 
3’-Chloro-4’-fluorobiphenyl-4-carboxylic acid40 (4.35c) 
The title compound was prepared from 4-iodobenzoic acid (173 mg, 0.7 mmol) and 3-chloro-
4-fluorophenylboronic acid (4.12, 122 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a grey solid (122 mg, 69 %); mp > 210 °C. RP-HPLC 
(220 nm): 100 % (tR = 26.3 min, k = 10.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.53 (t, 
J 9.0 Hz, 1H), 7.76 (m, 1H), 7.82 (d, J 8.5 Hz, 2H), 7.93-8.05 (m, 3H), 13.05 (br s, 1H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 117.2, 117.5, 120.0, 126.9, 127.6, 128.9, 129.8, 
130.0, 136.8, 141.7, 166.9. MS (ES-MS) m/z (rel. int. in %) 498.9 ([2M-H+]-, 5), 294.9 
([M+HCOO-], 100), 248.9 ([M-H+]-, 5). HRMS (ESI) m/z [M-H+]- calculated for C13H7ClFO2-: 
250.0158, found 250.0158. C13H8ClFO2 (250.02). 
 
3’-Chlorobiphenyl-3,4’-dicarboxylic acid (4.36b) 
The title compound was prepared from 3-iodobenzoic acid (173 mg, 0.7 mmol) and 
4-borono-2-chlorobenzoic acid (4.13, 140 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (105 mg, 54 %); RP-HPLC (220 nm): 98 % 
(tR = 19.3 min, k = 7.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.64 (t, J 7.8 Hz, 1H), 7.77 
(m, 1H), 7.90 (m, 2H), 8.01 (m, 2H), 8.23 (s, 1H), 13.32 (br s, 1H). 13C-NMR (75 MHz, 
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[D6]DMSO): δ (ppm) 125.5, 127.5, 128.6, 129.3, 129.4, 130.1, 131.4, 131.57, 131.63, 132.6, 
137.9, 143.2, 166.3, 166.9. MS (ES-MS) m/z (rel. int. in %) 596.9 ([2M+HCOO-], 70), 551.1 
([2M-H], 30), 366.9 ([M+HCOO-+HCOOH], 100), 320.9 ([M-H+]-, 65). HRMS (ESI) m/z [M-H+]- 
calculated for C14H8ClO4-: 276.015, found 276.0147. C14H9ClO4 (276.02). 
 
5’-tert-Butyl-2’-methoxybiphenyl-3-carboxylic acid (4.37b) 
The title compound was prepared from 3-iodobenzoic acid (89 mg, 0.36 mmol) and 
5-tert-butyl-2-methoxyphenylboronic acid (4.14, 75 mg, 0.36 mmol) according to the general 
procedure. Flash chromatography yielded a brown solid (32 mg, 31 %); mp 118-128 °C. RP-
HPLC (220 nm): 100 % (tR = 26.7 min, k = 10.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
1.30 (s, 9H), 3.74 (s, 3H), 7.05 (d, J 8.7 Hz, 1H), 7.27 (d, J 2.5 Hz, 1H), 7.38 (m, 1H), 7.53 (t, 
J 7.7 Hz, 1H), 7.71 (d, J 7.9 Hz, 1H), 7.89 (d, J 7.8 Hz, 1H), 8.02 (s, 1H), 12.98 (br s, 1H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 31.2, 33.7, 55.5, 111.4, 125.8, 127.1, 127.5, 128.1, 
128.2, 129.9, 130.4, 133.7, 138.8, 142.9, 153.8, 167.3. MS (ES-MS) m/z (rel. int. in %) 
283.1339 ([M-H+]-). HRMS (ESI) m/z [M-H+]- calculated for C18H19O3-: 284.1374, found 
284.1373. C18H20O3 (284.14). 
 
5’-tert-Butyl-2’-methoxybiphenyl-4-carboxylic acid (4.37c) 
The title compound was prepared from 4-iodobenzoic acid (89 mg, 0.36 mmol) and 
5-tert-butyl-2-methoxyphenylboronic acid (4.14, 75 mg, 0.36 mmol) according to the general 
procedure. Flash chromatography yielded a brown solid (90 mg, 88 %); mp 146-157 °C. RP-
HPLC (220 nm): 100 % (tR = 27.2 min, k = 10.7). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
1.29 (s, 9H), 3.75 (s, 3H), 7.06 (d, J 8.7 Hz, 1H), 7.30 (d, J 2.5 Hz, 1H), 7.39 (m, 1H), 7.60 (d, 
J 8.3 Hz, 2H), 7.97 (d, J 8.3 Hz, 2H), 12.89 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ 
(ppm) 31.2, 33.7, 55.5, 111.4, 126.1, 127.1, 128.0, 128.8, 128.9, 129.4, 142.9, 143.0, 153.9, 
167.1. MS (ES-MS) m/z (rel. int. in %) 567.2 ([2M-H+]-, 100), 382.9 ([M+HCOO-], 80), 329.0 
([M-H+]-, 30). HRMS (ESI) m/z [M-H+]- calculated for C18H19O3-: 284.1413, found 284.1341. 
C18H20O3 (284.14). 
 
5’-tert-Butyl-4-hydroxy-2’-methoxybiphenyl-3-carboxylic acid (4.37d) 
The title compound was prepared from 5-iodosalicylic acid (126 mg, 0.48 mmol) and 
5-tert-butyl-2-methoxyphenylboronic acid (4.14, 100 mg, 0.48 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (61 mg, 42 %); mp 140-150 °C. RP-
HPLC (220 nm): 100 % (tR = 27.2 min, k = 10.7). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
1.28 (s, 9H), 3.73 (s, 3H), 7.00 (m, 2H), 7.23 (d, J 2.5 Hz, 1H), 7.32 (m, 1H), 7.62 (m, 1H), 
7.87 (d, J 2.3 Hz, 1H), 11.26 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 31.2 (3 
interfering carbon signals), 33.7, 55.5, 111.3, 112.4, 116.7, 125.2, 126.8, 127.8, 129.4, 
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130.5, 136.6, 142.8, 153.8, 159.9, 171.8. MS (ES-MS) m/z (rel. int. in %) 599.2 ([2M-H+]-, 
60), 345.0 ([M+HCOO-], 100), 299.0 ([M-H+]-, 30). HRMS (ESI) m/z [M-H+]- calculated for 
C18H19O4-: 300.1363, found 299.1290. C18H20O4 (300.14). 
 
4’-Cyano-3’-fluorobiphenyl-3-carboxylic acid (4.38b) 
The title compound was prepared from 3-iodobenzoic acid (173 mg, 0.7 mmol) and 4-cyano-
3-fluorophenylboronic acid (4.15, 115 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a white solid (111 mg, 66 %); mp 185-190 °C. RP-HPLC 
(220 nm): 100 % (tR = 20.4 min, k = 7.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.65 (t, 
J 7.8 Hz, 1H), 7.78 (m, 1H), 7.89-8.07 (m, 4H), 8.26 (s, 1H), 13.24 (br s, 1H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 98.9, 113.9, 114.5, 114.8, 123.7, 127.8, 129.5, 131.5, 134.3, 
137.4, 146.6, 161.1, 164.5, 166.8. MS (ES-MS) m/z (rel. int. in %) 480.9 ([2M-H+]-, 100), 
285.8 ([M+HCOO-], 30). HRMS (ESI) m/z [M-H+]- calculated for C14H7FNO2-: 241.0499, found 
241.0497. C14H8FNO2 (241.05). 
 
4’-Cyano-3’-fluorobiphenyl-4-carboxylic acid (4.38c) 
The title compound was prepared from 4-iodobenzoic acid (173 mg, 0.7 mmol) and 4-cyano-
3-fluorophenylboronic acid (4.15, 115 mg, 0.7 mmol) according to the general procedure. 
Flash chromatography yielded a grey solid (54 mg, 32 %); mp > 210 °C. RP-HPLC (220 nm): 
100 % (tR = 20.7 min, k = 7.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.81 (m, 1H), 7.95 
(m, 3H), 8.04 (t, J 7.6 Hz, 3H), 13.15 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
99.3, 113.9, 114.6, 114.9, 123.9, 127.5, 129.9, 131.2, 134.3, 140.9, 146.4, 161.1, 164.5. MS 
(ES-MS) m/z (rel. int. in %) 480.9 ([2M-H+]-, 20), 285.8 ([M+HCOO-], 100). HRMS (ESI) m/z 
[M-H+]- calculated for C14H7FNO2-: 241.0499, found 241.0492. C14H8FNO2 (241.05). 
 
4’-(2-Carboxyethyl)biphenyl-4-carboxylic acid (4.39c) 
The title compound was prepared from 4-iodobenzoic acid (173 mg, 0.7 mmol) and 
4-(2-carboxyethyl)phenylboronic acid (4.16, 136 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (181 mg, 95 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 16.7 min, k = 6.2). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.58 
(t, J 7.5 Hz, 2H), 2.87 (t, J 7.5 Hz, 2H), 7.35 (d, J 8.2 Hz, 2H), 7.53-7.67 (m, 3H), 7.91 (m, 
2H), 8.16 (s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 30.0, 35.1, 126.8 (2 interfering 
carbon signals), 127.2, 128.1, 129.1 (2 interfering carbon signals), 129.4, 131.1, 131.5, 
137.1, 140.4, 140.8, 167.4, 173.9. MS (ES-MS) m/z (rel. int. in %) 331.0 ([M+HCOO-], 100), 
284.9 ([M-H+]-, 40). HRMS (ESI) m/z [M-H+]- calculated for C16H13O4-: 270.0894, found 
269.0822. C16H14O4 (270.09). 
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4’-(2-Carboxyethyl)-4-hydroxybiphenyl-3-carboxylic acid (4.39d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
4-(2-carboxyethyl)phenylboronic acid (4.16, 291 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (230 mg, 52 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 17.7 min, k = 6.6). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.56 
(t, J 7.6 Hz, 3H), 2.85 (t, J 7.5 Hz, 2H), 7.04 (d, J 8.6 Hz, 1H), 7.30 (d, J 8.2 Hz, 2H), 7.53 (d, 
J 8.2 Hz, 2H), 7.81 (m, 1H), 8.00 (d, J 2.4 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
30.2, 35.5, 113.7, 118.2, 126.5 (2 interfering carbon signals), 128.1, 129.3 (2 interfering 
carbon signals), 131.6, 134.2, 137.1, 140.2, 160.7, 172.1, 174.3. MS (ES-MS) m/z (rel. int. 
in  %) 571.0 ([2M-H+]-, 100), 330.9 ([M+HCOO-], 60), 284.9 ([M-H+]-, 20). HRMS (ESI) m/z 
[M-H+]- calculated for C16H13O5-: 286.0842, found 285.0769. C16H14O5 (286.08). 
 
(E)-4’-(2-carboxyvinyl)biphenyl-3-carboxylic acid (4.40b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
(E)-3-(4-boronophenyl)acrylic acid (4.17, 134 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a brown solid (180 mg, 92 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 17.6 min, k = 6.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 6.60 
(d, J 16.0 Hz, 1H), 7.63 (m, 8.4 Hz, 2H), 7.79 (q, J 8.5 Hz, 4H), 7.97 (m, 2H), 8.22 (s, 1H). 
MS (ES-MS) m/z (rel. int. in %) 535.1 ([2M-H+]-, 100), 313.0 ([M+HCOO-], 25). HRMS (ESI) 
m/z [M-H+]- calculated for C16H11O4-: 268.0739, found 267.0666. C16H12O4 (268.07). 
 
(E)-4’-(2-carboxyvinyl)-4-hydroxybiphenyl-3-carboxylic acid (4.40d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
(E)-3-(4-boronophenyl)acrylic acid (4.17, 288 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a brown solid (380 mg, 86 %); mp > 210 °C. RP-
HPLC (220 nm): 97 % (tR = 18.7 min, k = 7.0). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 6.56 
(d, J 16.0 Hz, 1H), 7.07 (d, J 8.7 Hz, 1H), 7.65 (m, 3H), 7.77 (d, J 8.4 Hz, 2H), 7.90 (m, 1H), 
8.09 (d, J 2.4 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 25.0, 66.9, 117.8, 118.9, 
126.4 (2 interfering carbon signals), 127.9, 128.8 (2 interfering carbon signals), 130.2, 132.9, 
133.8, 140.4, 143.3, 160.8, 167.5, 171.6. MS (ES-MS) m/z (rel. int. in %) 567.0 ([2M-H+]-, 
90), 328.9 ([M+HCOO-], 80), 282.9 ([M-H+]-, 100). C16H12O5 (284.07). 
 
2’,5’-Dimethoxybiphenyl-3-carboxylic acid (4.41b) 
The title compound was prepared from 3-iodobenzoic acid (174 mg, 0.7 mmol) and 
2,5-dimethoxyphenylboronic acid (4.18, 127 mg, 0.7 mmol) according to the general 
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procedure. Flash chromatography yielded a brown solid (150 mg, 83 %); mp 137-144 °C. 
RP-HPLC (220 nm): 100 % (tR = 20.6 min, k = 7.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
3.71 (s, 3H), 3.75 (s, 3H), 6.85-6.98 (m, 2H), 7.07 (d, J 8.9 Hz, 1H), 7.54 (t, J 7.7 Hz, 1H), 
7.72 (d, J 7.9 Hz, 1H), 7.90 (d, J 7.8 Hz, 1H), 8.04 (s, 1H), 12.96 (br s, 1H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 55.3, 55.9, 113.1, 115.7, 127.8, 128.5, 129.4, 129.8, 130.3, 
133.6, 138.0, 150.0, 153.1, 167.5. MS (EI-MS, 70 eV) m/z (rel. int. in %) 258.2 ([M+•], 100), 
243.2 ([M-CH3•], 10). HRMS (EI-MS) m/z [M+•] calculated for C15H14O4+•: 258.0892, found 
258.0892. C15H14O4 (258.09). 
 
2’,5’-Dimethoxybiphenyl-4-carboxylic acid41 (4.41c) 
The title compound was prepared from 4-iodobenzoic acid (174 mg, 0.7 mmol) and 
2,5-dimethoxyphenylboronic acid (4.18, 127 mg, 0.7 mmol) according to the general 
procedure. Flash chromatography yielded a grey solid (140 mg, 77 %); mp 174-181 °C. RP-
HPLC (220 nm): 100 % (tR = 20.8 min, k = 7.9). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 3.71 
(s, 3H), 3.75 (s, 3H), 6.88-6.99 (m, 2H), 7.08 (d, J 8.9 Hz, 1H), 7.61 (d, J 8.4 Hz, 2H), 7.96 
(d, J 8.4 Hz, 2H), 12.88 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 55.3, 55.9, 113.1, 
114.1, 115.8, 128.9 (2 interfering carbon signals), 129.3 (2 interfering carbon signals), 142.3, 
150.1, 153.1, 167.2. MS (EI-MS, 70 eV) m/z (rel. int. in %) 258.2 ([M+•], 100), 243.2 ([M-
CH3•], 10). HRMS (EI-MS) m/z [M+•] calculated for C15H14O4+•: 258.0892, found 258.0888. 
C15H14O4 (258.09). 
 
4-Hydroxy-2’,5’-dimethoxybiphenyl-3-carboxylic acid (4.41d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
2,5-dimethoxyphenylboronic acid (4.18, 273 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a grey solid (320 mg, 78 %); mp 177-184 °C. RP-
HPLC (220 nm): 100 % (tR = 21.6 min, k = 8.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 3.70 
(s, 3H), 3.74 (s, 3H), 6.81-6.93 (m, 2H), 7.01 (m, 2H), 7.64 (m, 1H), 7.89 (d, J 2.3 Hz, 1H), 
11.30 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 55.3, 55.9, 112.5, 113.0, 115.5, 
116.7, 128.7, 129.2, 130.5, 136.4, 150.0, 153.2, 160.0, 171.7. MS (ES-MS) m/z (rel. int. in %) 
547.0 ([2M-H+]-, 60), 318.9 ([M+HCOO-], 100), 272.9 ([M-H+]-, 40). HRMS (ESI) m/z [M-H+]- 
calculated for C15H13O5-: 274.0845, found 273.0772. C15H14O5 (274.08). 
 
4’-Cyclohexylbiphenyl-3-carboxylic acid (4.42b) 
The title compound was prepared from 3-iodobenzoic acid (84 mg, 0.35 mmol) and 
4-cyclohexylphenylboronic acid (4.19, 71 mg, 0.35 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (60 mg, 63 %); mp > 210 °C. RP-
HPLC (220 nm): 100 % (tR = 18.1 min, k = 6.8). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.37 
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(m, 6H), 1.77 (m, 5H), 7.34 (d, J 8.2 Hz, 2H), 7.54-7.64 (m, 3H), 7.89-7.94 (m, 2H), 8.15 (t, 
J 1.7 Hz, 1H), 13.02 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 25.9, 26.7 (2 
interfering carbon signals), 34.3 (2 interfering carbon signals), 43.8, 127.1 (2 interfering 
carbon signals), 127.4, 127.8 (2 interfering carbon signals), 128.4, 129.8, 131.3, 131.7, 
137.1, 140.8, 147.8, 167.8. MS (EI-MS, 70 eV) m/z (rel. int. in %) 280.2 ([M+•], 100). HRMS 
(EI-MS) m/z [M+•] calculated for C19H20O2+•: 280.1469, found 280.1463. C19H20O2 (280.15). 
 
4’-Cyclohexylbiphenyl-4-carboxylic acid42 (4.42c) 
The title compound was prepared from 4-iodobenzoic acid (84 mg, 0.35 mmol) and 
4-cyclohexylphenylboronic acid (4.19, 71 mg, 0.35 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (20 mg, 20 %; mp ref.:42 288 °C). RP-
HPLC (220 nm): 100 % (tR = 14.0 min, k = 5.0). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.37 
(m, 7H), 1.77 (m, 6H), 7.35 (d, J 8.3 Hz, 2H), 7.65 (d, J 8.3 Hz, 2H), 7.77 (d, J 8.4 Hz, 2H), 
8.00 (d, J 8.4 Hz, 2H), 12.92 (br s, 1H). MS (EI-MS, 70 eV) m/z (rel. int. in %) 280.2 ([M+•], 
100). HRMS (EI-MS) m/z [M+•] calculated for C19H20O2+•: 280.1463, found 280.1469. 
C19H20O2 (280.15). 
 
3-(7-Methoxynaphthalen-2-yl)benzoic acid (4.43b) 
The title compound was prepared from 3-iodobenzoic acid (183 mg, 0.74 mmol) and 
7-methoxynaphthalen-2-ylboronic acid (4.20, 141 mg, 0.69 mmol) according to the general 
procedure. Flash chromatography yielded a grey solid (152 mg, 74 %); mp > 210 °C. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 3.93 (s, 3H), 7.17 (m, 1H), 7.27 (d, J 2.5 Hz, 1H), 
7.58 (t, J 7.8 Hz, 1H), 7.76 (m, 1H), 7.87 (t, J 8.9 Hz, 2H), 7.93-8.03 (m, 2H), 8.06 (s, 1H), 
8.37 (s, 1H). HRMS (ESI) m/z [M-H+]- calculated for 278.0943, found 277.0870. C18H14O3 
(278.09). 
 
2-Hydroxy-5-(7-methoxynaphthalen-2-yl)benzoic acid (4.43d) 
The title compound was prepared from 5-iodosalicylic acid (412 mg, 1.56 mmol) and 
7-methoxynaphthalen-2-ylboronic acid (4.20, 304 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a white solid (277 mg, 60 %); mp > 210 °C. RP-
HPLC (220 nm): 98 % (tR = 26.4 min, k = 10.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 3.89 
(s, 3H), 7.09 (d, J 8.6 Hz, 1H), 7.19 (m, 1H), 7.34 (d, J 2.5 Hz, 1H), 7.76 (m, 1H), 7.93 (m, 
3H), 8.11 (d, J 1.5 Hz, 1H), 8.16 (d, J 2.4 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
55.1, 117.8, 118.9, 124.3, 125.0, 127.4, 128.7, 129.5, 130.2, 131.1, 133.2, 133.9, 146.6, 
147.6, 147.9, 157.2, 160.3, 171.7. MS (ES-MS) m/z (rel. int. in %) 587.1 ([2M-H+]-, 35), 339.0 
([M+HCOO-], 100) 293.0 ([M-H+]-, 55). HRMS (EI-MS) m/z [M-H+]- calculated for C18H13O4-: 
294.0895, found 293.0823. C18H14O4 (294.09). 
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3-(Benzo[d][1,3]dioxol-5-yl)benzoic acid43 (4.44b) 
The title compound was prepared from 3-iodobenzoic acid (177 mg, 0.71 mmol) and 
benzo[d][1,3]-5-ylboronic acid (4.21, 121 mg, 0.73 mmol) according to the general procedure. 
Flash chromatography yielded a brown solid (167 mg, 97 %); mp > 210 °C (ref.:43 
227-228 °C). RP-HPLC (220 nm): 98 % (tR = 20.8 min, k = 7.9). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 6.08 (s, 2H), 7.02 (d, J 8.1 Hz, 1H), 7.18 (m, 1H), 7.28 (d, J 1.8 Hz, 1H), 
7.55 (t, J 7.7 Hz, 1H), 7.82-7.92 (m, 2H), 8.10 (s, 1H). 13C-NMR (75 MHz, [D6]DMSO): 
δ (ppm) 101.2, 107.1, 108.7, 120.4, 127.7, 129.1, 130.8, 131.3, 133.4, 140.1, 147.1, 148.0, 
167.1. HRMS (EI-MS) m/z [M-H+]- calculated for C14H9O4-: 242.0578, found 241.0505. 
C14H10O4 (242.06). 
 
4-(Benzo[d][1,3]dioxol-5-yl)benzoic acid44 (4.44c) 
The title compound was prepared from 4-iodobenzoic acid (179 mg, 0.72 mmol) and 
benzo[d][1,3]-5-ylboronic acid (4.21, 122 mg, 0.73 mmol) according to the general procedure. 
Flash chromatography yielded a grey solid (127 mg, 73 %); mp > 210 °C. RP-HPLC 
(220 nm): 100 % (tR = 21.2 min, k = 8.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 6.09 (s, 
2H), 7.03 (d, J 8.1 Hz, 1H), 7.24 (m, 1H), 7.34 (d, J 1.8 Hz, 1H), 7.74 (d, J 8.4 Hz, 2H), 7.97 
(d, J 8.4 Hz, 2H), 12.89 (br s, 1H). 13C-NMR (75 MHz, DMSO): δ (ppm) 101.2, 107.1, 108.7, 
120.7, 126.4 (2 interfering carbon signals), 129.0, 129.8 (2 interfering carbon signals), 133.1, 
147.5, 148.0, 167.0. HRMS (EI-MS) m/z [M-H+]- calculated for C14H9O4-: 242.0580, found 
241.0507. C14H10O4 (242.06). 
 
5-(Benzo[d][1,3]dioxol-5-yl)-2-hydroxybenzoic acid45 (4.44d) 
The title compound was prepared from 5-iodosalicylic acid (402 mg, 1.52 mmol) and 
benzo[d][1,3]-5-ylboronic acid (4.21, 256 mg, 1.54 mmol) according to the general procedure. 
Flash chromatography yielded a brown solid (112 mg, 28 %); mp > 210 °C (ref.:45 
241-245 °C). RP-HPLC (220 nm): 100 % (tR = 21.5 min, k = 8.2). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 6.05 (s, 2H), 7.04 (m, 3H), 7.20 (d, J 1.8 Hz, 1H), 7.76 (m, 1H), 7.94 (d, 
J 2.5 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 101.0, 106.7, 108.6, 113.1, 117.6, 
119.6, 127.6, 131.1, 133.7, 142.9, 147.9, 160.1, 160.5, 171.7. MS (ES-MS) m/z (rel. int. in %) 
515.0 ([2M-H+]-, 35), 302.9 ([M+HCOO-], 100) 256.9 ([M-H+]-, 25). HRMS (EI-MS) m/z [M-H+]- 
calculated for C14H9O5-: 258.0533, found 257.0460. C14H10O5 (258.05). 
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5-(5-Chloropyridin-3-yl)-2-hydroxybenzoic acid (4.45d) 
The title compound was prepared from 5-iodosalicylic acid (396 mg, 1.5 mmol) and 
5-chloropyridin-3-ylboronic acid (4.22, 244 mg, 1.5 mmol) according to the general 
procedure. Flash chromatography yielded a yellow solid (160 mg, 42 %); mp > 210 °C. RP-
HPLC (220 nm): 98 % (tR = 25.8 min, k = 10.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.02 
(d, J 8.7 Hz, 1H), 7.12 (d, J 3.9 Hz, 1H), 7.31 (d, J 3.9 Hz, 1H), 7.77 (m, 1H), 7.91 (d, 
J 2.4 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.5, 118.1, 122.7, 123.4, 126.4, 
128.1, 132.3, 141.2, 160.7, 171.2. MS (ES-MS) m/z (rel. int. in %) 506.9 ([2M-H+]-, 100), 
299.0 [M+HCOO-], 90), 253.0 [M-H+]-, 40). HRMS (ESI) m/z [M-H+]- calculated for 
C11H6ClO3S-: 253.9763, found 253.9762. C11H7ClO3S (253.98). 
 
5-(5-Chlorothiophen-2-yl)-2-hydroxybenzoic acid (4.46d) 
The title compound was prepared from 5-iodosalicylic acid (378 mg, 1.52 mmol) and 
5-chlorotiophen-2-ylboronic acid (4.23, 220 mg, 1.54 mmol) according to the general 
procedure. Flash chromatography yielded a grey solid (190 mg, 51 %); mp > 210 °C. RP-
HPLC (220 nm): 97 % (tR = 18.1 min, k = 6.7). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.09 
(d, J 8.1 Hz, 1H), 7.94 (d, J 7.6 Hz, 1H), 8.18 (d, J 36.9 Hz, 2H), 8.59 (s, 1H), 8.83 (s, 1H), 
11.44 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 113.6, 118.0, 126.4, 128.8, 131.4, 
133.2, 134.2, 136.0, 145.5, 146.3, 161.3, 171.4. MS (ES-MS) m/z (rel. int. in %) 496.9 ([2M-
H+]-, 100), 293.9 [M+HCOO-], 95), 247.9 [M-H+]-, 50). HRMS (ESI) m/z [M-H]- calculated for 
C12H8ClNO3-: 249.0152, found 249.0146. C12H8ClNO3 (249.02). 
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5.1 Introduction 
In 1975, the anti-inflammatory drug indomethacin was reported as a hyaluronidase inhibitor 
for the first time.1 Investigations by Spickenreither on indomethacin and indole derivatives, 
such as N-substituted indole-3-butanoic acid, and N-acylated and N-alkylated indole-3-
alkanoic acid derivatives, showed that these compounds are inhibitors of the bacterial 
hyaluronidase SagHyal4755 and the mammalian enzymes BTH, Hyal-1 and PH-20.2 
Structurally related compounds of indomethacin designed in our work group by M. 
Spickenreither2 led to the discovery of substances that are among the most potent inhibitors 
of bacterial and mammalian hyaluronidases known so far. For example N-alkylated and 2-
phenyl-substituted indoles have been identified as potent inhibitors of streptococcal 
hyaluronidases with IC50 values in the lower micromolar range (Figure 5.1). 
 
 
Figure 5.1 Structures, inhibitory activity of SagHyal4755 and BTH and calculated logD5.0 of N-alkylated indole 1 and 
2-phenylindole 2. 
 
The two compounds 4-(1-decyl-2-(ethoxycarbonyl)-5-hydroxy-1H-indol-3-yl)butanoic acid (1) 
and 1-heptyl-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol (2) showed inhibition of SagHyal4755 
with IC50 values of 7.5 µM and 26 µM, respectively.2,3 Moreover, X-ray analysis confirmed 
that hydroxylated 2-phenylindoles bind to the active site of another streptococcal 
hyaluronidase, SpnHyl.3-5 
 
Searching for suiTable inhibitors for in vivo application, N-alkylated indoles proved to be 
inappropriate due to high logD5.0 values as a consequence of long lipophilic alkyl moieties 
and extremely high plasma-protein binding (cf. Figure 5.1). Furthermore, compounds 
possessing a negatively charged carboxyl group can have surfactant properties. Moreover, 
substances with a 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol scaffold are known for anti-
estrogenic activity at low nanomolar concentrations.6-8 
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In search for novel substitution patterns on the indole, 6,7-dichloro-1H-indole derivatives 
were investigated for inhibitory activity on SagHyal4755 and BTH. In addition, compounds 
derived from the β-carboline alkaloid bauerine C and originally developed as potent and 
selective kinase inhibitors, were tested. These substances were kindly provided by Prof. Dr. 
F. Bracher (Department of Pharmacy, LMU Munich).9-11 Among the investigated small 
molecules (data not shown; for detailed information cf. Textor5) compounds 3 and 4 
(Figure 5.2) were identified as moderate inhibitors of SagHyal4755. However, inhibitors of BTH 
were not identified among the 6,7-dichloro-1H-indoles.  
 
 
Figure 5.2 Structures, inhibitory activities of SagHyal4755 and BTH and calculated logD5.0 values of 6,7-dichloro-
1H-indole derivatives 3 and 4. 
 
Compound 3 bears an oxadiazole ring in position 2 of the indole scaffold. Such moieties are 
frequently used as bioisosteric replacements for ester and amide groups.12,13 
 
Inspired by compounds 3 and 4, novel 2-phenylindole derivatives were explored in our 
workgroup. Compound 5 (Figure 5.3) was found to be one of the most potent inhibitor of the 
bacterial hyaluronidase SagHyal4755 known so far with an IC50 value of 6 µM. Moreover, an 
IC50 value of 93 µM was determined on the streptococcal hyaluronidase SpnHyl. 
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Figure 5.3 Structure and inhibitory activity of SagHyal4755 and BTH of 4-[(6,7-dichloro-2-(4-hydroxyphenyl)-3-
methyl-1H-indol-1-yl)methyl]benzoic acid (5). 
 
It becomes obvious from compounds 3-5 that long lipophilic alkyl moieties, which are 
characteristic of previously identified inhibitors of streptococcal hyaluronidases, are not an 
essential structural feature. Moreover, antiestrogenic activities and cytostatic effects on 
hormone sensitive breast cancer cells were not observed for the indole-type hyaluronidase 
inhibitor 3.5 Therefore, in the present project, the 6,7-dichloro-1H-indole motif was selected 
as a core structures for the design of small molecules, aiming at more potent hyaluronidase 
inhibitors with improved drug-like properties. The structural modifications of compounds 3 
and 4 are outlined in Figure 5.4. 
 
 
Figure 5.4 Structural modifications of 3 and 4 for the development of inhibitors of SagHyal4755. 
 
Both, the 2-(6,7-dichloro-1H-indole-2-yl)-1,3,4-oxadiazole and 6,7-dichloro-1H-indole-2-
carboxylic acid structures were varied by introducing a methyl and ethyl group, respectively, 
in position 3 (cf. R1 in Figure 5.3). The 6,7-dichloro substitution pattern will be exchanged by 
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an O-benzyl and hydroxyl group, respectively, in position 5 (cf. Figure 5.3). Aiming at drug-
like inhibitors, based on the experience with previously identified inhibitors of hyaluronidase, 
the physicochemical properties were taken into consideration. The introduction of a benzyl or 
a chlorobenzyl moiety at the indole-N of the 1H-indole-2-carboxylic acid derivatives results in 
higher lipophilicity of the molecule, which is known to contribute to higher potency of 
inhibitors of the bacterial hyaluronidases. Moreover, by introducing an additional negatively 
charged carboxylic group at the benzyl moiety, the solubility of the compounds should be 
increased.  
 
5.2 Chemistry 
5.2.1 Synthesis of 2-(6,7-dichloro-1H-indol-2-yl)-1,3,4-oxadiazoles 
The synthesis of the 2-(6,7-dichloro-1H-indole-2-yl)-1,3,4-oxadiazole compounds was carried 
out as outlined in Scheme 5.1. 
 
 
Scheme 5.1 Synthesis of the 2-(indol-2-yl)-1,3,4-oxadiazole derivatives 5.12-5.14. Reagents and conditions: 
(i) NaNO2, HCl (conc.)/H2O, 0 °C; (ii) NaBF4, rt, 20 min; (iii) NaH, THF, C3H7I, reflux, 6 h; (iv) NaH, THF; (v) HCl 
(conc.), reflux 36 h; (vi) H4N2•H2O, reflux 72 h; (vii) HCOOH; (viii) POCl3.  
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The indole scaffold was prepared using the Japp-Klingemann variant of the Fischer indole 
synthesis.14-17 First, 2,3-dichlorophenyldiazonium tetrafluoroborate was prepared from 
2,3-dichloroaniline.18 Subsequently, the reaction of the diazonium salt with the respective 
oxobutanoate was carried out to give the hydrazono compounds 5.4 and 5.5. These, in turn 
were refluxed with concentrated hydrochloric acid to achieve the indole ring closure at high 
temperature.2,19 To obtain the 6,7-dichloro-1H-indole-2-carbohydrazides, ethyl 1H-indole-2-
carboxylates were refluxed for 3 days with hydrazine hydrate. Finally, oxadiazole ring closure 
was accomplished by treating the indole-2-carbohydrazides with formic acid and phosphoryl 
chloride.20-22 After removal of side-products by flash chromatography, compounds 5.12-5.14 
were obtained in moderate yields.  
 
5.2.2 Synthesis of 1H-indole-2-carboxylic acid compounds 
The N-benzylated 6,7-dichloro-1H-indole-2-carboxlic acid derivatives were synthesized 
according to the scheme outlined in Scheme 5.2. 
 
 
Scheme 5.2 Synthesis of the 6,7-dichloro-1H-indole derivatives 5.22-5.31. Reagents and conditions: (i) TBTA, 
BF3Et2O, cyclohexane/THF, rt, 17 h; (ii) NaH, DMF, R2-Br, 0 °C; (iii) LiOH, THF/EtOH/H2O = 3:0.2:1 (v/v/v). 
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The building blocks 5.6 and 5.7 were prepared as described in Section 5.2.1. N-benzylation 
of the indole scaffold was carried out by treating the indole-2-carboxylate with sodium 
hydride in dimethylformamide and benzylation with the corresponding benzyl bromide.23 
Saponification of the ester moieties in position 2 (5.6, 5.7, 5.16-5.21) and in position 4 of the 
N-benzyl residue (5.26, 5.29) with lithium hydroxide yielded the target molecules 
(5.22-5.31).5 The crude products were purified by RP-HPLC. 
 
The synthesis of the N-benzylated 5-benzyloxy- and 5-hydroxy-1H-indole-2-carboxylic acid 
derivatives is outlined in Scheme 5.3. 
 
iv
v
 
Scheme 5.3 Synthesis of the 5-benzyloxy- and 5-hydroxy-1H-indole-2-carboxylic acid derivatives 5.53-5.60. 
Reagents and conditions: (i/ii) NaNO2, HCl (conc.) / H2O, 0 °C; (ii) NaBF4, rt, 20 min; (iii) NaH, THF (iv) HCl 
(conc.), reflux, 36 h; (v) NaH, DMF, R2-Br, 0 °C; (vi) LiOH, THF/EtOH/H2O = 3:0.2:1 (v/v/v), RT, 72 h; (vii) 10 % 
Pd/C (cat.), H2 (atm), THF, rt, overnight. 
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The synthesis of the indole scaffold, as well as the N-benzylation was performed as 
described above. Hydrogenolytic cleavage of the benzyl ether compounds 5.45-5.52 was 
achieved in the presence of palladium on activated charcoal.2 Saponification of the ester 
moieties (5.37-5.44 and 5.58) was carried out as described above. RP-HPLC purification 
yielded the pure target compounds. 
5.3 Pharmacological results and discussion 
5.3.1 General conditions 
All synthesized indole compounds were investigated for inhibition of the bacterial hyaluronate 
lyase SagHyal4755 and the bovine testicular enzyme BTH (Neopermease®) in a turbidimetric 
assay based on the method of Di Ferrante as described in chapter 1.24 If IC50 values could 
not be determined, due to poor solubility in aqueous buffer, the percent inhibition of the 
compound was given. 
 
5.3.2 Inhibition of hyaluronidases by 2-(1H-indol-2-yl)-1,3,4-
oxadiazoles 
The IC50 values determined for the 2-(1H-indol-2-yl)-1,3,4-oxadiazoles (5.12-5.14) are 
summarized in Table 5.1. 
 
Table 5.1 Inhibitory activitya on hyaluronidases and calculated logD5.0 valuesb of 2-(1H-indol-2-yl)-1,3,4-
oxadiazoles 5.12-5.14. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
c 
5.12 20 % at 100 µMb inactive 2.7 
5.13 30 % at 200 µMb inactive 3.2 
5.14 inactive inactive 1.7 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b % inhibition of SagHyal4755 at indicated inhibitor concentration; c calculated with 
ACD-Labs (Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The structures of compounds 5.12-5.14 are similar to that of parent compound 3: compounds 
5.12 (20 % at 100 µM) and 5.13 (30 % at 200 µM) bear a methyl or an ethyl group, 
respectively, in position 3 of the indole scaffold. Nevertheless, compared to 3 (IC50 = 152 µM) 
these analogs are less potent hyaluronidase inhibitors. In compound 5.14 the 6,7-dichloro 
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substitution was omitted, resulting in reduced lipophilicity and a lower calculated logD5.0 value 
(logD5.0 = 1.7). However, the inhibitory effect on SagHyal4755 was completely lost. Due to poor 
solubility, IC50 values of compounds 5.12 and 5.13 could not be determined.  
None of the oxadiazole derivatives 5.12-5.14 revealed inhibition of BTH. In view of low 
activity and very poor solubility, the synthesis of compounds bearing an oxadiazole moiety 
was not further pursued.  
 
5.3.3 Inhibition of hyaluronidases by 6,7-dichloro-1H-indole-2-
carboxylic acid derivatives 
The IC50 values determined for the 6,7-dichloro-1H-indole-2-carboxylic acid derivatives (5.16, 
5.22-5.31) are summarized in Table 5.2. 
 
Table 5.2 Inhibitory activitya on hyaluronidases and calculated logD5.0 valuesb of 6,7-dichloro-1H-indole-2-
carboxylic acid derivatives 5.16 and 5.22-5.31. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
5.16 inactive inactive 6.2 
5.22 30 % at 100 µM inactive 1.4 
5.23 143 ± 53 20 % at 1 mM 1.8 
5.24 20 % at 100 µM inactive 3.7 
5.25 16 ± 1 inactive 4.2 
5.26 19 ± 3 inactive 4.8 
5.27 25 ± 5 inactive 4.1 
5.28 61 ± 14 inactive 4.6 
5.29 29 ± 15 inactive 5.1 
5.30 72 ± 6 inactive 2.1 
5.31 41 ± 3 inactive 2.5 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, 
Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of 5.25-5.27, 5.29 and 5.31 is depicted 
as concentration-response curves in Figure 5.5. 
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Figure 5.5 Enzymatic activity of SagHyal4755 in the presence of 5.25-5.27, 5.29 and 5.31. 
 
Whereas, the ethyl ester 5.16 was devoid of inhibitory effect, the corresponding carboxylic 
acid 5.24 showed weak inhibition of SagHyal4755 (20 % inhibition at 100 µM) and better 
solubility in aqueous buffer. Interestingly, compound 5.27, the 3-ethyl-substituted analog of 
5.24, revealed comparable solubility (100 µM) and higher inhibitory potency on SagHyal4755 
(IC50 = 25 µM).  
 
The only difference between compounds 5.22 (30 % at 100 µM) and 6,7-dichloro-1,3-
dimethyl-1H-indole-2-carboxylic acid (4, IC50 = 172 µM) is the methyl group at the indole 
nitrogen, but interestingly, the latter showed higher inhibitory activity on SagHyal4755 and 
weak inhibition of BTH (15 % at 1 mM), whereas 5.22 was inactive at the mammalian 
enzyme. The homolog of 5.22, substance 5.23, bearing an ethyl instead of a methyl group in 
position 3, proved to be superior (IC50 = 143 µM) to 5.22 and 5.24.  
 
The indole-2-carboxylic acids 5.22 (30 % at 100 µM) and 5.23 (IC50 = 143 µM) were slightly 
more potent as inhibitors of SagHyal4755, compared to the corresponding oxadiazoles 5.12 
(20 % at 100 µM) and 5.13 (30 % at 200 µM). All other compounds included in this section 
(5.25-5.31) showed moderate to good inhibition of SagHyal4755 in the two-digit micromolar 
range (IC50 = 16-72 µM). As expected, these compounds were not capable of inhibiting the 
mammalian enzyme BTH, except for compound 5.23 which showed very weak inhibition by 
20 % at 1 mM. Indole 5.25 (IC50 = 16 µM), bearing another chloro substituent in position 4 of 
the benzyl moiety turned out to be the most potent hyaluronidase inhibitor among these 
compounds, confirming again the correlation: the higher the lipophilicity (5.25: calculated 
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logD5.0 = 4.2) the higher the potency. However, differing from this statement, an ethyl group 
instead of a methyl group (5.25) in position 3 did not result in a further increase but in almost 
4-fold decrease in inhibitory activity (5.28, IC50 = 61 µM). 
 
Surprisingly, the tert-butyl ester protected compound 5.26 (IC50 = 19 µM) showed more than 
3-fold higher inhibitory activity than the deprotected compound 5.30 (IC50 = 72 µM). The 
same tendency became obvious for the 3-ethyl-substituted analogs: the tert-butyl ester 5.29 
(IC50 = 29 µM) and the corresponding deprotected carboxylic acid (5.31, IC50 = 41 µM). Thus, 
an additional carboxyl residue had minor influences on the IC50 values, whereas the bulky 
tert-butyl group increased lipophilicity and inhibitory activity. 
 
In summary, among the 6,7-dichloro-1H-indole-2-carboxylic acid derivatives, the 
N-benzylated compounds showed the highest inhibitory potencies. The 2-carboxylic group 
should be unprotected to increase both, the effect on SagHyal4755 and the solubility. In this 
group of compounds inhibitors of the streptococcal hyaluronidase SagHyal4755 were found 
with IC50 values in the lower two-digit micromolar range. With regard to the lipophilicity, for all 
compounds (5.22-5.31: logD5.0 = 1.4-5.1), except for 5.16 (logD5.0 = 6.2), the calculated 
logD5.0 values were below or at 5.1.  
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5.3.4 Inhibition of hyaluronidases by 5-benzyloxy- and 5-hydroxy-
1H-indole-2-carboxylic acid derivatives 
The IC50 values determined for the 5-benzyloxy- (5.43, 5.48-5.50 and 5.52) and 5-hydroxy-
1H-indole-2-carboxylic acid derivatives (5.53-5.57, 5.59 and 5.60) are summarized in 
Table 5.3. 
 
Table 5.3 Inhibitory activitya and calculated logD5.0 valuesb of 5-(benzyloxy)- and 5-hydroxy-1H-indole-2- 
carboxylic acid derivatives 5.43, 5.48-5.50, 5.52-5.57, 5.59 and 5.60. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
b 
5.43 inactive inactive 5.1 
5.48 20 ± 6 inactive 5.4 
5.49 10 % at 20 µM inactive 5.0 
5.50 60 % at 200 µM inactive 5.5 
5.52 inactive inactive 5.9 
5.53 inactive inactive -0.3 
5.54 inactive inactive -0.3 
5.55 20 % at 1 mM inactive 0.0 
5.56 inactive inactive 3.4 
5.57 inactive inactive 3.0 
5.59 50 % at 1 mM inactive 3.4 
5.60 40 % at 1 mM inactive 1.4 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b calculated with ACD-Labs (Advanced Chemistry Development Inc., Toronto, 
Canada) product version 12.0. 
 
The enzymatic activity of SagHyal4755 in the presence of 5.48 is depicted as concentration-
response curve in Figure 5.6. 
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Figure 5.6 Enzymatic activity of SagHyal4755 in the presence of 5.48. 
 
Most of the synthesized indole derivatives described in this section were inactive or showed 
only weak inhibition of the bacterial hyaluronidase SagHyal4755. Compound 5.43 bears an 
ethyl ester group in position 2 and a tert-butyl ester in position 4 of the benzyl moiety. Hence, 
the solubility of this substance was very poor and no inhibitory activity of SagHyal4755 could 
be detected. In compound 5.60 both carboxylic groups are unprotected, resulting in 
increased solubility. However, this compound showed only weak inhibition of the bacterial 
hyaluronidase by 40 % at a concentration of 1 mM. The corresponding 6,7-dichloro-
substituted compound (cf. section 5.3.3, 5.30: IC50 = 72 µM) was more potent and lipophilic 
(5.30: logD5.0 = 2.1, 5.60: logD5.0 = 1.4). 
 
The 5-benzyloxy-substituted indole 5.48 (IC50 = 20 µM, logD5.0 = 5.4) was the most potent 
hyaluronidase inhibitor among this group of compounds. Compared to substances 5.50 
(60 % at 200 µM) and 5.52 (inactive), 5.48 bears no residue in position 3. Interestingly, when 
the benzyloxy group of compound 5.48 was cleaved to give 1-(4-chlorobenzyl)-5-hydroxy-
1H-indole-2-carboxylic acid (5.52), the inhibitory activity was completely lost. The 
6,7-dichloro-substituted analogs 5.25 (IC50 = 16 µM) and 5.28 (IC50 = 61 µM), were superior 
to the compounds bearing the 5-benzyloxy-moiety (5.48, 5.50, 5.52), although the lipophilicity 
of the latter was higher than that of compounds 5.25 and 5.28 (logD5.0 5.25 = 4.2; 
logD5.0 5.28 = 4.6). The benzyloxy-substitution (5.48-50 and 5.52) increased the lipophilicity 
and reduced the solubility in aqueous buffer. This prevented the determination of IC50 values 
of compounds such as 5.49 (logD5.0 = 5.0).  
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With regard to inhibition of SagHyal4755, this series was less successful than the 6,7-dichloro-
1H-indole-2-carboxylic acid series. Only one compound (5.48) with an IC50 value in the 
two-digit micromolar range (IC50 = 20 µM) was identified. None of these compounds showed 
inhibition of bovine testicular hyaluronidase. 
 
5.4 Inhibitory activities of selected compounds on 
SpnHyl 
To compare the inhibition of SagHyal4755 with data from an additional bacterial enzyme, an 
ensemble of 10 inhibitors was investigated on hyaluronidase from S. pneumonia, SpnHyl. All 
compounds were tested in the 96-well plate format in duplicate at a final assay concentration 
of 200 µM. Under identical assay conditions (including the pH value) these substances were 
inactive or showed very weak inhibition of SpnHyl (Table 5.4). 
 
Table 5.4 Inhibitory activitiesa of compounds 5.23, 5.25-5.31 and 5.53-5.55 on SagHyal4755 and SpnHyl. 
Compound 
SagHyal4755 
IC50 (µM)a 
inhibitory activity of 
SpnHyl (%) at a 
concentration of 200 µM 
5.23 143 ± 53 inactive 
5.25 16 ± 1 40 
5.26 19 ± 3 12 
5.27 25 ± 5 10 
5.28 61 ± 14 30 
5.29 29 ± 15 inactive 
5.30 72 ± 6 inactive 
5.31 41 ± 3 inactive 
5.53 inactive inactive 
5.54 inactive inactive 
5.55 inactive 12 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes). 
 
Compound 5.55 showed very weak inhibition of SpnHyl by 12 % at 200 µM and was the only 
compound that was more active on the hyaluronidase from S. pneumonia than on the 
enzyme from S. agalactiae. 
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5.5 Summary 
Indole derivatives that are structurally related to 2-(6,7-dichloro-1H-indol-2-yl)-1,3,4-
oxydiazole (3) and 6,7-dichloro-1,3-dimethyl-1H-indole-2-carboxylic acid (4; cf. Figure 5.2) 
were synthesized and investigated for inhibition of the bacterial hyaluronidases SagHyal4755 
and SpnHyl. Out of this series, the most active inhibitors are characterized by 6,7-dichloro 
substitution, N-benzylation and a carboxylic group in position 2. Compound 5.25 
(6,7-dichloro-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid) showed the highest 
inhibition of SagHyal4755 (IC50 = 16 µM).  
 
Starting from the parent compounds (3) and (4), the hydrophobicity of the derivatives was 
increased by N-benzylation, resulting in increased inhibition of the bacterial hyaluronate 
lyase SagHyal4755. Moreover, instead of 6,7-dichloro substitution a hydroxyl group and the 
corresponding O-benzyl-protected phenolic moiety were introduced in position 5 of the indole 
scaffold. Although the latter resulted in higher lipophilicity, except for one compound this 
strategy did not positively influence the potency of the inhibitors. The calculated logD5.0 
values of the most potent compounds from this section (5.25-5.27, 5.29, 5.48) possess 
higher lipophilicity with regard to the logD5.0 value compared to the parent compounds (1, 2). 
The comparison of the four compounds 5.12, 5.13, 5.22 and 5.23, allows the conclusion that 
the presence of a carboxyl group in position 2 of the indole is better suited for inhibition of 
SagHyal4755 than an oxadiazole ring.  
 
The influence of a methyl or ethyl group in position 3 remained unclear: for some molecules 
the methyl group seems to be more suited, in other compounds the ethyl group leads to 
higher inhibitory activity on SagHyal4755. Generally, N-benzylated indoles were more potent 
than N-unsubstituted analogs. An additional chloro substituent (cf. 5.25, 5.48) or a tert-butyl 
carboxylate in position 4 of the attached benzyl-moiety, increased the inhibition of 
SagHyal4755. Interestingly, the conversion of the hydrophobic tert-butyl ester to the polar 
carboxylic group (5.30, 5.40) led to a slight decrease in inhibitory activity. 
 
Except for compound 5.16, in which the ester in position 2 moiety is still present, all 
1H-indole analogs bearing the 6,7-dichloro motif showed at least weak inhibition of 
SagHyal4755, most probably due to the lipophilicity contribution of the chlorine atoms. Except 
for 5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid (5.48, IC50 = 20 µM), all 
6,7-dichloro-1H-indole-2-carboxylic acid derivatives showed higher inhibitory activity on the 
bacterial hyaluronidase SagHyal4755 than the 5-benzyloxy- and 5-hydroxy-substitueted 
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1H-indole analogs. Although lipophilicity is obviously one of the most important 
physicochemical properties, the 6,7-dichloro-1H-indoles had lower logD5.0 values and were 
more potent than the 5-benzyloxy-substiuted derivatives. 
 
The most pronounced increase in inhibition of the hyaluronate lyase resulted from 
introduction of hydrophobic residues at the indole moiety. Especially, when the benzyl moiety 
was chloro-substituted, IC50 values in the lower two-digit micromolar range were achieved 
(cf. 5.25 and 5.48). A negatively charged carboxylic group was also found to increase the 
affinity of the inhibitors. 
 
In summary, the combination of the 6,7-dichloro substitution pattern with N-benzylation and a 
negatively charged carboxylic acid in position 2 proved to be most efficient and is considered 
promising to pursue further development of inhibitors for the bacterial hyaluronidase. The 
synthesized compounds showed very weak inhibition or were devoid of inhibitory activity on 
the second bacterial hyaluronidase, SpnHyl. Moreover, all hyaluronate lyase inhibitors of the 
indole series were inactive on the bovine testicular enzyme (BTH). 
 
5.6 Experimental section 
5.6.1 General conditions 
Cf. section 4.7.1 
5.6.2 Chemistry 
5.6.2.1 Preparation of compounds 5.1, 5.32 
General Procedure2,18,25  
To a suspension of the pertinent aniline (1 eq) in water (0.34 mL/mmol) and concentrated 
HCl (0.23 mL/mmol) was added dropwise a solution of sodium nitrite in water at 0 °C. After 
stirring for 10 min a solution of sodium tetrafluoroborate (1 eq) in water (0.24 mL/mmol) was 
added and the cooling bath was removed. Stirring was continued for additional 20 min at 
room temperature. The resulting orange solid was isolated by filtration and washed three 
times with ice cold water, methanol and ether. 
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2,3-Dichlorobenzenediazonium tetrafluoroborate (5.1) 
The title compound was prepared from 2,3-dichloroaniline (10 g, 61.7 mmol) according to the 
general procedure. After drying under reduced pressure the title compound was obtained as 
a pale orange solid. (11 g, 69%); mp 150-151 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
7.99 (t, J 8.4 Hz, 1H), 8.58 (m, 1H), 8.87 (m, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
118.8, 130.8, 133.4, 133.6, 134.6, 142.2. MS (ESI) m/z (rel. int. in %) 172.9 ([M+], 100). 
HRMS (ESI): m/z [M+] calculated for C6H3Cl2N2+: 172.9666, found 172.9665. HRMS (ESI): 
m/z [M+H+]+ calculated for C6H4Cl2N2+: 172.9666, found 172.9665. C6H3Cl2N2+•BF4- (259.97). 
 
4-(Benzyloxy)benzenediazonium tetrafluoroborate18 (5.32) 
The title compound was prepared from 4-benzyloxyaniline (15 g, 64 mmol) according to the 
general procedure. After drying under reduced pressure the title compound was obtained as 
a pale yellow solid (15.8 g, 89%); mp 152-153 °C (ref.18: 137 °C). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 5.42 (s, 2H,), 7.34-7.61 (m, 7H), 8.54-8.70 (m, 2H). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 71.26, 103.5, 117.8 (2 interfering carbon signals), 128.2 (2 interfering 
carbon signals), 128.6 (2 interfering carbon signals), 134.8, 135.0 (2 interfering carbon 
signals), 167.7. HRMS (ESI): m/z [M+] calculated for C13H11N2O+: 211.0866, found 211.0864. 
MS (ES-MS) m/z (rel. int. in %) 211.0 ([M+], 100). HRMS (ESI): m/z [M+H+]+ calculated for 
C13H12N2O+: 211.0866, found 211.0864. C13H11NO2+•BF4- (298.10). 
 
5.6.2.2 Preparation of ethyl 2-acetylpentanoate (5.3) 
General procedure26-28  
To a suspension of NaH (60 % in mineral oil, 1 g) in dry THF (25 mL) was added ethyl 
acetoacetate (10.4 g, 80 mmol) dropwise. The mixture was stirred at room temperature for 
30 min during which time the colorless suspension became a clear yellow solution. 
1-Iodopropane (20.4 g, 120 mmol) was added, and the mixture was refluxed overnight. After 
cooling to room temperature, sat aq. NH4Cl was added. The aqueous layer was separated 
and extracted with ethyl acetate three times. The combined organic layers were dried 
(MgSO4), filtered and concentrated under reduced pressure. The crude product was purified 
by flash chromatography (petroleum ether/EtOAc 70/30 v/v) to give a yellowish liquid (5.62 g, 
42 %). Rf = 0.89, 1H-NMR (300 MHz, CDCl3): δ (ppm) 0.86 (t, J 7.3 Hz, 3H), 1.20 (t, J 7.1 Hz, 
5H), 1.73 (q, J 1.0 Hz, 2H), 2.15 (s, 3H), 3.35 (t, J 7.4 Hz, 1H), 4.12 (q, J 5.0 Hz, 2H). 13C-
NMR (75 MHz, [D1]CHCl3): δ (ppm) 13.8, 14.1, 20.6, 28.7, 30.2, 59.7, 61.3, 169.9, 203.4. MS 
(CI-MS) (NH3) m/z (rel. int. in %) 207.2 ([M+NH4++NH3], 10), 190.1 ([M+NH4+], 100), 173.1 
([M+H+]+, 5). HRMS (ESI): m/z [M+H+]+ calculated for C9H17O3+: 173.1199, found 173.1189. 
C9H16O3 (172.22). 
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5.6.2.3 Preparation of compounds 5.4-5.5, 5.34-5.36 
General procedure2 
To a suspension of NaH (60 % suspension in mineral oil, 1.14 eq) in anhydrous THF was 
added dropwise a solution of the pertinent butanoate (5.2, 5.3, 5.33; 1.02 eq). The mixture 
was refluxed for 30 min. After cooling to -5 °C, 5.1 or 5.32 (1 eq) was added in portions, and 
the resulting dark red solution was stirred overnight at room temperature. The mixture was 
poured into water and extracted with ether three times. The combined organic layers were 
washed with water, dried over MgSO4, filtered, and evaporated.  
 
(E)-Ethyl 2-[2-(2,3-dichlorophenyl)hydrazono]butanoate (5.4) 
The title compound was prepared from 5.1 (11.4 g, 44 mmol) and 5.2 (7.5 g, 45 mmol), 
according to the general procedure. The crude product, a dark oil, was used for the next step 
without further purification (13 g, 98 %). C12H14Cl2N2O2 (288.04). 
 
(E)-Ethyl 2-[2-(2,3-dichlorophenyl)hydrazono]pentanoate (5.5) 
The title compound was prepared from 5.1 (11.4 g, 44 mmol) and 5.3 (8 g, 45 mmol), 
according to the general procedure. The crude product, a dark oil, was used for the next step 
without further purification (12 g, 86 %). C13H16Cl2N2O2 (302.06). 
 
(E)-Ethyl 2-{2-[4-(benzyloxy)phenyl]hydrazono}propanoate (5.34) 
The title compound was prepared from 5.32 (13.7 g, 46 mmol) and 5.36 (5.37 g, 47 mmol), 
according to the general procedure. The crude product, a dark oil, was used for the next step 
without further purification (19.2 g, 62 %). C18H20N2O3 (312.15). 
 
(E)-Ethyl 2-{2-[4-(benzyloxy)phenyl]hydrazono}butanoate (5.35) 
The title compound was prepared from 5.32 (10 g, 47 mmol) and 5.2 (5.73 g, 47 mmol), 
according to the general procedure. The crude product, which was a dark oil, was used for 
the next step without further purification (13.7 g, 100 %). C19H22N2O3 (325.16). 
 
(E)-Ethyl 2-{2-[4-(benzyloxy)phenyl]hydrazono}pentanoate (5.36) 
The title compound was prepared from 5.32 (3.9 g, 13.1 mmol) and 5.3 (2.3 g, 13.4 mmol), 
according to the general procedure. The crude product, a dark oil, was used for the next step 
without further purification (5 g, 100 %). C20H24N2O3 (340.18). 
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5.6.2.4 Preparation of compounds 5.6, 5.7, 5.37-5.39 
General procedure 
A solution of the pertinent hydrazone (5.4-5.5, 5.34-5.36) and concentrated HCl in anhydrous 
EtOH was refluxed for 3 days. After cooling the solution was diluted with water and extracted 
three times with CHCl3. The combined organic layers were washed with water, dried 
over MgSO4, filtered, and evaporated. The crude product was purified with flash 
chromatography (PE/EtOAc 80/20 v/v) and recrystallized from petroleum ether.  
 
Ethyl 6,7-dichloro-3-methyl-1H-indole-2-carboxylate (5.6) 
The title compound was prepared from 5.4 (15.2 g, 53 mmol), according to the general 
procedure. The purified product was recrystallized from petroleum ether to yield yellow 
crystals (1.3 g, 12 %); mp 141-148 °C, Rf = 0.73, 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
1.36 (t, J 7.1 Hz, 3H, COOCH2CH3), 2.50 (s, 3H, CH3), 4.35 (q, J 7.1 Hz, 2H, COOCH2CH3), 
7.25 (d, J 8.6 Hz, 1H, indole-H), 7.64 (d, J 8.6 Hz, 1H, indole-H), 11.77 (br s, 1H, NH). 13C-
NMR (75 MHz, [D6]DMSO): δ (ppm) 11.3, 13.8, 25.8, 61.1, 112.0, 115.2, 121.8, 128.8, 131.7, 
134.0, 141.3, 162.8. MS (EI-MS, 70 eV) m/z (rel. int. in %) 271.1 ([M+•], 45), 225.0 ([M-EtOH], 
100). HRMS (ESI): m/z [M+H+]+ calculated for C12H13Cl2NO2+: 272.0240, found 272.0240. 
C12H11Cl2NO2 (271.02). 
 
Ethyl 6,7-dichloro-3-ethyl-1H-indole-2-carboxylate (5.7) 
The title compound was prepared from 5.5 (11.4 g, 38 mmol), according to the general 
procedure. The purified product was recrystallized from petroleum ether to yield a white solid 
(2.2 g, 20 %); Rf = 0.69, mp 120-121 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.18 (t, 
J 7.5 Hz, 3H), 1.36 (t, J 7.1 Hz, 3H), 3.03 (q, J 7.4 Hz, 2H), 4.36 (q, J 7.1 Hz, 2H), 7.27 (d, 
J 8.6 Hz, 1H), 7.70 (d, J 8.6 Hz, 1H), 11.79 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): 
δ (ppm) 14.1, 15.4, 17.4, 60.4, 114.9, 120.1, 121.3, 125.0, 125.5, 127.0, 127.4, 134.0, 161.0. 
MS (EI-MS, 70 eV) m/z (rel. int. in %) 285.0 ([M+•], 70), 255.0 ([M-C2H5•], 100). HRMS (ESI): 
m/z [M+H+]+ calculated for C13H14Cl2NO2+: 285.0398, found 285.0395. C13H13Cl2NO2 
(285.03). 
 
Ethyl 5-(benzyloxy)-1H-indole-2-carboxylate29 (5.37) 
The title compound was prepared from 5.34 (19.3 g, 62 mmol), according to the general 
procedure. The purified product was recrystallized from petroleum ether to yield a yellow 
solid (1.4 g, 8 %); mp 157-158 °C (ref.:29 161-163 °C) 1H-NMR (300 MHz, [D6]DMSO): δ 
(ppm) 1.33 (t, J 7.1 Hz, 3H, COOCH2CH3), 4.32 (q, J 7.1 Hz, 2H, COOCH2CH3), 5.09 (s, 2H, 
benzyl-CH2), 5.95-7.07 (m, 2H), 7.21 (d, J 2.4 Hz, 1H), 7.28-7.43 (m, 4H), 7.44-7.52 (m, 2H), 
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11.76 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 14.2, 60.2, 69.5, 103.4, 107.1, 
113.4, 115.6, 125.9, 127.6 (2 interfering carbon signals), 128.3 (2 interfering carbon signals), 
132.7, 137.3, 152.9, 161.1. MS (EI-MS, 70 eV) m/z (rel. int. in %) 295.2 ([M+•], 55), 204.1 ([M-
C7H7•], 75), 204.1 ([M-C7H7•-EtOH], 50), 91.1 ([C7H7]+, 100). C18H17NO3 (295.33). 
 
Ethyl 5-(benzyloxy)-3-methyl-1H-indole-2-carboxylate (5.38) 
The title compound was prepared from 5.35 (13.66 g, 42 mmol), according to the general 
procedure. The purified product was recrystallized from petroleum ether to yield a white-
yellow solid (4.8 g, 44 %); mp 143-145 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.35 (t, 
J 7.1 Hz, 3H), 2.50 (s, 3H), 4.32 (q, J 7.1 Hz, 2H), 5.12 (s, 2H), 5.99 (m, 1H), 7.20 (d, 
J 2.3 Hz, 1H), 7.26-7.45 (m, 4H), 7.49 (d, J 5.8 Hz, 2H), 11.34 (br s, 1H). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 9.8, 14.3, 59.9, 69.6, 101.9, 113.2, 115.8, 118.2, 123.5, 127.6 (2 
interfering carbon signals), 127.7, 128.3, 131.6, 137.2, 152.4, 161.8. MS (EI-MS, 70 eV) m/z 
(rel. int. in %) 309.2 ([M+•], 45), 218.1 ([M-C7H7•], 100), 172.0 ([M-C7H7•-EtOH], 95), 91.1 
([C7H7]+, 60). HRMS (ESI): m/z [M+H+]+ calculated for C19H20NO3+: 310.1438, found 
310.1438. C19H19NO3 (309.14). 
 
Ethyl 5-(benzyloxy)-3-ethyl-1H-indole-2-carboxylate (5.39) 
The title compound was prepared from 5.36 (5 g, 14.6 mmol), according to the general 
procedure. The purified product was recrystallized from petroleum ether to yield an orange 
solid (638 g, 14 %); mp 150-158 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.17 (t, J 
7.4 Hz, 3H), 1.34 (t, J 7.1 Hz, 3H), 3.01 (q, J 7.4 Hz, 2H), 4.33 (q, J 7.1 Hz, 2H), 5.12 (s, 2H), 
5.99 (m, 1H), 7.20 (d, J 2.3 Hz, 1H), 7.27-7.45 (m, 4H), 7.45-7.51 (m, 2H), 11.33 (br s, 1H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 14.2, 15.4, 59.9, 69.6, 101.8, 113.3, 115.7, 122.7, 
124.6, 125.7, 127.6, 127.6, 128.3, 131.7, 137.4, 152.4, 161.4. MS (EI-MS, 70 eV) m/z (rel. 
int. in %) 323.1 ([M+•], 35), 232.1 ([M-C7H7•], 90), 185.0 ([M-C7H7•-EtOH], 95), 91.1 ([C7H7]+, 
60). C20H21NO3 (323.15). 
 
5.6.2.5 Preparation of compounds 5.9-5.11 
General procedure20,30 
The pertinent indole ester (5.6-5.8, 1 eq) was dissolved in ethanol (5.2 mL/mmol). Hydrazine 
monohydrate (21 eq) was added, and the mixture was heated to reflux overnight. The 
reaction mixture was cooled to -15 °C to give a precipitate.  
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6,7-Dichloro-3-methyl-1H-indole-2-carbohydrazide (5.9) 
The title compound was prepared from 5.6 (800 mg, 2.94 mmol), according to the general 
procedure. The precipitate was filtered off to give the product as white-yellow crystals 
(530 mg, 70 %); mp > 210 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.50 (s, 3H), 4.56 (s, 
2H), 7.25 (d, J 8.5 Hz, 1H), 7.61 (d, J 8.5 Hz, 1H), 9.55 (br s, 1H), 11.35 (br s, 1H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 9.5, 114.0, 115.4, 119.6, 120.8, 125.0, 127.96, 128.04, 133.1, 
160.8. HRMS (ESI): m/z [M+H+]+ calculated for C10H10Cl2N3O+: 258.0200, found 258.0197. 
C10H9Cl2N3O (257.01). 
 
6,7-Dichloro-3-ethyl-1H-indole-2-carbohydrazide (5.10) 
The title compound was prepared from 5.6 (190 mg, 0.51 mmol), according to the general 
procedure. The precipitate was filtered off to give the product as orange solid (103 mg, 
56 %); Rf = 0.95, 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.22 (t, J = 7.3 Hz, 3H), 3.06 (q, 
J 7.4 Hz, 2H), 5.23 (s, 2H), 5.80 (d, J 5.5 Hz, 2H), 7.07-7.21 (m, 4H), 7.53 (d, J 8.5 Hz, 1H). 
13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 15.0, 19.1, 115.7, 120.5, 122.9, 125.1, 125.8 (2 
interfering carbon signals), 127.8, 129.4 (2 interfering carbon signals), 130.2, 134.3, 135.2, 
141.6, 167.5. HRMS (ESI): m/z [M+H+]+ calculated for C18H18Cl2N3O+: 362.0818, found 
362.0817. C18H17Cl2N3O (361.07). 
 
1H-Indole-2-carbohydrazide31 (5.11) 
The title compound was prepared from 5.8 (1 g, 5.3 mmol), according to the general 
procedure. The precipitate was filtered off to give the product as white crystals (1.6 g, 85 %); 
mp > 210 °C (ref.31: 250-251 °C dec). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.07 (m, 1H), 
7.15 (m, 1H), 7.26 (m, 1H), 7.46 (m, 1H), 7.66 (m, 1H), 11.89 (br s, 1H). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 101.7, 112.1, 119.6, 121.3, 123.0, 127.0, 130.4, 135.2, 161.1. HRMS 
(ESI): m/z [M+H+]+ calculated for C9H10N3O+: 175.0817, found 175.0817. C9H9N3O (175.07). 
 
5.6.2.6 Preparation of compounds 5.12-5.14 
General procedure20,32 
The pertinent indole carbohydrazide (5.9-5.11, 1 eq) was dissolved in formic acid 
(9.3 mL/mmol) and heated to reflux for 3 h. After cooling to room temperature, the solvent 
was removed under pressure. The precipitate was dissolved in methanol and cooled with ice 
to give the product as a precipitate which was filtered off and dried under pressure. 
Subsequently, the precipitate was suspended in phosphoryl chloride (7.7 mL/ mmol) and 
heated to reflux for 20 min. The reaction mixture was put on ice to cool down, neutralized 
with 2.5 M NaOH and washed three times with ethyl acetate. The combined organic layers 
116 Experimental section 
 
were dried over MgSO4, filtered, and the solvent evaporated. The crude product was purified 
by flash chromatography (PE/EtOAc 50/50 v/v). 
 
2-(6,7-Dichloro-3-methyl-1H-indol-2-yl)-1,3,4-oxadiazole (5.12) 
The title compound was prepared from 5.9 (250 mg, 0.97 mmol), according to the general 
procedure. Flash chromatography yielded a red solid (30 mg, 12 %); Rf = 0.66, RP-HPLC 
(220 nm): 76 % (tR = 26.0 min, k = 10.2).1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.59 (s, 
3H), 7.32 (d, J 8.5 Hz, 1H), 7.70 (d, J 8.5 Hz, 1H), 9.45 (br s, 1H), 12.36 (br s, 1H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 9.5, 115.0, 115.9, 119.8, 119.9, 121.5, 125.7, 127.8, 134.7, 
153.7, 158.4. MS (ES-MS) m/z (rel. int. in %) 268.0 ([M+H+]+, 100). HRMS (ESI): m/z [M+H+]+ 
calculated for C11H8Cl2N3O+: 268.0039, found 268.0039. C11H7Cl2N3O (267.00). 
 
2-(6,7-Dichloro-3-ethyl-1H-indol-2-yl)-1,3,4-oxadiazole (5.13) 
The title compound was prepared from 5.10 (130 mg, 0.55 mmol), according to the general 
procedure. Flash chromatography yielded a red solid (70 mg, 45 %); 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 1.30 (t, J 7.5 Hz, 3H), 3.16 (q, J 7.5 Hz, 2H), 7.23 (d, J 8.6 Hz, 1H), 7.61 
(d, J 8.6 Hz, 1H), 8.08 (s, 1H), 9.06 (br s, 1H). MS (ES-MS) m/z (rel. int. in %) 595.0 
([2M+Na+], 20), 285.0 ([MH+]+, 100). HRMS (ESI): m/z [M+H+]+ calculated for C12H10Cl2N3O+: 
282.0198, found 282.0197. C12H9Cl2N3O (281.01). 
 
2-(1H-Indol-2-yl)-1,3,4-oxadiazole (5.14) 
The title compound was prepared from 5.11 (500 mg, 2.85 mmol), according to the general 
procedure. Flash chromatography yielded a red solid (500 mg, 95 %); mp 190 °C. RP-HPLC 
(220 nm): 97 % (tR = 17.1 min, k = 5.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.10 (t, 
J 7.5 Hz, 1H), 7.20-7.25 (m, 1H), 7.28 (d, J 7.0 Hz, 1H), 7.51 (s, 1H), 7.68 (d, J 7.4 Hz, 1H), 
9.37 (br s, 1H), 12.30 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 104.9, 112.2, 
120.3, 120.8, 121.4, 124.1, 127.1, 137.7, 153.8, 158.9. MS (ES-MS) m/z (rel. int. in %) 185.1 
([M+H+]+, 100). HRMS (ESI): m/z [M+H+]+ calculated for C10H8N3O+: 185.0662, found 
185.065. C10H7N3O (185.06). 
 
5.6.2.7 Preparation of tert-butyl 4-(bromomethyl)benzoate (5.15) 
General procedure19 
4-(Bromomethyl)benzoic acid (5.15a; 3.22 g, 15 mmol, 1 eq) was dissolved in anhydrous 
THF (1.33 mL/mmol). Under an atmosphere of nitrogen, tert-butyl 2,2,2-trichloroacetimidate 
(TBTA, 5.6 g, 30 mmol, 2 eq) was dissolved in anhydrous cyclohexane (0.33 mL/mmol) and 
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added dropwise. After adding boron trifluoride etherate (BF3Et2O; 340 mg, 2.4 mmol, 
0.16 eq), the reaction mixture was stirred for 17 h at ambient temperature. To the crude 
product, solid NaHCO3 was added and stirred for additional 30 min. Subsequently, the 
reaction mixture was filtered over celite, washed twice with cyclohexane, and evaporated 
under reduced pressure. The crude brown oil was purified by flash chromatography 
(PE/EtOAc 80/20 v/v) to yield white crystals (2.9 g, 72 %); mp 139-144 °C, Rf = 0.75, 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.54 (s, 9H), 4.75 (s, 2H), 7.57 (t, J 9.6 Hz, 2H), 
7.90 (t, J 13.3 Hz, 2H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 27.7 (3 interfering carbon 
signals), 33.1, 80.3, 125.0 (2 interfering carbon signals), 128.8 (2 interfering carbon signals), 
128.9, 147.7, 164.8. MS (EI-MS, 70 eV) m/z (rel. int. in %) 272.1 ([M+•], 5), 255.0 ([M–CH3•]+, 
5), 215.0 ([M–C7H7•]+, 45), 135.1 (100). HRMS (ESI): m/z [M+H+]+ calculated for C12H16BrO2+: 
271.0327, found 273.0302. C12H15BrO2 (270.03). 
5.6.2.8 Preparation of compounds 5.16-5.21, 5.40-5.44 
General procedure5 
With ice cooling, NaH (60 % suspension in mineral oil, 1.14 eq) was suspended in anhydrous 
DMF (1.5 mL/mmol) and stirred for 15 min under an atmosphere of nitrogen. Subsequently, 
the pertinent indole compound (5.6, 5.7, 5.37, 5.38 and 5.39, 1.0 eq) in anhydrous DMF 
(2.25 mL/mmol) was added dropwise at 0 °C under an atmosphere of nitrogen. After stirring 
for 45 min at 0 °C, the corresponding benzyl halide (1.2 eq) in anhydrous DMF 
(4.5 mL/mmol) was slowly added. After removing the cooling bath, the mixture was stirred for 
additional 2.5 h at ambient temperature and then poured into ice water. The aqueous 
solution was extracted at least three times with EtOAc. The combined organic layers were 
washed with water and dried over MgSO4. The solvent was removed under reduced 
pressure, and the crude product was purified by RP flash chromatography (MeCN/H2O 
20/80-95/5 v/v).  
 
Ethyl 1-benzyl-6,7-dichloro-3-methyl-1H-indole-2-carboxylate (5.16) 
The title compound was prepared from 5.6 (1 g, 3.7 mmol) and (bromomethyl)-benzene 
(805 mg, 1.25 mmol), according to the general procedure. Flash chromatography yielded a 
white solid (910 mg, 68 %); mp 110 °C. 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.24 (t, 
J 7.1 Hz, 3H), 2.51 (s, 3H), 4.28 (q, J 7.1 Hz, 2H), 5.14 (s, 2H), 5.82 (d, J 5.9 Hz, 2H), 7.13-
7.31 (m, 3H), 7.36 (d, J 8.6 Hz, 1H), 7.75 (d, J 8.6 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ 
(ppm) 10.3, 13.8, 48.4, 60.8, 114.5, 120.7, 120.8, 122.1, 125.1, 125.7, 127.7, 128.2, 128.4, 
128.6, 129.7, 133.7, 139.5, 161.2. MS (EI-MS, 70 eV) m/z (rel. int. in %) 361.0 ([M+•], 10), 
91.1 ([C7H7]+, 100). HRMS (ESI): m/z [M+H+]+ calculated for C19H18Cl2NO2+: 362.0712, found 
362.0710. C19H17Cl2NO2 (361.06). 
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Ethyl 6,7-dichloro-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylate (5.17) 
The title compound was prepared from 5.6 (340 mg, 1.25 mmol) and 1-(bromomethyl)-4-
chlorobenzene (321 mg, 1.56 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (140 mg, 28 %) which was used for the 
preparation of 5.25 without further purification. 
 
Ethyl 1-[4-(tert-butoxycarbonyl)benzyl]-6,7-dichloro-3-methyl-1H-indole-2-carboxylate 
(5.18) 
The title compound was prepared from 5.6 (430 mg, 1.6 mmol) and tert-butyl 4-
(bromomethyl)benzoate (543 mg, 2 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (220 mg, 30 %) which was used for the 
preparation of 5.26 without further purification. 
 
Ethyl 1-benzyl-6,7-dichloro-3-ethyl-1H-indole-2-carboxylate (5.19) 
The title compound was prepared from 5.7 (890 mg, 3.11 mmol) and (bromomethyl)benzene 
(665 mg, 3.89 mmol), according to the general procedure. RP flash chromatography yielded 
a white solid (240 mg, 21 %); Rf = 0.88, 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.19 (t, 
J 7.5 Hz, 3H), 1.25 (t, J 5.4 Hz, 3H), 3.02 (q, J 7.4 Hz, 2H), 4.29 (q, J 7.1 Hz, 2H), 5.14 (s, 
2H), 5.82 (d, J 7.0 Hz, 2H), 7.15-7.30 (m, 3H), 7.38 (d, J 8.5 Hz, 1H), 7.80 (d, J 8.6 Hz, 1H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 13.7, 15.4, 17.8, 48.5, 60.9, 120.5, 122.2, 125.1 (2 
interfering carbon signals), 125.7, 127.0, 127.3, 127.4, 127.7, 128.4 (2 interfering carbon 
signals), 129.6, 133.7, 139.6, 161.1. MS (EI-MS, 70 eV) m/z (rel. int. in %) 375.1 ([M+•], 20), 
284.0 ([M-C7H7•], 20), 91.1 ([C7H7]+, 100). C20H19Cl2NO2 (375.08). 
 
Ethyl 6,7-dichloro-1-(4-chlorobenzyl)-3-ethyl-1H-indole-2-carboxylate (5.20) 
The title compound was prepared from 5.7 (1 g, 3.5 mmol) and 1-(bromomethyl)-4-
chlorobenzene (864 mg, 4.2 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (120 mg, 8 %) which was used for the preparation 
of 5.28 without further purification. 
 
Ethyl 1-[4-(tert-butoxycarbonyl)benzyl]-6,7-dichloro-3-ethyl-1H-indole-2-carboxylate 
(5.21) 
The title compound was prepared from 5.7 (430 mg, 1.58 mmol) and tert-butyl 
4-(bromomethyl)benzoate (543 mg, 2 mmol), according to the general procedure. RP flash 
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chromatography yielded a white fluffy solid (240 mg, 33 %) which was used for the 
preparation of 5.29 without further purification. 
 
Ethyl 5-(benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylate (5.40) 
The title compound was prepared from 5.37 (470 mg, 1.6 mmol) and 1-(bromomethyl)-4-
chlorobenzene (411 mg, 2 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (260 mg, 39 %), which was used for the 
preparation of 5.48 without further purification. 
 
Ethyl 1-benzyl-5-(benzyloxy)-3-methyl-1H-indole-2-carboxylate (5.41) 
The title compound was prepared from 5.38 (500 mg, 1.62 mmol) and 1-(bromomethyl)-4-
chlorobenzene (350 mg, 2.02 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (415 mg, 65 %); mp 200 °C. 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 1.27 (t, J 7.1 Hz, 3H), 2.53 (s, 3H), 4.27 (q, J 7.1 Hz, 2H), 5.14 (s, 2H), 
5.75 (s, 2H), 5.94 (m, 2H), 7.05 (m, 1H), 7.17-7.31 (m, 3H), 7.31-7.52 (m, 7H). 13C-NMR 
(75 MHz, [D6]DMSO): δ (ppm) 10.7, 14.0, 20.7, 59.7, 69.6, 102.2, 111.8, 117.2, 119.6, 124.4, 
125.0 (2 interfering carbon signals), 125.8, 125.9, 127.6 (3 interfering carbon signals), 128.3 
(4 interfering carbon signals), 133.5, 137.2, 138.8, 152.7, 161.5. MS (EI-MS, 70 eV) m/z (rel. 
int. in %) 399.2 ([M+•], 10), 308.2 ([M-C7H7•]+, 25), 91.1 ([C7H7+], 100). C26H25NO3 (399.18). 
 
Ethyl 5-(benzyloxy)-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylate (5.42) 
The title compound was prepared from 5.38 (500 mg, 1.6 mmol) and 1-(bromomethyl)-4-
chlorobenzene (410 mg, 2 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (120 mg, 17 %), which was used for the 
preparation of 5.50 without further purification. 
 
Ethyl 5-(benzyloxy)-1-(4-(tert-butoxycarbonyl)benzyl)-3-methyl-1H-indole-2-carboxylate 
(5.43) 
The title compound was prepared from 5.38 (500 mg, 1.6 mmol) and 1-(bromomethyl)-4-
chlorobenzene (545 mg, 1.25 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (560 mg, 70 %); mp 110-120 °C. RP-HPLC 
(220 nm): 100 % (tR = 34.9 min, k = 14.0). 1H-NMR (300 MHz, [D6]Acetone): δ (ppm) 1.33 (t, 
J 7.1 Hz, 3H), 1.55 (s, 9H), 2.59 (s, 3H), 4.31 (q, J 7.1 Hz, 2H), 5.17 (s, 2H), 5.89 (s, 2H), 
7.03-7.13 (m, 3H), 7.27-7.45 (m, 5H), 7.52 (d, J 7.4 Hz, 2H), 7.85 (d, J 8.3 Hz, 2H). 13C-NMR 
(75 MHz, [D6]Acetone): δ (ppm) 11.2, 14.6, 28.3 (3 interfering carbon signals), 48.6, 61.1, 
71.0, 81.2, 103.4, 112.6, 118.3, 121.3, 125.8, 127.0 (2 interfering carbon signals), 128.5 (2 
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interfering carbon signals), 128.6, 129.3 (2 interfering carbon signals), 130.3 (2 interfering 
carbon signals), 131.7, 135.0, 138.8, 145.2, 154.7, 163.2, 165.8. HRMS (ESI): m/z [M+H+]+ 
calculated for C31H34NO5+: 500.2437, found 500.2432. C31H33NO5 (499.24). 
 
Ethyl 5-(benzyloxy)-1-(4-chlorobenzyl)-3-ethyl-1H-indole-2-carboxylate (5.44) 
The title compound was prepared from 5.39 (500 mg, 1.6 mmol) and 1-(bromomethyl)-4-
chlorobenzene (390 mg, 1.9 mmol), according to the general procedure. RP flash 
chromatography yielded a white fluffy solid (230 mg, 34 %), which was used for the 
preparation of 5.52 without further purification. 
 
5.6.2.9 Preparation of compounds 5.22-5.31, 5.45-5.52, 5.60 
General procedure5 
A suspension of the pertinent carboxylate (5.16-5.21, 5.40-5.44, 1 eq) and LiOH (2.5 eq) in a 
3:1:0.2 mixture of THF, H2O and EtOH (v/v/v) was stirred at room temperature for 3 days. 
The reaction mixture was acidified with 0.5 N HCl to pH 2 to yield the product as precipitate. 
 
6,7-Dichloro-3-methyl-1H-indole-2-carboxylic acid (5.22) 
The title compound was prepared from 5.6 (70 mg, 0.26 mmol), according to the general 
procedure. Precipitation yielded a yellow solid (60 mg, 94 %); mp > 210 °C. RP-HPLC 
(220 nm): 100 % (tR = 23.1 min, k = 8.9). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 2.56 (s, 
3H, indole-CH3-3), 7.18 (d, J 8.6 Hz, 1H, indole-H-5), 7.55 (d, J 8.6 Hz, 1H; indole-H-4). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 9.7 (indole-CH3-3), 114.7 (Cquat, indole-C-7), 119.3 
(Cquat, indole-C-9), 120.1 (indole-C-4), 121.0 (indole-C-5), 125.5 (Cquat, indole-C-2), 127.1 
(Cquat, indole-C-6), 128.1 (Cquat, indole-C-8), 133.8 (Cquat, indole-C-3), 162.8 (COOH). MS 
(ES-MS) m/z (rel. int. in %) 485.9 ([2M-H+]-, 100) 288.0 ([M+HCOO-], 20). HRMS (ESI): m/z 
[M-H+]- calculated for C10H6Cl2NO2-: 242.9813, found 242.9811. C10H7Cl2NO2 (242.99). 
 
6,7-Dichloro-3-ethyl-1H-indole-2-carboxylic acid (5.23) 
The title compound was prepared from 5.7 (25 mg, 0.1 mmol), according to the general 
procedure. Precipitation yielded a yellow solid (25 mg, 97 %); mp > 210 °C. RP-HPLC 
(220 nm): 100 % (tR = 23.9 min, k = 9.3). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.24 (t, 
J 7.5 Hz, 3H, indole-CH3-3), 3.11 (q, J 7.5 Hz, 2H, indole-CH2-3), 7.19 (d, J 8.6 Hz, 1H, 
indole-H-5), 7.58 (d, J 8.6 Hz, 1H, indole-H-4). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 15.9 
(indole-CH3-3), 18.9 (indole-CH2-3), 115.6 (Cquat, indole-C-7), 120.9 (Cquat, indole-C-9), 122.6 
(indole-C-4), 128.5 (indole-C-5), 128.7 (Cquat, indole-C-2), 129.4 (Cquat, indole-C-6), 134.1 
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(Cquat, indole-C-8), 135.8 (Cquat, indole-C-3), 164.6 (Cquat, COOH). MS (ES-MS) m/z (rel. int. 
in %) 514.9 ([2M-H+]-, 100) 302.0 ([M+HCOO-], 35). HRMS (ESI): m/z [M-H+]- calculated for 
C11H8Cl2NO2-: 255.997, found 255.9968. C11H9Cl2NO2 (257.00). 
 
1-Benzyl-6,7-dichloro-3-methyl-1H-indole-2-carboxylic acid (5.24) 
The title compound was prepared from 5.16 (64 mg, 0.18 mmol), according to the general 
procedure. Precipitation yielded a white solid (40 mg, 60 %); mp 200 °C. RP-HPLC (220 nm): 
100 % (tR = 29.5 min, k = 11.6). Rf = 0.78, 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.53 (s, 
3H), 5.22 (s, 2H), 5.81 (d, J 7.0 Hz, 2H), 7.14-7.29 (m, 3H), 7.36 (d, J 8.5 Hz, 1H), 7.75 (d, 
J 8.5 Hz, 1H), 13.46 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 9.9, 47.8, 113.8, 
120.4, 120.6, 121.9, 125.1, 125.6, 128.4, 128.5, 128.7, 129.3, 133.6, 139.6, 162.5. MS (ES-
MS) m/z (rel. int. in %) 332.0 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- calculated for 
C17H12Cl2NO2-: 333.0283, found 333.0288. C17H13Cl2NO2 (333.03). 
 
6,7-Dichloro-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid (5.25) 
The title compound was prepared from 5.17 (60 mg, 0.15 mmol), according to the general 
procedure. Precipitation yielded a white-yellow solid (50 mg, 91 %); mp > 210 °C. RP-HPLC 
(220 nm): 96 % (tR = 30.6 min, k = 12.1). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.52 (s, 
3H), 5.18 (s, 2H), 5.84 (d, J 8.4 Hz, 2H), 7.24-7.48 (m, 3H), 7.75 (d, J 8.5 Hz, 1H) 13.49 (br 
s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 10.4, 47.8, 114.4, 120.5, 120.7, 122.0, 127.0 
(2 interfering carbon signals), 128.4 (2 interfering carbon signals), 128.8, 129.4, 131.2, 133.4, 
138.9, 162.9. MS (ES-MS) m/z (rel. int. in %) 365.0 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- 
calculated for C17H11Cl3NO2-: 365.9893, found 365.9895. C17H12Cl3NO2 (365.99). 
 
1-[4-(tert-Butoxycarbonyl)benzyl]-6,7-dichloro-3-methyl-1H-indole-2-carboxylic acid 
(5.26) 
The title compound was prepared from 5.18 (70 mg, 0.16 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 250 x 21 
mm; gradient: 0-30 min: MeCN/0.1% aq. TFA 60/40-95/5, tR = 21. 9 min) and removal of the 
eluate by evaporation and lyophilisation afforded 5.25 as a white fluffy solid (20 mg, 29 %); 
mp 200 °C. RP-HPLC (220 nm): 100 % (tR = 19.3 min, k = 7.3) 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 1.50 (s, 9H), 2.53 (s, 3H), 5.25 (s, 2H), 5.93 (d, J 8.4 Hz, 2H), 7.38 (d, 
J 8.5 Hz, 1H), 7.78 (m, 3H), 13.47 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 10.3, 
27.6 (3 interfering carbon signals), 80.3, 113.7, 120.7, 125.2 (2 interfering carbon signals), 
127.8, 128.5, 128.7, 128.8, 129.2 (2 interfering carbon signals), 129.4, 129.8, 133.6, 137.5, 
162.9, 164.5. MS (ES-MS) m/z (rel. int. in %) 432.1 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- 
calculated for C22H20Cl2NO4-: 432.0788, found 432.0788. C22H21Cl2NO4 (433.08). 
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1-Benzyl-6,7-dichloro-3-ethyl-1H-indole-2-carboxylic acid (5.27) 
The title compound was prepared from 5.19 (50 mg, 0.13 mmol), according to the general 
procedure. Precipitation yielded a white solid (36 mg, 80 %); mp 200 °C. RP-HPLC (220 nm): 
83 % (tR = 30.9 min, k = 12.2). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.24 (t, J 7.5 Hz, 3H), 
3.03 (q, J 7.5 Hz, 2H), 5.16 (s, 2H), 5.85 (d, J 7.0 Hz, 2H), 7.13-7.30 (m, 3H), 7.36 (d, 
J 8.5 Hz, 1H), 7.77 (d, J 8.6 Hz, 2H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 15.5, 17.7, 
105.2, 105.8, 114.6, 120.3, 122.0, 125.1 (2 interfering carbon signals), 125.6, 125.7, 127.9, 
128.2, 128.4 (2 interfering carbon signals), 129.3, 139.7, 162.7. MS (ES-MS) m/z (rel. int. 
in %) 348.1 ([M+H+], 100). HRMS (ESI): m/z [M-H+]- calculated for C18H14Cl2NO2-: 345.0407, 
found 345.0417. C18H15Cl2NO2 (347.05). 
 
6,7-Dichloro-1-(4-chlorobenzyl)-3-ethyl-1H-indole-2-carboxylic acid (5.28) 
The title compound was prepared from 5.20 (100 mg, 0.351 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-25 min: MeCN/0.1% aq. TFA 28/72-95/5, tR = 22.2 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.28 as a white fluffy solid 
(60 mg, 45 %); mp > 210 °C. RP-HPLC (220 nm): 96 % (tR = 32.7 min, k = 13.0). 1H-NMR 
(300 MHz, [D6]Aceton): δ (ppm) 1.26 (t, J 7.5 Hz, 3H), 3.15 (q, J 7.5 Hz, 2H), 5.32 (s, 2H), 
5.94 (t, J 5.6 Hz, 2H), 7.20-7.37 (m, 3H), 7.75 (d, J 8.6 Hz, 1H). 13C-NMR (75 MHz, 
[D6]Aceton): δ (ppm) 15.0, 19.0, 49.1, 121.0, 123.1, 128.3 (2 interfering carbon signals), 
129.3 (2 interfering carbon signals), 129.4, 130.7, 133.8, 135.1, 140.4. HRMS (ESI): m/z [M-
H+]- calculated for C18H13Cl3NO2-: 381.9990, found 380.0020. C18H14Cl3NO2 (381.01). 
 
1-[4-(tert-Butoxycarbonyl)benzyl]-6,7-dichloro-3-ethyl-1H-indole-2-carboxylic acid 
(5.29) 
The title compound was prepared from 5.21 (100 mg, 0.2 mmol), according to the general 
procedure. Precipitation yielded a white solid (80 mg, 89 %); mp 140 °C. RP-HPLC (220 nm): 
96 % (tR = 34.8 min, k = 13.9). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.25 (t, J 7.4 Hz, 3H), 
1.53 (s, 9H), 3.08 (q, J 7.4 Hz, 2H), 5.29 (s, 2H), 5.87 (t, J 8.2 Hz, 2H), 7.20 (d, J 8.5 Hz, 1H), 
7.56 (d, J 8.5 Hz, 1H), 7.75 (d, J 8.3 Hz, 2H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 15.6, 
17.3, 27.6 (3 interfering carbon signals), 27.7, 68.3, 70.8, 80.3, 114.2, 119.4, 121.1, 125.4 (2 
interfering carbon signals), 127.2, 128.6, 129.0 (2 interfering carbon signals), 129.5, 132.2, 
143.2, 145.0, 164.5. MS (ES-MS) m/z (rel. int. in %) 445.1 ([M-H+]-, 100). HRMS (ESI): m/z 
[M-H+]- calculated for C23H22Cl2NO4-: 447.0964, found 447.095. C23H23Cl2NO4 (447.10). 
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1-(4-Carboxybenzyl)-6,7-dichloro-3-methyl-1H-indole-2-carboxylic acid (5.30) 
The title compound was prepared from 5.26 (70 mg, 0.16 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-25 min: MeCN/0.1% aq. TFA 28/72-95/5, tR = 10.1 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.30 as a white fluffy solid 
(60 mg, 45 %); mp 200 °C. RP-HPLC (220 nm): 100 % (tR = 24.4 min, k = 9.5). 1H-NMR 
(300 MHz, [D6]DMSO): δ (ppm) 2.55 (s, 3H, indole-CH3-3), 5.26 (s, 2H, NCH2), 5.94 (d, 
J 8.3 Hz, 2H, benzyl-H), 7.37 (d, J 8.6 Hz, 1H, indole-H-5), 7.78 (d, J 8.5 Hz, 1H, indole-H-4), 
7.84 (d, J 8.3 Hz, 2H, benzyl-H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 10.1 (indole-
CH3-3), 48.3 (NCH2), 114.3 (Cquat, indole-C-7), 120.5 (indole-C-4), 120.7 (Cquat, indole-C-9), 
122.0 (indole-C-5), 125.1 (benzyl-C-2,6), 128.2 (Cquat, indole-C-2), 128.7 (Cquat, indole-C-6), 
129.2 (Cquat, benzyl-C-4), 129.4 (Cquat, indole-C-8), 129.5 (benzyl-C-3,5), 133.4 (Cquat, indole-
C-3), 144.8 (Cquat, benzyl-C-1), 162.8 (Cquat, indole-COOH), 165.8 (Cquat, benzyl-COOH). MS 
(ES-MS) m/z (rel. int. in %) 375.0 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- calculated for 
C18H12Cl2NO4-: 377.0182, found 377.0185. C18H13Cl2NO4 (377.02).  
 
1-(4-Carboxybenzyl)-6,7-dichloro-3-ethyl-1H-indole-2-carboxylic acid (5.31) 
The title compound was prepared from 5.29 (70 mg, 0.16 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-20 min: MeCN/0.1% aq. TFA 55/45-90/10, tR = 11.8 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.31 as a white fluffy solid 
(40 mg, 64 %); RP-HPLC (220 nm): 99 % (tR = 19.4 min, k = 7.3). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 1.19 (t, J 7.4 Hz, 3H), 3.05 (q, J 7.4 Hz, 2H), 5.24 (s, 2H), 5.94 (d, 
J 8.3 Hz, 2H), 7.37 (d, J 8.5 Hz, 1H), 7.81 (m, 3H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
15.4, 17.9, 48.3, 114.5, 120.5, 122.1, 125.2 (2 interfering carbon signals), 125.8, 127.77, 
127.82, 129.1, 129.4, 129.5 (2 interfering carbon signals), 133.5, 145.0, 162.8, 165.8. MS 
(ES-MS) m/z (rel. int. in %) 435.0 ([M+HCOO-], 100). HRMS (ESI): m/z [M-H+]- calculated for 
C19H14Cl2NO4-: 391.0338, found 391.0335. C19H15Cl2NO4 (391.04). 
 
5-(Benzyloxy)-1H-indole-2-carboxylic acid29,33 (5.45) 
The title compound was prepared from 5.37 (80 mg, 0.27 mmol), according to the general 
procedure. Precipitation yielded a white solid (40 mg, 55 %; mp ref.:33 190 °C). 1H-NMR 
(300 MHz, [D4]MeOH): δ (ppm) 5.08 (s, 2H), 7.00 (m, 1H), 7.06 (d, J 0.8 Hz, 1H), 7.16 (d, 
J 2.2 Hz, 1H), 7.34 (m, 4H), 7.43-7.49 (m, 2H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 71.7, 
105.0, 114.1, 118.1, 128.7 (3 interfering carbon signals), 128.8 (2 interfering carbon signals), 
128.9, 129.5, 134.6, 139.2, 154.9. HRMS (ESI): m/z [M+H+]+ calculated for C16H14NO3+: 
265.0810, found 265.0812. C16H13NO3 (267.09). 
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5-(Benzyloxy)-3-methyl-1H-indole-2-carboxylic acid (5.46) 
The title compound was prepared from 5.38 (100 mg, 0.32 mmol), according to the general 
procedure. Precipitation yielded a white solid (100 mg, 100 %); 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 2.53 (s, 3H), 5.08 (s, 2H), 7.00 (m, 1H), 7.12 (d, J 2.2 Hz, 1H), 7.25-7.41 
(m, 4H), 7.43-7.50 (m, 2H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 10.1, 71.8, 103.4, 114.0, 
118.3, 120.1, 125.6, 128.7 (2 interfering carbon signals), 128.8, 129.5 (2 interfering carbon 
signals), 129.8, 133.6, 139.2, 154.5, 165.7. HRMS (ESI): m/z [M-H+]- calculated for 
C17H14NO3-: 280.0972, found 280.0972. C17H16NO3 (281.11). 
 
5-(Benzyloxy)-3-ethyl-1H-indole-2-carboxylic acid (5.47) 
The title compound was prepared from 5.39 (80 mg, 0.25 mmol), according to the general 
procedure. Precipitation yielded a white solid (40 mg, 54 %); 1H-NMR (300 MHz, [D4]MeOH): 
δ (ppm) 1.21 (t, J 5.1 Hz, 3H), 3.07 (q, J 7.5 Hz, 2H), 5.10 (s, 2H), 7.00 (m, 1H), 7.13 (d, 
J 2.3 Hz, 1H), 7.25-7.41 (m, 4H), 7.43-7.50 (m, 2H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 
15.9, 18.9, 71.9, 103.5, 114.1, 118.2, 127.0, 128.75 (2 interfering carbon signals), 128.78, 
128.80, 129.5 (2 interfering carbon signals), 130.6, 133.6, 139.2, 154.4, 165.5. HRMS (ESI): 
m/z [M-H+]- calculated for C18H16NO3-: 294.1128, found 294.1128. C18H17NO3 (295.12). 
 
5-(Benzyloxy)-1-(4-chlorobenzyl)-1H-indole-2-carboxylic acid (5.48) 
The title compound was prepared from 5.40 (50 mg, 0.12 mmol), according to the general 
procedure. Precipitation yielded a white solid (35 mg, 75 %); RP-HPLC (220 nm): 93 % 
(tR = 29.2 min, k = 11.5). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 5.08 (s, 2H), 5.82 (s, 2H), 
5.96-7.05 (m, 3H), 7.19-7.25 (m, 3H), 7.28 (d, J 5.2 Hz, 2H), 7.30-7.40 (m, 3H), 7.45 (m, 2H). 
13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 45.8, 62.0, 69.5, 103.6, 125.3, 127.48, 127.53, 
127.88, 127.91, 128.1, 128.3, 128.7, 131.1, 137.5, 152.7. HRMS (ESI): m/z [M-H+]- 
calculated for C23H17ClNO3-: 390.0902, found 390.0902. C23H18ClNO3 (391.10). 
 
1-Benzyl-5-(benzyloxy)-3-methyl-1H-indole-2-carboxylic acid (5.49) 
The title compound was prepared from 5.41 (100 mg, 0.25 mmol), according to the general 
procedure. Precipitation yielded a white solid (77 mg, 83 %); RP-HPLC (220 nm): 95 % 
(tR = 19.3 min, k = 7.3). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.52 (s, 3H), 5.13 (s, 2H), 
5.78 (s, 2H), 5.92-5.99 (m, 2H), 7.02 (m, 1H), 7.13-7.28 (m, 4H), 7.29-7.52 (m, 6H), 12.98 (br 
s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 10.7, 47.1, 69.6, 102.2, 111.8, 115.6, 119.3, 
125.1, 125.0 (2 interfering carbon signals), 125.7, 127.0, 127.6 (2 interfering carbon signals), 
138.27 (2 interfering carbon signals), 128.29 (2 interfering carbon signals), 133.3, 137.2, 
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138.9, 152.7, 163.5. MS (ES-MS) m/z (rel. int. in %) 372.2 ([M-H+]-, 100). HRMS (ESI): m/z 
[M-H+]- calculated for C24H20NO3-: 370.1449, found 370.1455. C24H21NO3 (371.15). 
 
5-(Benzyloxy)-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid (5.50) 
The title compound was prepared from 5.42 (120 mg, 0.28 mmol), according to the general 
procedure. Precipitation yielded a white solid (100 mg, 88 %); 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 2.52 (s, 3H), 5.10 (s, 2H), 5.76 (s, 2H), 5.89-7.00 (m, 3H), 7.11-7.23 (m, 
4H), 7.25-7.41 (m, 3H), 7.46 (d, J 7.2 Hz, 2H). 13C-NMR (151 MHz, [D4]MeOH): δ (ppm) 10.6, 
49.6, 72.0, 104.0, 112.2, 115.3, 128.66 (2 interfering carbon signals), 128.73, 129.2 (2 
interfering carbon signals), 129.3 (2 interfering carbon signals), 129.4 (2 interfering carbon 
signals), 133.5, 133.9, 134.4, 139.3, 139.9, 154.6, 172.4. HRMS (ESI): m/z [M-H+]- calculated 
for C24H19ClNO3-: 404.1039, found 404.1043. C24H20ClNO3 (405.11). 
 
5-(Benzyloxy)-1-(4-chlorobenzyl)-3-ethyl-1H-indole-2-carboxylic acid (5.52) 
The title compound was prepared from 5.44 (230 mg, 0.51 mmol), according to the general 
procedure. Precipitation yielded a white-yellow solid (200 mg, 94 %); mp 135-145 °C. RP-
HPLC (220 nm): 85 % (tR = 31.2 min, k = 12.4). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.14 
(t, J 7.0 Hz, 3H), 3.07 (q, J 7.0 Hz, 2H), 5.09 (s, 2H), 5.86 (s, 2H), 5.86 (m, 1H), 7.00-7.17 (m, 
3H), 7.18-7.43 (m, 6H), 7.47 (d, J 5.8 Hz, 2H). HRMS (ESI): m/z [M-H+]- calculated for 
C25H21ClNO3-: 418.1199, found 418.1198. C25H22ClNO3 (419.13). 
 
5.6.2.10 Preparation of compounds 5.53-5.59 
General procedure2 
The pertinent 5-benzyloxyindole derivative (5.45-5.52, 1 eq) was dissolved in a 1:1 mixture of 
MeOH and THF (v/v) and a catalytic amount of palladium on activated charcoal (10 % Pd) 
was added. A slow stream of hydrogen was then bubbled through the suspension overnight. 
Insoluble material was filtered off, and the solvent was evaporated to yield the target 
compound.  
 
5-Hydroxy-1H-indole-2-carboxylic acid34 (5.53) 
The title compound was prepared from 5.45 (40 mg, 0.23 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-30 min: MeCN/0.1% aq. TFA 28/72-95/5, tR = 7.9 min) and removal 
of the eluate by evaporation and lyophilisation afforded 5.53 as a light brown fluffy solid 
(30 mg, 74 %); mp > 210 °C (ref.:34 246 °C, decomposed). RP-HPLC (220 nm): 83 % 
126 Experimental section 
 
(tR = 8.18 min, k = 2.5). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 5.78 (m, 1H), 5.88 (s, 2H), 
7.23 (d, J 8.8 Hz, 1H), 8.88 (s, 1H), 11.45 (s, 1H), 12.73 (br s, 1H). MS (ES-MS) m/z (rel. int. 
in %) 175.0 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- calculated for C9H6NO3-: 177.0385, 
found 175.0384. C9H7NO3 (177.04). 
 
5-Hydroxy-3-methyl-1H-indole-2-carboxylic acid (5.54) 
The title compound was prepared from 5.46 (100 mg, 0.52 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-30 min: MeCN/0.1% aq. TFA 28/72-95/5, tR = 8.7 min) and removal 
of the eluate by evaporation and lyophilisation afforded 5.54 as a light violet fluffy solid 
(50 mg, 50 %); mp 210 °C. RP-HPLC (220 nm): 94 % (tR = 10.3 min, k = 3.4). 1H-NMR 
(300 MHz, [D6]DMSO): δ (ppm) 2.42 (s, 3H), 5.78 (m, 1H), 5.84 (d, J 2.3 Hz, 1H), 7.18 (d, 
J 8.7 Hz, 1H), 8.85 (s, 1H), 11.06 (s, 1H), 12.70 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): 
δ (ppm) 9.7, 102.6, 112.7, 115.9, 115.4, 124.1, 128.3, 130.7, 150.6, 163.4. MS (ES-MS) m/z 
(rel. int. in %) 190.1 ([M-H+]-, 100). HRMS (ESI): m/z [M-H+]- calculated for C10H8NO3-: 
191.0542, found 191.0541. C10H9NO3 (191.06). 
 
3-Ethyl-5-hydroxy-1H-indole-2-carboxylic acid (5.55) 
The title compound was prepared from 5.47 (40 mg, 0.2 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-30 min: MeCN/0.1% aq. TFA 28/72-95/5, tR = 11.4 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.55 as a light brown fluffy 
solid (20 mg, 49 %); mp 208-209 °C. RP-HPLC (220 nm): 100 % (tR = 19.4 min, k = 7.3). 1H-
NMR (300 MHz, [D6]DMSO): δ (ppm) 1.15 (t, J 7.4 Hz, 3H), 2.95 (q, J 7.4 Hz, 2H), 5.77 (m, 
1H), 5.87 (d, J 2.2 Hz, 1H), 7.19 (d, J 8.8 Hz, 1H), 8.84 (s, 1H), 11.06 (s, 1H), 12.70 (br s, 
1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 15.4, 17.4, 102.5, 112.9, 115.8, 123.2, 123.4, 
127.3, 130.8, 150.5, 163.3. MS (ES-MS) m/z (rel. int. in %) 204.1 ([M-H+]-, 100). HRMS (ESI): 
m/z [M-H+]- calculated for C11H10NO3-: 205.0698, found 205.0697. C11H11NO3 (205.07). 
 
1-(4-Chlorobenzyl)-5-hydroxy-1H-indole-2-carboxylic acid35 (5.56) 
The title compound was prepared from 5.48 (35 mg, 0.1 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-20 min: MeCN/0.1% aq. TFA 40/60-75/25, tR = 12.4 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.56 as a white fluffy solid 
(30 mg, 99 %); RP-HPLC (220 nm): 90.5 % (tR = 17.93 min, k = 6.7). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 5.73 (s, 2H), 5.81 (m, 1H), 5.94 (m, 3H), 7.12-7.34 (m, 4H), 9.00 (s, 1H), 
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12.89 (br s, 1H). HRMS (ESI): m/z [M-H+]- calculated for C16H11ClNO3-: 300.0430, found 
300.0430. C16H12ClNO3 (301.05). 
 
1-Benzyl-5-hydroxy-3-methyl-1H-indole-2-carboxylic acid (5.57) 
The title compound was prepared from 5.49 (37 mg, 0.1 mmol), according to the general 
procedure. Precipitation yielded the product as a brown solid (23 mg, 82 %); RP-HPLC 
(220 nm): 100 % (tR = 17.5 min, k = 5.5). 1H-NMR (300 MHz, [D1]CHCl3): δ (ppm) 2.55 (s, 
3H), 5.71 (s, 2H), 5.92 (m, 3H), 7.04 (d, J 2.3 Hz, 1H), 7.07-7.19 (m, 4H). 13C-NMR (75 MHz, 
[D6]DMSO): δ (ppm) 10.7, 103.1, 111.5, 115.3, 118.6, 124.8, 125.1 (benzyl-C-2,6), 125.7, 
127.4, 128.2 (benzyl-C-3,5), 132.8, 139.1, 139.2, 151.2, 163.5. MS (ES-MS) m/z (rel. int. 
in %) 561.2 ([2M-H+]-, 20) 325.1 ([M+HCOO-], 100). HRMS (ESI): m/z [M-H+]- calculated for 
C17H14NO3-: 281.1012, found 281.1011. C17H15NO3 (281.11). 
 
5-(Benzyloxy)-1-(carboxybenzyl)-3-methyl-1H-indole-2-carboxylic acid (5.58) 
The title compound was prepared from 5.43 (200 mg, 0.4 mmol), according to the general 
procedure. Precipitation yielded a white solid (85 mg, 20 %); 1H-NMR (300 MHz, [D6]DMSO): 
δ (ppm) 2.53 (s, 3H), 5.14 (s, 2H), 5.85 (s, 2H), 7.04 (m, 3H), 7.24-7.44 (m, 5H), 7.49 (d, 
J 5.8 Hz, 2H), 7.74-7.86 (m, 2H), 12.92 (br s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 
10.7, 51.7, 69.6, 102.4, 111.8, 119.5, 125.2, 125.0 (2 interfering carbon signals), 127.0, 
127.6 (2 interfering carbon signals), 128.3 (2 interfering carbon signals), 129.3, 129.4, 133.4, 
137.3, 144.2, 152.9, 163.5, 167.0. HRMS (ESI): m/z [M-H+]- calculated for C25H20NO5-: 
414.1343, found 414.1341. C25H21NO5 (415.14). 
 
1-Benzyl-3-ethyl-5-hydroxy-1H-indole-2-carboxylic acid (5.59) 
The title compound was prepared from 5.52 (50 mg, 0.12 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-15 min: MeCN/0.1% aq. TFA 46/54-73/27, tR = 11.5 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.59 as a white fluffy solid 
(20 mg, 56 %); RP-HPLC (220 nm): 97.9 % (tR = 19.27 min, k = 7.3). 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 1.24 (t, J 7.5 Hz, 3H), 3.08 (q, J 7.5 Hz, 2H), 5.74 (s, 2H), 5.85 (m, 1H), 
5.90-5.99 (m, 2H), 7.01 (d, J 2.3 Hz, 1H), 7.08-7.27 (m, 4H). 13C-NMR (75 MHz, [D4]MeOH): 
δ (ppm) 15.06, 19.7, 104.5, 112.6, 117.4, 125.7, 127.3 (2 interfering carbon signals), 127.9, 
128.3, 128.5, 129.4 (2 interfering carbon signals), 135.5, 140.7, 152.4, 165.7. HRMS (ESI): 
m/z [M-H+]- calculated for C18H16NO3-: 194.1143, found 294.1142. C18H17NO3 (295.12). 
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1-(4-Carboxybenzyl)-5-hydroxy-3-methyl-1H-indole-2-carboxylic acid (5.60) 
The title compound was prepared from 5.51 (50 mg, 0.12 mmol), according to the general 
procedure. The product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-20 min: MeCN/0.1% aq. TFA 46/54-95/5, tR = 13.1 min) and 
removal of the eluate by evaporation and lyophilisation afforded 5.60 as a white fluffy solid 
(36 mg, 92 %); mp > 210 °C. RP-HPLC (220 nm): 100 % (tR = 14.3 min, k = 5.1). 1H-NMR 
(300 MHz, [D6]DMSO): δ (ppm) 2.48 (s, 3H, indole-CH3-3), 5.80 (s, 2H, benzyl-CH2), 5.83 (m, 
1H, indole-H-6), 5.95 (d, J 2.2 Hz, 1H, indole-H-4), 7.04 (d, J 8.4 Hz, 2H, benzyl-H-2,6), 7.28 
(d, J 8.9 Hz, 1H, indole-H-7), 7.82 (d, J 8.3 Hz, 2H, benzyl-H-3,5), 9.02 (s, 1H, OH), 12.88 (br 
s, 2H, COOH). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 10.69 (indole-CH3), 45.9 (benzyl-
CH2), 103.2 (indole-C-4), 111.4 (indole-C-7), 115.4 (indole-C-6), 118.8 (Cquat, indole-C-2), 
124.9 (Cquat, indole-C-3), 125.1 (benzyl-C-2,6), 127.5 (Cquat, indole-C-9), 129.3 (Cquat, benzyl-
C-4), 129.4 (benzyl-C-3,5), 132.8 (Cquat, indole-C-8), 144.3 (Cquat, benzyl-C-1), 151.4 (Cquat, 
indole-C-5), 163.5 (indole-COOH), 167.0 (benzyl-COOH). HRMS (ESI): m/z [M-H+]- 
calculated for C18H14NO5-: 324.0885, found 324.0885. C18H15NO5 (325.10). 
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6.1 Introduction 
Indoles and indolizines are constitutional isomers. Whereas the concept of isosterism1 refers 
to the similarity of molecules or ions, which have the same number of atoms and valence 
electrons, bioisosteres are often more alike regarding biological rather than in physical or 
chemical properties. This means that compounds bearing isosteric molecular features do not 
necessarily represent bioisosteres. Therefore, the biological effects and biochemical mimicry 
are more important than the similarity of their physicochemical properties. In medicinal 
chemistry the concept of bioisosterism represents a rational approach to the design and 
discovery of new lead compounds.2-4 
 
Previously, 32 inhibitors of SagHyal4755 from our laboratory were selected for the computer-
assisted evaluation by means of COSMOsim (cf. Textor,5 Appendix II). The COSMOsim 
program enables an σ-profile-based drug similarity search for the discovery of new 
bioisosteres, for instance, as potential drug candidates. This approach to the quantification of 
drug similarity is based on the conductor-like screening model for realistic solvation 
(COSMO-RS) and considers the conductor surface polarization charge densities σ. The 
σ-profiles for surface interactions of molecules in liquid states were found to most likely carry 
a lot of information required for the estimation of desolvation and binding processes.6 The 
COSMOsim calculations, based on the aforementioned compound library, proposed 
indolizines as novel, putative bioisosteres possessing inhibitory activity on the target enzyme, 
the streptococcal hyaluronidase SagHyal4755. In collaboration with Origenis GmbH 
(Martinsried, Germany) virtual screening was performed, taking into consideration synthetic 
accessibility, drug-like properties and innovational character.5 Figure 6.1 outlines the 
previously synthesized 2-phenylindolizines. 
 
 
Figure 6.1 Structures and inhibitory activities of SagHyal4755 of previously reported 2-phenylindolizine 
derivatives 1-3. 
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The “minimal pharmacophore” 2-phenylindolizine (1) and ethyl 2-(4-bromophenyl)-3-
methylindolizine-8-carboxylate (2) were inactive, whereas the corresponding carboxylic 
acid (3) showed inhibitory activity on SagHyal4755 with an IC50 values in the two-digit 
micromolar range (IC50 = 85 µM). A negatively charged residue, such as the carboxylic acid 
moiety, most likely plays an important role for inhibitory activity.5 
 
Indolizine comprises two condensed rings (5- and 6-membered) and a bridging nitrogen 
atom. It was discovered by Angeli in 18907 and first synthesized from α-picoline and acetic 
acid anhydride by Scholtz in 1912.8-10 The generally accepted numbering of indolizines 
compared to indoles is outlined in Figure 6.2. 
 
 
Figure 6.2 Molecular structure of indolizine, indole (including numbering system). 
 
The indolizine ring system is a structural motif frequently found in natural products and has 
been used as a scaffold in pharmaceuticals. Synthetic indolizines have found wide-spread 
application in biological and pharmaceutical research.11,12 As the substituted indolizines 
display a broad spectrum of potential pharmacological activities, they are associated with a 
wide range of biological activities, including anti-inflammatory,13 hypoglycemic,14,15 anti-
acetylcholine,16 anti-bacterial,17 anti-cancer18 activities, and estrogen receptor binding19 and 
are reported as histamine H3 receptor antagonists20 and 15-lipoxygenase inhibitors.21 
 
The current investigation considers 2-phenylindolizine derivatives with and without carboxylic 
groups. The synthesis and the structure-activity relationships of a small collection of 
2-phenylindolizineschemically derived from compounds 1-3 is described in this chapter. 
 
6.2 Chemistry 
The synthesis of indolizine derivatives has been extensively investigated and many synthetic 
strategies for producing indolizine derivatives have been described in literature.10,22 The 
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preparation of the 2-phenylindolizine derivatives 6.15-6.22 was accomplished as outlined in 
Scheme 6.1. 
 
 
Scheme 6.1 Synthesis of substituted 2-phenylindolizine derivatives 6.15-6.22. Reagents and conditions: (i) Et2O, 
dioxane, Br2, 0°C; (ii) ethanol, H2SO4, reflux, 12 h; (iii) acetone, microwave irradiation (130 °C, 4 min); (iv) K2CO3, 
H2O, microwave irradiation (150 °C, 4 min); (v) LiOH, THF/EtOH/H2O = 3:0.2:1 (v/v/v), RT, 72 h. 
 
The synthesis of the 2-phenylindolizine derivatives was performed according to the 
Tschitschibabin indolizine synthesis in which a quarternary pyridinium halide, resulting from 
the reaction of a 2-alkyl pyridine and an α-halo carbonyl compound, undergoes an 
intramolecular condensation to the indolizine product.23 Bromination of the pertinent 
4-substituted acetophenones (6.1-6.3) afforded the corresponding α-bromoketones 6.4-6.6. 
In a two-step reaction the respective 2-methylpyridine 6.7-6.9 was alkylated with the 
substituted 2-bromo-1-phenylethanones 6.4-6.6, followed by ring closure in the presence of a 
base (potassium carbonate). The synthesis of 6.15-6.19 was carried out as a microwave 
assisted reaction.5 Subsequently, the ester groups of compounds 6.17 and 6.19 were 
hydrolyzed with lithium hydroxide to yield the target compounds 6.20-6.22. 
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2,4-Dimethylpyridine (lutidine) is insoluble in acetone. Therefore, a different synthetic route 
according to Dann, et al.24, was applied. The synthesis of the 2-(4-bromophenyl)- and 
2-(4-chlorophenyl)-7-methylindolizine is outlined in Scheme 6.2. 
 
 
Scheme 6.2 Synthesis of the substituted 2-phenylindolizine derivatives 6.25 and 6.26. Reagents and conditions: 
125-135 °C; (ii) NaHCO3, H2O, reflux. 
 
The respective 4-substituted 2-bromo-1-phenylethanone (6.4, 6.5) and 2,4-dimethylpyridine 
(lutidine) were melted at 125-135 °C until the mass solidified. The quaternary pyridinium 
halide was suspended in water and heated to reflux in the presence of a base (sodium 
hydrogen carbonate) to afford the 4-substituted 7-methyl-2-phenylindolizine compounds 6.25 
and 6.26.  
 
Because of its electron-rich character, the indolizine core structure was reported to be prone 
to oxidation, therefore, electron withdrawing groups on the indolizine nucleus are supposed 
to make the compounds much less susceptible to oxidation by air.25 For the synthesized 
2-phenylindolizine derivatives 6.15, 6.16, 6.19-6.22, 6.25 and 6.26 autoxidation or 
decomposition was not observed. 
 
6.3 Pharmacological results and discussion 
6.3.1 General conditions 
All synthesized 2-phenylindolizine derivatives were investigated for inhibition of the bacterial 
hyaluronate lyase SagHyal4755 and the bovine testicular enzyme BTH (Neopermease®) in a 
turbidimetric assay based on the method of Di Ferrante26 as described in chapter 1. In case 
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that IC50 values could not be determined, due to poor solubility in aqueous buffer, the effect 
was expressed as percent inhibition of the compound at the highest concentration achieved 
in the assay. 
 
6.3.2 Inhibitory activity of 2-phenylindolizine compounds 
The IC50 values determined for the 2-phenylindolizine compounds 6.15, 6.16, 6.18, 
6.20-6.22, 6.24, 6.25 are summarized in Table 6.1. 
 
Table 6.1 Inhibitory activitya and calculated logD5.0 valuesc of 2-phenylindolizine derivatives 6.15, 6.16, 6.18, 
6.20-6.22, 6.24, 6.25. 
Compound 
SagHyal4755 
IC50 (µM)a 
BTH 
IC50 (µM)a logD5.0
c 
6.15 inactive inactive 4.5 
6.16 inactive inactive 4.7 
6.18 inactive inactive 5.8 
6.20 56 ± 1 inactive 2.1 
6.21 30 % at 50 µMb inactive 2.0 
6.22 inactive inactive 3.5 
6.25 inactive inactive 5.6 
6.26 inactive inactive 5.8 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate), IC50 values determined at pH 5.0 in the 
turbidimetric assay (cuvettes); b % inhibition of SagHyal4755 at indicated concentration; c calculated with ACD-Labs 
(Advanced Chemistry Development Inc., Toronto, Canada) product version 12.0. 
 
The concentration dependent enzymatic activity of SagHyal4755 in presence of 6.15, 6.20 and 
6.22 is depicted in Figure 6.3. 
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Figure 6.3 Enzymatic activity of SagHyal4755 in the presence of 6.15, 6.20 and 6.21. 
 
The majority of the synthesized 2-phenylindolizine derivatives described in this chapter were 
inactive on the bacterial hyaluronidase SagHyal4755. Inhibitory activity was detected for 
compound 6.20, which showed an IC50 value of 56 µM. In case of compound 6.21, it was 
impossible to determine an IC50 value due to poor solubility in aqueous buffer. However, this 
compound showed 30 % inhibition at a concentration of 50 µM. It needs to be kept in mind 
that, in general; indolizines are very poorly soluble in aqueous buffer. Despite the negatively 
charged carboxyl group, compound 6.22, which also bears a bromine residue (solubility ca. 
50 µM) shows no inhibitory activity of SagHyal4755. Regardless of that, the presence of a 
negatively charged group is important for inhibition of the hyaluronate lyase: all compounds 
devoid of a carboxylic acid were inactive.  
 
Interestingly, with regard to the logD5.0 value, the two most active compounds (6.20, 6.21) 
were the ones offering the lowest lipophilicity (6.20 logD5.0 = 2.1, 6.21 logD5.0 = 2.0), whereas 
those with higher logD5.0 values around 4.5-5.8 (6.15, 6.16, 6.18, 6.24, 6.25), were devoid of 
inhibitory activity on SagHyal4755. This is in contrast to the general observation that 
lipophilicity determines inhibitory potency of hyaluronidase inhibitors. Most probably, in case 
of the more lipophilic indolizine derivatives, poor solubility is the decisive factor. The 
mammalian enzyme BTH was not inhibited by molecules analyzed in this section. 
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6.4 Summary 
The calculations of the σ-profile based drug similarity measure for the detection of new 
bioisosteric drugs, COSMOsim, suggested an indolizine skeleton as core structure of 
bioisosteric inhibitors of the bacterial hyaluronidase from Streptococcus agalactiae 
SagHyal4755. A small library of eight compounds was designed, synthesized, and tested for 
inhibition of the bacterial hyaluronidase from Streptococcus agalactiae SagHyal4755 and the 
mammalian hyaluronidase from bovine testis (BTH). Most of the tested compounds in this 
series were found to be inactive on the SagHyal4755. 2-(4-chlorophenyl)-indolizine-7-
carboxylic acid (6.20; IC50 = 56 µM) was the only compound that showed an IC50 value in the 
two-digit micromolar range. The inhibitory activity of compound 6.20 was increased 
compared to 2-(4-bromophenyl)-3-methylindolizine-8-carboxylic acid 3 (IC50 = 85 µM; 
cf. Figure 6.1) and was selective for the bacterial hyaluronidase SagHyal4755 since it was 
inactive on BTH.  
 
Although, the hydrophobicity of the substituents appeared to be key to high affinity of the 
inhibitors, it becomes clear that the structure-activity relationships are different for the 
investigated 2-phenylindolizine derivatives. The presence of a negatively charged carboxyl 
group, which also contributes to better solubility in aqueous buffer, seems to be more 
important than lipophilic residues. The successful combination of the carboxyl group together 
with the cyano residue in compound 6.20 (IC50 = 56 µM) should be kept in mind for the future 
development of hyaluronidase inhibitors. The indolizine scaffold should not yet be considered 
inappropriate, because a wide variety of substitution patterns has not been investigated. 
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6.5 Experimental section 
6.5.1 General conditions 
Cf. section 4.7.1 
6.5.2 Chemistry 
6.5.2.1 Preparation of compounds 6.4-6.6 
General procedure5 
To a solution of the pertinent 4-substituted phenylethanone (1 eq) in dioxane (3.3 mL/mmol) 
and dichloromethane (1.6 mL/mmol), bromine (1 eq) was slowly added under vigorous 
stirring. The solution was cooled with ice to maintain the temperature below 20 °C. 
Subsequently, the reaction mixture was stirred at ambient temperature for 1 hour. After 
washing with water (2 x 200 mL) the aqueous solution was extracted with EtOAc 
(4 x 250 mL). The combined organic layers were dried over MgSO4 and the solvent was 
removed in vacuo. The crude product was purified by recrystallization from ethanol.  
 
2-Bromo-1-(4-chlorophenyl)ethanone27 6.4 
The title compound was prepared from 1-(4-chlorophenyl)ethanone (4.64 g, 30 mmol), 
according to the general procedure. Recrystallization yielded a white solid (3.9 g, 56 %); 
mp 98 °C (lit.27 mp 270-272 °C), Rf = 0.68, 1H-NMR (400 MHz, [D1]CHCl3): δ (ppm) 4.40 (s, 
2H), 6.48 (m, 2H), 6.93 (m, 2H). 13C-NMR (101 MHz, [D1]CHCl3): δ (ppm) 30.3, 129.3 (2 
interfering carbon signals), 130.4 (2 interfering carbon signals), 132.3, 140.6, 190.2. MS (EI-
MS, 70 eV) m/z (rel. int. in %) 231.9 ([M+•], 5), 139.0 ([M-•CH2Br]+, 100). HRMS (ESI): m/z 
[M+H+]+ calculated for C8H7BrClO+: 234.9344, found 234.9345. C8H6BrClO (231.93). 
 
2-Bromo-1-(4-bromophenyl)ethanone28 6.5 
The title compound was prepared from 1-(4-bromophenyl)ethanone (6 g, 30 mmol), 
according to the general procedure. Recrystallization yielded a white solid (5.3 g, 56 %); 
mp 113 °C, Rf = 0.68, 1H-NMR (400 MHz, [D1]CHCl3): δ (ppm) 4.40 (s, 2H), 6.64 (m, 2H), 
6.85 (m, 2H). 13C-NMR (101 MHz, [D1]CHCl3): δ (ppm) 30.3, 129.3, 130.4 (2 interfering 
carbon signals), 132.3 (2 interfering carbon signals), 132.7, 190.4. MS (EI-MS, 70 eV) m/z 
(rel. int. in %) 276.9 ([M+•], 5), 183.0 ([M-•CH2Br]+, 80). HRMS (ESI): m/z [M+H+]+ calculated 
for C8H7Br2O+: 278.8840, found 278.8841.C8H6Br2O (275.88). C8H6Br2O (275.88). 
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Ethyl 4-(2-bromoacetyl)benzoate29 6.6 
The title compound was prepared from ethyl-4-acetylbenzoate (4 g, 20.8 mmol), according to 
the general procedure. Recrystallization yielded white crystals (3 g, 53 %); mp 79 °C (lit.29 
mp 73-75 °C), Rf = 0.49 1H-NMR (400 MHz, [D1]CHCl3) δ (ppm) 1.42 (t, J 6.1 Hz, 3H), 4.42 
(q, J 6.1 Hz, 2H), 4.47 (s, 2H), 8.01-8.07 (m, 2H), 8.12-8.19 (m, 2H). 13C-NMR (75 MHz, 
[D6]DMSO) δ (ppm) 14.0, 61.1, 65.6, 126.8 (2 interfering carbon signals), 129.3 (2 interfering 
carbon signals), 130.7, 136.9, 164.9, 198.9. MS (EI-MS, 70 eV) m/z (rel. int. in %) 270.0 
([M+•], 5), 226.0 ([M-•EtO]+, 5), 176.1 ([M-•CH2Br], 100). C11H11BrO3 (269.99).  
 
6.5.2.2 Preparation of ethyl 2-methylisonicotinoate30 6.8 
A mixture of 2-methylpyridine-4-carboxylic acid (1 eq, 200 mg, 1.45 mmol), ethanol 
(2 mL/mmol) and H2SO4 (0.05 mL/mmol) was refluxed for 12 h in a round-bottomed flask. 
After evaporation of the solvent under reduced pressure, about 20 mL of Na2CO3 solution 
(1 M) were added into the mixture. The combined phases were extracted with ether. After 
evaporation of the solvent, the product was obtained as a yellowish liquid (0.1 g, 42 %). 
Rf = 0.2. 1H-NMR (400 MHz, [D6]DMSO): δ (ppm) 1.39 (t, J 7.1 Hz, 3H), 2.60 (s, 3H), 4.40 (q, 
J 7.1 Hz, 2H), 7.72 (d, J 5.2 Hz, 1H), 7.80 (s, 1H), 8.57 (d, J 5.2 Hz, 1H). 13C-NMR (101 MHz, 
[D6]DMSO): δ (ppm) 14.50, 23.89, 63.03, 121.56, 124.13, 140.30, 150.41, 160.69, 166.23. 
MS (EI-MS, 70 eV) m/z (rel. int. in %) 165.12 ([M+•], 70), 137.09 ([M-C2H4], 80), 120.07 ([M-
OEt]•, 100). C9H11NO2 (165.08). 
 
6.5.2.3 Preparation of compounds 6.15-6.19 
General procedure24 
The pertinent 2-methylpyridine (1 eq) and the 4-substituted α-bromo-acetophenone (1 eq) 
were melted under stirring in a round-bottom flask in a pre-heated heating block. After 5-10 
min the liquefied material became brown-orange solid. After cooling to room temperature the 
solid was pulverized and heated to reflux in petroleum ether to dissolve and remove residual 
starting material. The product was insoluble in petroleum ether and the supernatant was 
decanted. This procedure was repeated 5-10 times. The solid was filtered off and taken up in 
H2O (10.7 mL/mmol starting material), NaHCO3 was added in surplus, and the mixture was 
heated to reflux for a few minutes. The product precipitated under foaming of the reaction 
mixture. After cooling to room temperature the product was filtered off, washed with water, 
and dried in vacuo.  
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2-(4-Chlorophenyl)indolizine-6-carbonitrile 6.15 
The title compound was prepared from 6.4 (810 mg, 3.47 mmol) and 6.7 (410 mg, 
3.47 mmol), according to the general procedure to yield the product as a red-brown solid 
(300 mg, 34 %); mp 192-195 °C, Rf = 0.68, RP-HPLC (220 nm): 87 % (tR = 19.1 min, 
k = 7.2). 1H-NMR (400 MHz, [D6]DMSO): δ (ppm) 6.87 (m, 1H), 6.01 (s, 1H), 6.47 (d, 
J 8.5 Hz, 2H), 6.55 (d, J 9.3 Hz, 1H), 6.77 (d, J 8.5 Hz, 2H), 8.11 (s, 1H), 9.03 (s, 1H). 13C-
NMR (101 MHz, [D6]DMSO): δ (ppm) 94.9, 99.2, 112.0, 116.5, 116.9, 119.4, 126.6 (2 
interfering carbon signals), 128.8 (2 interfering carbon signals), 129.6, 131.7, 132.0, 132.5, 
133.4. MS (EI-MS, 70 eV) m/z (rel. int. in %) 252.04 ([M+•], 100), 216.11 ([M-HCl]+, 25). 
HRMS (EI-MS): m/z [MH+•] calculated for C15H9ClN2: 252.0454, found 252.0456. C15H9ClN2 
(252.05). 
 
2-(4-Bromophenyl)indolizine-6-carbonitrile24 6.16 
The title compound was prepared from 6.5 (150 mg, 0.55 mmol) and 6.7 (65 mg, 0.55 mmol), 
according to the general procedure to yield the product as a yellow solid (70 mg, 43 %); 
RP-HPLC (220 nm): 95.3 % (tR = 19.1 min, k = 7.2). 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 
6.88 (m, 1H), 6.02 (s, 1H), 6.55 (d, J 9.3 Hz, 1H), 6.58-6.66 (m, 2H), 6.66-6.75 (m, 2H), 8.13 
(d, J 1.3 Hz, 1H), 9.04 (m, 1H). 13C-NMR (75 MHz, [D6]DMSO) δ (ppm) 94.9, 99.2, 112.0, 
116.5, 116.9, 119.5, 120.2, 126.9 (2 interfering carbon signals), 129.6, 131.8 (2 interfering 
carbon signals), 132.0, 132.9, 133.5. MS (EI-MS, 70 eV) m/z (rel. int. in %) 296.00 ([M+•], 
100), 216.11 ([M-HBr]+, 80). HRMS (EI-MS) m/z calculated for 295.9949 [M+•], found 
295.9952 [M+•]. C15H9BrN2 (295.99). 
 
Ethyl 4-(6-cyanoindolizin-2-yl)benzoate 6.17 
The title compound was prepared from 6.6 (500 mg, 1.8 mmol) and 6.7 (215 mg, 1.8 mmol), 
according to the general procedure to yield the product as a yellow solid (344 mg, 66 %); 
RP-HPLC (220 nm): 94.7 % (tR = 22.4 min, k = 8.6). 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 
1.34 (t, J 6.1 Hz, 3H), 4.32 (q, J 6.1 Hz, 2H), 6.89 (m), 6.09 (s, 1H), 6.58 (d, J 9.3 Hz, 1H), 
6.84-6.93 (m, 2H), 6.96-8.04 (m, 2H), 8.21 (d, J 1.3 Hz, 1H), 9.06 (d, J 1.1 Hz, 1H). 13C-NMR 
(75 MHz, [D6]DMSO) δ (ppm) 14.1, 60.6, 95.2, 99.5, 112.8, 116.7, 116.8, 119.7, 125.9 (2 
interfering carbon signals), 128.2, 129.5, 129.8 (2 interfering carbon signals), 132.1, 133.6, 
138.3, 165.4. MS (EI-MS, 70 eV) m/z (rel. int. in %) 290.1 ([M+•], 100), 262.2 ([M-C2H4]+, 50), 
245.1 ([M-EtO•]+, 50), 216.1 ([M-COOEt•]+, 50). HRMS (EI-MS) m/z calculated for 
C18H14N2O2: 290.1055 [M+•], found 290.1058 [M+•]. C18H14N2O2 (290.11). 
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Ethyl 4-(8-bromoindolizin-2-yl)benzoate 6.18 
The title compound was prepared from 6.6 (500 mg, 1.8 mmol) and 6.8 (310 mg, 1.8 mmol), 
according to the general procedure to yield the product as a yellow solid (380 mg, 62 %); 
RP-HPLC (220 nm): 93.6 % (tR = 22.6 min, k = 8.7). 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 
1.34 (t, J 6.1 Hz, 3H), 4.33 (q, J 6.1 Hz, 2H), 6.54 (t, J 6.0 Hz, 1H), 6.94 (d, J 0.7 Hz, 1H), 
6.08 (d, J 6.0 Hz, 1H), 6.85-6.95 (m, 2H), 6.95-8.03 (m, 2H), 8.27 (d, J 1.8 Hz, 1H), 8.31 (d, 
J 6.9 Hz, 1H). 13C-NMR (75 MHz, [D6]DMSO) δ (ppm) 14.1, 60.5, 98.0, 110.8, 111.7, 113.1, 
120.7, 125.5, 125.6 (2 interfering carbon signals), 126.2, 126.8, 129.7 (2 interfering carbon 
signals), 131.8, 165.4. MS (EI-MS, 70 eV) m/z (rel. int. in %) 343.0 ([M+•], 100), 316.9 ([M-
C2H4]+, 60). HRMS (EI-MS) m/z calculated for 343.0208 [M+•], found 343.0212 [M+•]. 
C17H14BrNO2 (343.02). 
 
Ethyl 2-(4-chlorophenyl)indolizine-7-carboxylate 6.19 
The title compound was prepared from 6.4 (350 mg, 1.5 mmol) and 6.9 (250 mg, 1.5 mmol), 
according to the general procedure to yield the product as a yellow solid (51 mg, 13 %); 
RP-HPLC (220 nm): 92.8 % (tR = 22.8 min, k = 8.8). 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 
6.90 (m, 1H), 6.09 (s, 1H), 6.58 (d, J 9.3 Hz, 1H), 6.88 (d, J 8.3 Hz, 2H), 6.99 (d, J 8.3 Hz, 
2H), 8.21 (s, 1H), 9.07 (s, 1H), 12.93 (s, 1H). 13C-NMR (75 MHz, [D6]DMSO) δ (ppm) 95.1, 
99.5, 112.7, 116.6, 116.8, 119.6, 125.8 (2 interfering carbon signals), 129.1, 129.7, 130.0 (2 
interfering carbon signals), 132.1, 133.6, 136.9, 166.0. HRMS (EI-MS) m/z calculated for 
C16H9N2O2-: 261.0672 [M-H+]-, found 261.0671 [M-H+]-. C16H10N2O2 (262.07). 
 
6.5.2.4 Preparation of compounds 6.20-6.22 
General procedure5 
A suspension of the pertinent ethyl carboxylate (1 eq) and LiOH (2.5 eq) in a 3:1:0.2 mixture 
of THF, H2O and EtOH (v/v/v) was stirred at room temperature for 3 days. The reaction 
mixture was adjusted to pH2 by addition of 0.5 M HCl to yield the product as precipitate. 
 
4-(6-Cyanoindolizin-2-yl)benzoic acid 6.20 
The title compound was prepared from 6.17 (344 mg, 1.18 mmol), according to the general 
procedure. The crude product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-15 min: MeCN/0.1% aq. TFA 30/70-80/20, tR = 12.7 min) and 
removal of the eluate by evaporation and lyophilisation afforded 6.20 as a white fluffy solid 
(100 mg, 32 %); RP-HPLC (220 nm): 97.8 % (tR = 22.2 min, k = 8.5). 1H-NMR (300 MHz, 
[D6]DMSO) δ (ppm) 6.90 (m, 1H), 6.09 (s, 1H), 6.58 (d, J 9.3 Hz, 1H), 6.88 (d, J 8.3 Hz, 2H), 
6.99 (d, J 8.3 Hz, 2H), 8.21 (s, 1H), 9.07 (s, 1H), 12.93 (br s, 1H). 13C-NMR (75 MHz, 
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[D6]DMSO) δ (ppm) 95.1, 99.5, 112.7, 116.6, 116.8, 119.6, 125.8 (2 interfering carbon 
signals), 129.1, 129.7, 130.0 (2 interfering carbon signals), 132.1, 133.6, 136.9, 166.0. 
HRMS (EI-MS) m/z calculated for C16H9N2O2-: 261.0672 [M-H+]-, found 261.0671 [M-H+]-. 
C16H10N2O2 (262.07). 
 
4-(8-Bromoindolizin-2-yl)benzoic acid 6.21 
The title compound was prepared from 6.18 (280 mg, 0.81 mmol), according to the general 
procedure. The crude product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-15 min: MeCN/0.1% aq. TFA 30/70-80/20, tR = 11.7 min) and 
removal of the eluate by evaporation and lyophilisation afforded 6.21 as a white fluffy solid 
(100 mg, 39 %); RP-HPLC (220 nm): 98.3 % (tR = 18.9 min, k = 7.1). 1H-NMR (400 MHz, 
[D6]DMSO) δ (ppm) 6.53 (t, J 6.0 Hz, 1H, indozline-H-6), 6.93 (d, J 0.8 Hz, 1H, indozline-H-
1), 6.08 (d, J 6.6 Hz, 1H, indozline-H-7), 6.88 (d, J 8.6 Hz, 2H, phenyl-H-2,6), 6.97 (d, 
J 8.5 Hz, 2H, phenyl-H-3,5), 8.25 (d, J 1.8 Hz, 1H, indozline-H-3), 8.31 (d, J 6.9 Hz, 1H, 
indozline-H-5). 13C-NMR (101 MHz, [D6]DMSO) δ (ppm) 98.2 (indolizine-C-1), 110.8 
(indolizine-C-6), 111.7 (indolizine-C-8), 113.0 (indolizine-C-3), 120.7 (indolizine-C-7), 125.4 
(indolizine-C-4), 125.5 (phenyl-C-2,6), 126.4 (indolizine-C-2), 128.7 (phenyl-C-4), 129.9 
(phenyl-C-3,5), 131.9 (indolizine-C-9), 138.5 (phenyl-C-1),166.0 (COOH). HRMS (ESI): m/z 
[M-H+]- calculated for C15H9BrNO2-: 313.9819, found 315.9800. C15H10BrNO2 (314.99). 
 
2-(4-Chlorophenyl)indolizine-7-carboxylic acid 6.22 
The title compound was prepared from 6.19 (51 mg, 0.17 mmol), according to the general 
procedure. The crude product was purified with preparative HPLC (column: Nucleodur 
250 x 21 mm; gradient: 0-15 min: MeCN/0.1% aq. TFA 30/70-80/20, tR = 14.2 min) and 
removal of the eluate by evaporation and lyophilisation afforded 6.22 as a white fluffy solid 
(30 mg, 65 %); RP-HPLC (220 nm): 93.8 % (tR = 22.6 min, k = 8.7). v1H-NMR (600 MHz, 
[D6]DMSO) δ (ppm) 6.95 (m, 1H, indolizine-H-6), 6.13 (s, 1H, indolizine-H-1), 6.43-6.51 (m, 
2H, phenyl-H-3,5), 7-70-6.79 (m, 2H, phenyl-H-2,6), 8.09 (s, 1H, indolizine-H-8), 8.18 (d, 
J 1.1 Hz, 1H, indolizine-H-3), 8.24 (d, J 6.3 Hz, 1H, indolizine-H-5), 12.80 (br s, 1H, COOH). 
13C-NMR (150 MHz, [D6]DMSO) δ (ppm) 101.4 (indolizine-C-1), 109.6 (indolizine-C-6), 113.1 
(indolizine-C-3), 119.6 (Cquat, indolizine-C-7), 122.3 (indolizine-C-8), 125.4 (indolizine-C-5), 
126.6 (phenyl-C-2,6), 128.8 (Cquat, indolizine-C-2), 129.0 (phenyl-C-3,5), 131.5 (Cquat, phenyl-
C-1’), 131.9 (Cquat, indolizine-C-9), 133.3 (Cquat, phenyl-C-4), 166.8 (Cquat, COOH). HRMS (EI-
MS) m/z calculated for C15H9ClNO2-: 270.0331 [M-H+]-, found 270.0326 [M-H+]-. C15H10ClNO2 
(271.04). 
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6.5.2.5 Preparation of compounds 6.25, 6.26 
General procedure5,24,31 
A mixture of 2-methylpyridine (1 eq) and the pertinent 4-substituted α-bromo-acetophenone 
(1 eq) was dissolved in 2 mL of anhydrous acetone. After microwave irradiation (130 °C, 
4 min), the quaternary pyridinium halide was filtered off. The precipitate was re-dissolved in 
2 mL of hot H2O with the aid of sonification. Subsequently, K2CO3 (1 eq) was added to the 
solution. After microwave irradiation (150 °C, 4 min) the remaining precipitate was dissolved 
in DCM. The organic layer was washed with H2O and dried over MgSO4. After evaporation of 
the solvent, the product was purified as indicated. 
 
2-(4-Chlorophenyl)-7-methylindolizine32 6.25 
The title compound was prepared from 6.4 (933 mg, 4 mmol), according to the general 
procedure. Evaporation of the solvent yielded a silver colored, shiny solid as the pure product 
(310 mg, 32 %); mp >210 °C, Rf = 0.64, RP-HPLC (220 nm): 94.5 % (tR = 18.9 min, k = 7.1). 
1H-NMR (400 MHz, [D6]DMSO) δ (ppm) 2.22 (s, 3H, CH3), 6.39 (m, 1H, indolizine-H-6), 6.60 
(s, 1H, indolizine-H-1), 6.14 (s, 1H, indolizine-H-8), 6.41-6.43 (m, 2H, phenyl-H-3,5), 6.69-
6.71 (m, 2H, phenyl-H-2,6), 6.88 (d, J 1.4 Hz, 1H, indolizine-H-3), 8.11 (d, J 6.1 Hz, 1H, 
indolizine-H-5). 13C-NMR (101 MHz, [D6]DMSO) δ (ppm) 20.5 (CH3), 94.6 (indolizine-C-1), 
109.2 (indolizine-C-3), 113.2 (indolizine-C-6), 116.4 (indolizine-C-8), 125.2 (Cquat, indolizine-
C-5), 126.7 (Cquat. Indolizine-C-2), 126.0 (phenyl-C-2,6), 126.3 (indolizine-C-7), 128.6 
(phenyl-C-3,5), 130.5 (Cquat, phenyl-C-1), 133.2 (Cquat, indolizine-C-9), 133.9 (Cquat, phenyl-C-
4). MS (EI-MS, 70 eV) m/z (rel. int. in %) 241.1 ([M+•], 100), 240.1 ([M-H+], 35). HRMS (EI-
MS): m/z [MH+•] calculated for C15H12ClN: 241.0658, found 241.0658. C15H12ClN (241.07). 
 
2-(4-Bromophenyl)-7-methylindolizine33 6.26 
The title compound was prepared from 6.5 (1.3 g, 4.67 mmol), according to the general 
procedure. Evaporation of the solvent yielded a silver colored, shiny solid as the pure product 
(1.15 mg, 86 %; ref.:33 mp 214-215 °C); RP-HPLC (220 nm): 95.1 % (tR = 18.9 min, k = 7.1). 
1H-NMR (400 MHz, [D6]DMSO) δ (ppm) 2.22 (s, 3H), 6.40 (m, 1H), 6.61 (s, 1H), 6.14 (s, 1H), 
6.50-6.59 (m, 2H), 6.59-6.70 (m, 2H), 6.89 (d, J 1.4 Hz, 1H), 8.12 (d, J 6.0 Hz, 1H). 13C-NMR 
(101 MHz, [D6]DMSO) δ (ppm) 20.5, 94.5, 109.2, 113.2, 116.4, 125.2, 126.7, 126.3, 126.4 (2 
interfering carbon signals), 128.6, 131.5 (2 interfering carbon signals), 133.5, 134.3. MS (EI-
MS, 70 eV) m/z (rel. int. in %) 285.07 ([M+•], 100), 204.14 ([M-HBr]+, 40). HRMS (EI-MS) m/z 
calculated for 285.0153 [M+•], found 285.0149 [M+•]. C15H12BrN (285.02). 
 
 2-Phenylindolizines as hyaluronidase inhibitors 145 
 
6.6 References 
1. Langmuir, I. Isomorphism, isosterism and covalence. J. Am. Chem. Soc. 1919, 41, 
1543-1559. 
2. Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in Drug 
Design. J. Med. Chem. 2011, 54, 2529-2591. 
3. Thornber, C. W. Isosterism and Molecular Modification in Drug Design. Chem. Soc. 
Rev. 1979, 8, 563-580. 
4. Patani, G. A.; LaVoie, E. J. Bioisosterism: A rational approach in drug design. Chem. 
Rev. 1996, 96, 3147-3176. 
5. Textor, C. Small molecules as inhibitors of streptococcal hyaluronidase: a computer-
assisted and multicomponent synthesis approach. Doctoral thesis, University of 
Regensburg, Regensburg, 2012. 
6. Thormann, M.; Klamt, A.; Hornig, M.; Almstetter, M. COSMOsim: Bioisosteric 
similarity based on COSMO-RS sigma profiles. J. Chem. Inf. Model. 2006, 46, 1040-
1053. 
7. Scholtz, M.; Fraude, W. Nature of Picolide and Pyrindole and the Action of Propionic 
Anhydride on α-Picoline. Ber. Dtsch. Chem. Ges. 1913, 46, 1069-1082. 
8. Scholtz, M. Action of Acetic Anhydride on α-Picoline. Ber. Dtsch. Chem. Ges. 1912, 
45, 734-746. 
9. Scholtz, M. Nature of Picolide and Pyrrocoline. Ber. Dtsch. Chem. Ges. 1912, 45, 
1718-1725. 
10. Uchida, T.; Matsumoto, K. Methods for the construction of the indolizine nucleus. 
Synthesis 1976, 209-236. 
11. Harrell, W. B.; Doerge, R. F. Mannich Bases from 2-Phenylindolizines .I. 3-Alkyl-1-
Dialkylaminomethyl Derivatives. J. Pharm. Sci. 1967, 56, 225-&. 
12. Vemula, V. R.; Vurukonda, S.; Bairi, C. K. Indolizine derivatives: recent advances and 
potential pharmacological activities. Int. J. Pharm. Sci. Rev. Res. 2011, 11, 159-163. 
13. Kallay, K. R.; Doerge, R. F. p-substituted 1,2-diphenylindolizines as anti-inflammatory 
agents. J. Pharm. Sci. 1972, 61, 949-951. 
14. De, A. U.; Saha, B. P. Search for potential oral hypoglycemic agents: Synthesis and 
activity of 2-(N-alkylaminomethyl)indolizines. J. Pharm. Sci. 1973, 62, 1897-1898. 
15. De, A. U.; Saha, B. P. Indolizines II: Search for potential oral hypoglycemic agents. J. 
Pharm. Sci. 1975, 64, 249-252. 
16. Antonini, I.; Claudi, F.; Gulini, U.; Micossi, L.; Venturi, F. Indolizine derivatives with 
biological activity IV: 3-(2-Aminoethyl)-2-methylindolizine, 3-(2-aminoethyl)-2-methyl-
5,6,7,8-tetrahydroindolizine, and their iv-alkyl derivatives. J. Pharm. Sci. 1979, 68, 
321-324. 
17. Gundersen, L.-L.; Charnock, C.; Negussie, A. H.; Rise, F.; Teklu, S. Synthesis of 
indolizine derivatives with selective antibacterial activity against Mycobacterium 
tuberculosis. Eur. J. Pharm. Sci. 2007, 30, 26-35. 
18. James, D. A.; Koya, K.; Li, H.; Liang, G.; Xia, Z.; Ying, W.; Wu, Y.; Sun, L. Indole- and 
indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell 
lines. Bioorg. Med. Chem. Lett. 2008, 18, 1784-1787. 
19. Jorgensen, A. S.; Jacobsen, P.; Christiansen, L. B.; Bury, P. S.; Kanstrup, A.; Thorpe, 
S. M.; Naerum, L.; Wassermann, K. Synthesis and estrogen receptor binding affinities 
of novel pyrrolo[2,1,5-cd]indolizine derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 
2383-2386. 
20. Chai, W. Y.; Breitenbucher, J. G.; Kwok, A.; Li, X. B.; Wong, V.; Carruthers, N. I.; 
Lovenberg, T. W.; Mazur, C.; Wilson, S. J.; Axe, F. U.; Jones, T. K. Non-imidazole 
146 References 
 
heterocyclic histamine H-3 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 
1767-1770. 
21. Gundersen, L.-L.; Malterud, K. E.; Negussie, A. H.; Rise, F.; Teklu, S.; Ostby, O. B. 
Indolizines as novel potent inhibitors of 15-lipoxygenase. Biorg. Med. Chem. 2003, 
11, 5409-5415. 
22. Gogoi, S.; Dutta, M.; Gogoi, J.; Boruah, R. C. Microwave promoted synthesis of 
cycl[3.2.2]azines in water via a new three-component reaction. Tetrahedron Lett. 
2011, 52, 813-816. 
23. Tschitschibabin, A. E. Tautomerie in der Pyridin-Reihe. Ber. Dtsch. Chem. Ges. (A 
and B Series) 1927, 60, 1607-1617. 
24. Dann, O.; Fernbach, R.; Pfeifer, W.; Demant, E.; Bergen, G.; Lang, S.; Luerding, G. 
Trypanocidal Diamidines with 3 Rings in 2 Isolated Ring Systems. Justus Liebigs Ann. 
Chem. 1972, 760, 37-87. 
25. Hagishita, S.; Yamada, M.; Shirahase, K.; Okada, T.; Murakami, Y.; Ito, Y.; Matsuura, 
T.; Wada, M.; Kato, T.; et al. Potent Inhibitors of Secretory Phospholipase A2: 
Synthesis and Inhibitory Activities of Indolizine and Indene Derivatives. J. Med. Chem. 
1996, 39, 3636-3658. 
26. Di Ferrante, N. Turbidimetric measurement of acid mucopolysaccharides and 
hyaluronidase activity. J. Biol. Chem. 1956, 220, 303-306. 
27. Fefer, M.; King, L. C. Reaction of ethylenethiourea with phenacyl and p-substituted 
phenacyl halides. J. Org. Chem. 1961, 26, 828-835. 
28. Langley, W. D. p-Bromophenacyl Bromide. Organic Syntheses 1929, 9, 20-21. 
29. Phillips, G. H.; Williamson, C. Substituted pyrimidin-2-ones, salts thereof, and 
pharmaceutical compositions containing them. EP 0044704 A1, 1982. 
30. Xu, Y. D.; Qu, W.; Yang, Q.; Zheng, J. K.; Shen, Z. H.; Fan, X. H.; Zhou, Q. F. 
Synthesis and Characterization of Mesogen-Jacketed Liquid Crystalline Polymers 
through Hydrogen-Bonding. Macromolecules 2012, 45, 2682-2689. 
31. Chai, W. Y.; Kwok, A.; Wong, V.; Carruthers, N. I.; Wu, J. J. A practical parallel 
synthesis of 2-substituted indolizines. Synlett 2003, 2086-2088. 
32. Buu-Hoi, N. P.; Jacquignon, P.; Xuong, N. D.; Lavit, D. 2-Arylpyrrocolines and 2-
arylpyrimidazoles. J. Org. Chem. 1954, 19, 1370-1375. 
33. Zaporozhets, O. B.; Ryashentseva, M. A.; Polosin, V. M.; Poponova, R. V. 
Hydrogenation of 6- and 7-alkyl-2-(4'-bromophenyl)indolizines. Izv. Akad. Nauk, Ser. 
Khim. 1993, 1267-1268. 
  
7 Characterization of snake venoms regarding 
hyaluronidase activity 
  
148 Introduction 
 
7.1 Introduction 
Snakes are widely distributed all over the world, particularly present in high species diversity 
in the tropics. Currently, 2,700 species of snakes are recognized, divided into 420 genera 
and 18 families, of which 20 % are venomous.1 Members of the four families Elapidae 
(cobras, coral snakes and their relatives), Viperidae (vipers, adders and pit vipers), 
Colubridae (colubrid snakes) and Atractaspididae (western rat snakes and mole vipers) 
represent major venomous snakes.2 
 
Venoms of the puff adder Bitis arietans and the cobra Naja siamensis were investigated in 
this thesis with regard to their hyaluronidase activity. The puff adder Bitis arietans 
(Figure 7.1) can be identified because of its rough-scaled appearance and the alternating 
pattern of dark and light chevron-shaped markings. It is distributed in the savannah and 
grasslands of Morocco and western Arabia as well as throughout Africa, except for the 
Sahara and rain forest regions. Cobras of the genus Naja (Figure 7.1) are found over much 
of southern Asia and Africa. All cobras have an expandable hood, and usually the ventral 
surface of the neck is brightly marked.3 Both, the Indian Cobras (Naja naja) and Siamese 
cobra (Naja siamensis) have a spectacle-like marking which is shown in Figure 7.1. 
 
  
Figure 7.1 Puff adder Bitis arietans (left)4 and Indian cobra Naja naja with its hood spread(right)1. 
 
Snake venoms are a complex and highly concentrated mixture of proteins and polypeptides, 
which possess enzymatic and a number of other biological activities and toxic properties that 
induce diverse pathological and pathophysiological effects.5 The venom composition is highly 
variable among snake species, populations, and even among individual snakes. 
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Polypeptides without enzymatic activity are toxins with specific activity towards nerve 
structures and cell membranes or peptides with inhibitory activities towards enzymes, 
synergistic effects, and other nontoxic venom components.6 The enzymes present in snake 
venom are mostly hydrolases and amino acid oxidases with digestive function, for instance 
proteinases, exo- and endopeptidases, phosphodiesterases, and phospholipases. 
Snakebites cause a wide variety of symptoms, including impairment of blood coagulation, 
bleeding, massive tissue destruction, and necrosis, cardiovascular irregularities and shock, 
and muscular paralysis, each of which can cause death.6-9 
 
Hyaluronidase which is present in all snake venoms has a “spreading action”, thereby 
facilitating the distribution of the other venom components throughout the tissues of the prey 
by hydrolyzing the dermal barrier hyaluronic acid and destroying the structural integrity.10 
Therefore, the extent of the hyaluronidase activity can modulate the degree of venom 
toxicity.11 As early as 1936, Duran-Reynals described the extraordinarily powerful spreading 
action of snake venom from rattlesnakes and cobras.12 Moreover, it was found that the 
spreading power differs considerably in various species and the spreading action is 
independent of the toxic effect of the snake venoms.13 However, in contrast to mammalian 
and microbial hyaluronidases, the enzyme from snake venoms has been least studied in 
animal venoms because it was claimed non-toxic without any significant properties. In the 
treatment of snakebites, the inhibition of the snake venom hyaluronidases represents a 
therapeutic target, since they will not only minimize local tissue damage, but will also retard 
the distribution of lethal toxins.14-16 
 
Previously, snake venoms from Bitis gabonica rhinoceros, Bitis nasicornis, Bitis arietans, 
Naja kaouthia, Naja siamensis, Naja melanoleuca and Naja mossambica were characterized 
in our laboratory with regard to hyaluronidase activity.17 Moreover, compounds from different 
substance classes, such as flavonoids and chalcone analogs, ascorbic acid and indole 
derivatives18 as well as glucurono-6,3-lactones, were tested in the turbidimetric assay for 
inhibition of the snake venom hyaluronidases. In this chapter, the characterization of two 
different snake venoms from Bitis arietans and Naja siamensis regarding hyaluronidase 
activity and the investigation of possible hyaluronidase inhibitors are described. 
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7.2 Materials and methods 
The freeze-dried snake venoms from Bitis arietans and Naja siamensis were a gift from 
Dr. Marc Kunze. 
7.2.1 Determination of protein content 
The protein content of the snake venoms was determined by the Bradford method.19 Human 
serum albumin (Behringwerke, Marburg, Germany) was used for calibration at 
concentrations of 50-600 µg/mL. The determination was carried out in a miniaturized version 
of the Bio-Rad protein assay. Different dilutions of the snake venoms from Bitis arietans and 
Naja siamensis (c = 400 µg/mL and 600 µg/mL) were made. 25 µL of the calibration 
standards and the sample dilutions were transferred to an acryl cuvette (in duplicate). 
1.25 mL of the 1:5 diluted Bio-Rad protein assay dye reagent concentrate (Bio-Rad, Munich, 
Germany) was added. After 5 min of incubation, absorbance at λ = 595 nm was measured 
using a Cary 100 UV-Vis spectrometer (Varian, Darmstadt, Germany). All dilutions were 
within the calibrated concentration range and therefore used for the calculation of the protein 
content. 
 
7.2.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
The proteins present in snake venoms from Bitis arietans and Naja siamensis were analyzed 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing 
conditions according to the protocol of Laemmli.20 Molecular masses were assigned with the 
help of PeqGold Protein-Marker I (PeqLab, Erlangen, Germany), which contains: 
β-galactosidase from E. coli (molecular weight: 116.0 kDa), BSA from bovine blood 
(molecular weight: 66.2 kDa), ovalbumin from chicken eggs (molecular weight: 45.0 kDa), 
lactate dehydrogenase from pork muscle (molecular weight: 35.0 kDa), 98I from E. coli 
(molecular weight: 25.0 kDa), β-lactoglobulin from cow’s milk (molecular weight: 18.4 kDa) 
and lysozyme from chicken eggs (molecular weight: 14.4 kDa).21 The buffers for 
polyacrylamide gels and gel electrophoresis were prepared as follows: 
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buffer A: 1.5 M tris/HCl (pH 8.8), 0.4 % SDS (m/v) 
buffer B: 0.5 M tris/HCl (pH 6.8), 0.4 % SDS (m/v) 
running buffer: 0.025 M tris/HCl (pH 8.3), 0.2 M glycine, 0.1 % SDS (m/v) 
sample buffer: 0.075 M tris/HCl (pH 6.8), 0.5 M glycine, 0.3 % SDS (m/v), 4.5 % glycerol 
(v/v), 0.05 % bromophenol blue (m/v), 1 % mercaptoethanol (v/v) 
 
12 % separation gel mixtures contained 2.2 mL of water, 2 mL of buffer A and 3.2 mL 
acrylamide/bisacrylamide solution 30 % (Sigma-Aldrich, Munich, Germany). Polymerization 
was initiated by adding 3.5 µL N,N,N’,N’-tetramethylethylenediamine (TEMED, Serva, 
Heidelberg, Germany) and 35 µL of a 10 % (m/v) solution of ammonium peroxodisulfate 
(APS) (Serva, Heidelberg, Germany) in water. The mixture was filled into gel chambers 
(10 cm x 10 cm x 0.8 cm) and overlaid with saturated isobutyl alcohol. Before casting the 
stacking gel, the isobutyl alcohol was discarded. 5 % stacking gels contained 3.25 mL of 
water, 1.25 mL of buffer B and 0.5 mL of acrylamide/bisacrylamide solution 30 %. 3.75 µL 
TEMED and 50 µL of APS (10 % solution in water) were added to start polymerization. 
Electrophoresis was performed with a PerfectBlue gel electrophoresis system (Twin S, 
Peqlab, Erlangen, Germany) at 150 V for approximately 2 hours. The electrode chambers 
were filled with running buffer. Snake venom samples (c = 50 mg/mL) were mixed with a 
one-third volume of sample buffer and heated for 5 min at 100 °C. The proteins were stained 
with a 0.1 % (m/v) solution of Coomassie Brilliant Blue G-250 (Serva, Heidelberg, Germany) 
in 50 % (v/v) methanol (Merck, Darmstadt, Germany) and 10 % (v/v) acetic acid (Merck, 
Darmstadt, Germany). Destaining of the gel was carried out in an aqueous solution of 7 % 
(v/v) acetic acid and 10 % (v/v) methanol. The gels were analyzed with a Bio-Rad gel 
detection system (GS-710 Imaging Densitometer) using Quantity One quantification 
software, version 4.0.3 (Bio-Rad, Munich, Germany). 
 
7.2.3 Zymography 
Zymography with HA substrate gels is an SDS-polyacrylamide gel electrophoresis to 
visualize enzymatic activity and determine the molecular weight of the hyaluronidase. It was 
first described by Cherr et al.22 and essentially carried out according to Hamberger.23 SDS 
polyacrylamide gels were prepared as described in section 7.2.2 with additional 67 µg/mL 
hyaluronan (5 mg/mL stock solution) in the separation gel. Samples for zymography were 
mixed with sample buffer (200 mM tris/HCl pH 6.8, 20 % (v/v) glycerol, 10 % (m/v) SDS, 
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0.05 % (m/v) bromophenol blue) in ratio of 1:1 and directly applied to the gel. After 
electrophoresis at 150 V for approximately 2 hours, SDS was replaced by triton X-100 (Carl 
Roth, Karlsruhe, Germany). The SDS was removed by shaking the gels in a 2.5 % (v/v) 
solution of triton X-100 for 30 min at room temperature. Subsequently, the gel was washed 
with water for 5 min and with incubation buffer for additional 30 min. The McIlvaine’s 
incubation buffer was prepared as described in section 3.2.2 and adjusted to pH 5.0. After 
incubation at 37 °C for 24 h, the gel was stained with a 0.5 % (m/v) solution of alcian blue 8 
GX (Sigma, St. Louis, MO, USA) in acetic acid for 1 h. The gel was unstained in 7 % acetic 
acid until light bands (regions of hyaluronan digest) became visible on the blue background. 
The proteins were counterstained with Coomassie Brilliant Blue G-250 in 50 % (v/v) 
methanol and 10 % (v/v) acetic acid. After a final unstaining step in an aqueous solution of 
7 % (v/v) acetic acid and 10 % (v/v) methanol, the gels were analyzed with a Bio-Rad 
GS-710 gel scanner as described in section 7.2.2. 
 
7.2.4 Colorimetric hyaluronidase activity assay (Morgan-Elson 
assay) 
7.2.4.1 General procedures 
The required reagents and solutions were prepared as described in section 3.2.2.1 
McIlvaine’s buffer was adjusted to the required pH value (pH 5.0). 
 
7.2.4.2 Determination of hyaluronidase activity 
The enzymatic activity of hyaluronidases can be quantified according to the definition of the 
International Union of Biochemistry by defining 1 unit (U) as the amount of enzyme that 
catalyzes the liberation of 1 µmol N-acetyl-D-glucosamine at the reducing ends of sugars per 
min under specified conditions. For this purpose, references of known N-acetyl-D-
glucosamine (GlcNAc) concentration were used to create a linear calibration graph. The 
absorbance resulting from the formation of the red colored product measured at a 
wavelength of 586 nm was plotted against a dilution series of GlcNAc. The GlcNAc 
concentrations typically covered a range from 0.1 mM to 2 mM, incubation time was set to 
75 minutes. The incubation mixture containing 200 µL buffer, 50 µL BSA solution (0.2 mg/mL 
in water), 50 µL of the respective GlcNAc dilution (replacing HA), 82 µL H2O, and 50 µL BSA 
(replacing the enzyme solution) was treated as described previously. Additionally, a blank 
probe with 50 µL HA solution (instead of GlcNAc) was added. Snake venom solutions were 
prepared with and without protease inhibitor. For the quantification of hyaluronidase activity 
 Characterization of snake venoms regarding hyaluronidase activity 153 
 
50 µL of the respective snake venom solution (c = 5 mg/mL) was incubated with 50 µL HA 
(5 mg/mL in water). Enzymatic activity was calculated according to Equation 7.1. 
 
 1 U = 1 μmol GlcNAcmin   
Equation 7.1 
 
U: enzymatic activity (U) 
GlcNAc: N-acetyl-D-glucosamine at the reducing ends of sugars 
 
According to this definition, a hyaluronidase activity of 0.1 mU (0.1 nmol GlcNAc/min) is 
equivalent to approximately 1 international unit (IU), 1 (relative) turbidity reducing unit 
((r)TRU), 1 national formulatory unit (NFU), 1.5 Benger units and 3.3 viscosity units, 
respectively.24 
 
7.2.5 Turbidimetric hyaluronidase activity assay 
The turbidimetric assay was performed in 96-well titer plates as described in detail in 
chapter 3 (Section 3.5.2.1). Identical assay conditions (including the pH value) were applied. 
The lowest concentration of both snake venom solutions that led to 100 % turbidity was used 
in the turbidimetric assay. As determined by M. Kunze, in case of Bitis arietans and 
Naja siamensis, this concentration was c = 50 mg/mL.17 10 µL of the snake venom solution 
was added to the incubation mixture. 
 
7.2.6 Plasma protein binding 
An HPLC-based method, based upon work published by Valko et al.25-28, for the 
determination of the lipophilicity of selected compounds was performed by Origenis GmbH, 
Martinsried, Germany. The substances were characterized with three different methods. A 
C18-column was used for the determination of the chromatographic hydrophobicity index 
(CHI, logD = 7.4), a human serum albumin (HSA) column for the determination of protein 
binding and an immobilized artificial membrane column (IAM) for the determination of 
membrane affinity. UV/VIS was used for detection (Dr. M. Thormann, personal 
communication 2013). 
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7.3 Results and discussion 
7.3.1 Protein content and determination of molecular mass 
The protein content of the snake venom samples was determined in three independent 
experiments each performed in duplicate. The results are shown in Table 7.1. 
 
Table 7.1 Protein content (Bradford assay) of the snake venoms from Bitis arietans and Naja siamensis. 
Snake species 
amount of protein 
(µg/mL)a 
amount of protein 
in % 
Bitis arietans 248.6 ± 36 62 (52)b 
Naja siamensis 218.2 ± 25 55 (35)b 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate); b values in parentheses reported by M. 
Kunze17. 
 
The amounts of protein found in the venoms of Bitis arietans and Naja siamensis were 
249 µg/mL and 218 µg/mL, respectively, corresponding to 62 % and 55 %, which is about 
10-20 % lower than the values M. Kunze (Table 7.1). However, the results agreed in the fact 
that the venom from Bitis arietans contains more protein than the venom from 
Naja siamensis. 
 
The separation of the complex mixture of proteins and polypeptides in the venoms from both 
snakes was performed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 
Figure 7.2). 500 µg of the freeze dried, unpurified snake venom was applied onto the gel. 
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Figure 7.2 SDS-PAGE analysis of snake venoms from Bitis arietans and Naja siamensis. 
 
The separation of the snake venom from Bitis arietans revealed two prominent protein bands 
at approximately 60 kDa and 23 kDa. In the area between 45 to 70 kDa several separated 
protein bands can be found in the lanes of both snake venoms. Additionally, in both lanes 
two very strong and broad protein bands can be observed in the area between 10 to 16 kDa 
of small protein fragments. Since the hyaluronidases present in the snake venoms are 
expected to possess a molecular mass > 33 kDa, this area can be neglected. 
 
7.3.2 Hyaluronidase activity 
Hyaluronidases from snake venoms are neutral pH endo-β-N-acetyl-D-hexosaminidases 
characterized as having molecular weights ranging from approximately 33 kDa 
to ~110 kDa.29 For the determination and quantification of hyaluronidase activity in snake 
venoms, two different methods were in the present study: zymography and the colorimetric 
Morgan-Elson assay. After gel electrophoresis incubation at pH 5.0 and staining of the gel, 
light bands on dark background indicated hyaluronan degradation, i. e. enzymatic activity 
(Figure 7.3). 
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Figure 7.3 Determination of hyaluronidase activity by zymography (incubation at pH 5.0) followed by alcian blue 
staining and Coomassie counterstaining. Light bands on dark background indicate enzymatic activity. 
 
Hyaluronidase activity was found in both snake venoms. In the venom from Bitis arietans two 
protein bands (66 kDa and 45 kDa) showed hyaluronidase activity. The presence of 
hyaluronidase isoforms in snake venoms, for example in Naja naja, was reported by 
Girish.30,31 However, in the venom from Naja siamensis, no isoform of hyaluronidase was 
detected, only the protein band at approximately 65 kDa showed hyaluronidase activity. 
Kunze determined slightly higher molecular weights for the hyaluronidases in Bitis arietans 
(60 kDa and 70 kDa) and Naja siamensis (59 kDa). The reason why smaller molecular 
weights of the hyaluronidases were observed in this experiment may be that the snake 
venom, which was dissolved in water, was frozen and thawed for several times.17 The 
molecular weight of hyaluronidases from different sources, such as human plasma or urine 
or animal venoms (snakes, scorpions, lizards, spiders and caterpillars), are between 
32.5 kDa and 70.4 kDa31-40. This is in good agreement with the determined molecular weight 
of the investigated snake venoms from Bitis arietans and Naja siamensis. 
 
The hyaluronidase activity of the two venoms from Bitis arietans and Naja siamensis was 
determined using the colorimetric Morgan-Elson assay at pH 5.0. The specific 
activity (mU/mg) takes the protein content of the freeze dried venoms into consideration 
(c (freeze dried venom) = 5 mg/mL). The enzymatic (mU/mL) and specific activities (mU/mg) 
are summarized in Table 7.2. 
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Table 7.2 Hyaluronidase enzymatic and specific activity (Morgan-Elson assay) of the snake venoms from Bitis 
arietans and Naja siamensis. 
Snake species pH of activity determination 
enzymatic activity 
(mU/mL)a 
specific activity 
(mU/mg)a 
Bitis arietans 5.0 12.5 ± 1.4 (8.4)b 2.8 ± 0.7 (1.6)b 
Naja siamensis 5.0 4.4 ± 2.0 (6.2)b 1.4 ± 0.8 (1.8)b 
a
 Mean values ± SEM (N = 2, experiments performed in duplicate); b as determined by M. Kunze17. 
 
The hyaluronidase activity of the investigated venom sample from Bitis arietans 
(12.5 mU/mL) was almost 3-fold higher than the enzymatic activity of the venom from 
Naja siamensis (4.4 mU/mL). However, with regard to the protein content, the specific activity 
of the venom from Bitis arietans (2.8 mU/mg) was only 2-fold higher than the specific activity 
of the venom from Naja siamensis (1.4 mU/mg). The results determined by M. Kunze also 
revealed higher enzymatic activity in the venom from Bitis arietans (8.4 mU/mL) than in the 
venom from Naja siamensis (6.2 mU/mL), but the values were more similar. Moreover, with 
regard to the protein amount in the freeze dried snake venoms, the specific activity of 
hyaluronidase in the venom from Naja siamensis (1.8 mU/mg) was higher compared to the 
venom from Bitis arietans (1.6 mU/mg).17 
 
Compared to the venoms from Bitis arietans and Naja siamensis, characterized by M. Kunze, 
the Bradford and Morgan-Elson assay showed slightly different results. It is important to 
characterize each venom sample regarding the amount of protein and hyaluronidase 
enzymatic and specific activity with respect to the investigation of potential hyaluronidase 
inhibitors. 
 
7.3.3 Influence of pH on enzymatic activity 
Animal and bacterial hyaluronidases exhibit their maximum enzymatic activity at acidic to 
neutral pH values (pH 4-7). According to a summary by Kemparaju, snake venom 
hyaluronidases exhibit their maximum activities between pH 4 and 7.16 Previous studies by 
Hoechstetter showed that the pH optima of the bovine testicular hyaluronidase (BTH) is 
assay dependent (turbidimetric assay: pH 6; colorimetric assay: pH 4).41 Therefore, it was of 
interest to investigate the pH profiles of the snake venom hyaluronidases.  
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In previous investigations by M. Kunze, the pH optima of several snake venom 
hyaluronidases were determined. The pH profiles of Bitis arietans and Naja siamensis are 
shown in Figure 7.4.  
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Figure 7.4 pH profiles of Bitis arietans (left) and Naja siamensis (right) as determined in the turbidimetric assay 
(red squares) and colorimetric assay (black circles) by M. Kunze.17 
 
The resulting pH profiles of the snake venom hyaluronidases were similar to the profiles of 
BTH. The pH maximum was shifted towards more acidic pH values in the colorimetric 
Morgan-Elson assay. In the colorimetric assay, the curve of the pH profiles of the 
hyaluronidases in the venoms from the two snakes Bitis arietans and Naja siamensis showed 
sharp pH maxima (Bitis arietans: pH 5.5; Naja siamensis: pH 4). In the turbidimetric assay, 
however, both snake venom hyaluronidases showed broad areas of high activity between 
pH 4.5 and 7.5.17 
 
The pH activity profiles of the hyaluronidases in the snake venoms from Bitis arietans and 
Naja siamensis (Figure 7.5) were determined in a pH range from 2 to 9 using both the 
colorimetric and turbidimetric assay. Identical parameters were chosen for both assay types. 
Only, the hyaluronan concentration in the turbidimetric assay differed by a factor of 2.5 to 
guarantee linearity in the turbidimetric assay.42 
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Figure 7.5 Enzymatic activity of the hyaluronidases from Bitis arietans (left) and Naja siamensis (right) as 
determined in the turbidimetric (red squares) and colorimetric assay (black circles). Maximum values set as 
100 %. 
 
In the colorimetric assay, the maximum activity of the hyaluronidase from Bitis arietans was 
detected at pH 5. As already described by Kunze17, in the turbidimetric assay, the 
hyaluronidase revealed high activity between pH 3.5 and 6.5. The hyaluronidase in the 
venom from Naja siamensis showed its maximum activity at pH 5 in the colorimetric assay 
and at pH 5.5 in the turbidimetric assay. However, there was no sharp maximum in the curve 
of the pH profile when the Morgan-Elson assay was applied. 
 
7.3.4 Inhibitory activities of selected compounds on snake venom 
hyaluronidases 
The degradation of hyaluronic acid in the extracellular matrix of local tissues is presumed to 
be the key event in the enzyme mediated spreading process during snake envenomation.30 
Inhibition of the snake venom hyaluronidases appears to be a promising target in the 
treatment of snakebites. It would widen the time gap between the bite and the anti-venom 
administration by limiting easy diffusion of venom components, and it would, also, reduce the 
anti-venom load to achieve affective neutralization and hence the side effects of the 
therapy.15 Sodium cromoglycate and sodium auro-thiomalate were reported to reduce the 
local tissue damage and to delay the time of death of mice injected with Naja kaouthia and 
Calloselasma rhodaostoma venoms.43 In vitro testing of sodium cromoglycate in our 
laboratory confirmed the inhibition of several snake venom hyaluronidases only at very high 
concentrations (36 % inhibition at 10 mM).17 To prevent local tissue damage and increase 
survival by retarding the diffusion of systemic toxins, inhibitors of the local acting venom 
hyaluronidases could be a useful tool in the treatment of snakebites.16 
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An selection of 4 compounds (Figure 7.6) was tested for inhibition of the hyaluronidases in 
the raw venoms from Bitis arietans and Naja siamensis (c (raw snake venom) = 50 mg/mL; 
according to M. Kunze17) in the turbidimetric assay (96-well plate format). 
 
 
Figure 7.6 Structures of compounds 5.21, 5.25, 5.60 and diflunisal that were selected for investigation of plasma 
protein binding. 
 
Each compound was tested in duplicate at a final assay concentration between 1 mM and 
100 µM (depending on solubility of the compound in aqueous buffer). The results are 
summarized in Table 7.3.  
 
Table 7.3 Inhibitory activity of selected compounds 5.22, 5.25, 5.60 and diflunisal. 
Compound 
inhibitory activity (%)a 
Bitis arietansa Naja siamensisa 
5.22 inactiveb 8 % 500 µM 
5.25 inactivec inactiveb 
5.60 inactived 20 % 1 mM 
diflunisal inactived 28 % 1 mM 
a
 Inhibitory activity determined at pH 5.0 in the turbidimetric assay (96-well plate); b final assay concentration: 
500 µM; c final assay concentration: 100 µM; d final assay concentration: 1 mM. 
 
None of the tested substances showed inhibitory activity on the tested snake venom 
hyaluronidase from Bitis arietans. Whereas, compound 5.25 was inactive, weak inhibition 
was detected for compound 5.22 (8 % at 500 µM) and 5.60 (20 % at 1 mM) and diflunisal 
(28 % at 1 mM) on the hyaluronidase from Naja siamensis. However, it should be considered 
that without further purification the raw snake venom was applied in the turbidimetric assay. 
The poor inhibitory activity may be caused by high binding of the investigated compounds to 
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the proteins present in the raw snake venom. Therefore, the plasma protein binding of the 
tested compounds was determined. 
 
7.3.5 Plasma protein binding of selected compounds 
Human serum albumin (HSA) is the most prevalent protein in blood plasma. It has multiple 
hydrophobic binding sites and binds a diverse set of drugs, especially negatively charged 
hydrophobic compounds.44 Therefore, lipophilicity is an important parameter in the process of 
designing new drugs.45 Lipophilicity correlates positively with the logarithm of the n-octanol-
water-partition coefficient logP.46-49 Reversed-phase high performance liquid chromatography 
(HPLC) has been recognized as a method for the determination of lipophilicity, and it is 
based upon the direct correlation between logP (logD for ionized compounds) and the 
retention factor (logk’).50-52 Stationary phases for HPLC which imitate the phospholipid 
bilayers of physiological membranes by covalently linking phospholipids to silica particles, 
immobilized artificial membranes (IAM), were developed for the fast and accurate prediction 
of drug-membrane interactions.45,53 The conversion of retention times into the 
chromatographic hydrophobicity index (CHI) with a set of standards, which refers to IAM 
chromatography (CHIIAM), was proposed by Valko et al.25 The relation between IAM binding 
data (CHIIAM) of known drug molecules and HSA binding, both obtained by chromatography, 
showed that compounds with a certain lipophilicity bind to both membrane and HSA. The 
CHIIAM values, which are more suiTable for interlaboratory comparison and high throughput 
screening, are a measure of compound interaction with phospholipids.26,27 The HSA binding 
values were derived from the gradient retention times that were converted to the logarithm of 
the eliquibrium constants logK HSA using data from a calibration set of molecules. 
 
The percentual protein bound to plasma values (% PPB; e. g. from literature) can be 
converted into the linear free energy related logK values (logarithm of apparent affinity 
constant) using Equation 7.2. 
 
log - = log . % //0101 − % //01  
Equation 7.2 
 
The value of 101 was taken arbitrarily to be able to calculate a logK for compounds that bind 
100 % to HSA.27 With the assumption that a binary complex is formed between the ligand 
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and HSA in the blood, and an excess of albumin compared to the concentration of the drug, 
these logK values can be converted to the logkA affinity constant (Equation 7.3).44 
 
log 23 = log [56]1 − [56]  − log[HSA] 
Equation 7.3 
 
kA: equivalent binding affinity to HSA under the assumption that binding occurs exclusively to 
HSA 
fb: fraction bound to plasma proteins 
c (HSA) = 0.6 mM 
 
The plasma protein binding of three selected compounds, 5.22, 5.25 and 5.60 
(cf. Figure 7.6), was determined. The HSA binding affinities and measured chromatographic 
lipophilicity values of the tested compounds are summarized in Table 7.4. 
 
Table 7.4 HSA binding affinities and measured chromatographic lipophilicity values of compounds 5.22, 5.25 and 
5.60, respectively, each calculated in 2 independent experiments. 
Cpd. % PPBa logKa (HSA) 
logk 
(HSA) 
confid.b 
HSA CHI
c logD confid.
b
 
logD 
CHI 
IAMd 
confid.b 
IAM 
5.22 
99.37 5.38 2.19 2 65.51 2.00 2 33.81 2 
99.29 5.33 2.14 2    32.25 1 
5.25 
   0 82.28 2.56 2 53.50 1 
99.61 5.59 2.41 1    51.72 2 
5.60 
99.40 5.40 2.22 2 2.85 -2.96 2 2.88 2 
99.02 5.26 2.08 2    2.07 1 
a
 Calculated percentual plasma protein binding; HPLC conditions: solvent A (5 % (v/v) isopropanol in 50 mM 
ammonium acetate buffer; pH 7.4)/isopropanol (100 %): 0 min: 100/0, 3.5 min: 0/30, 4.5 min: 0/30, 4.6 min: 100/0, 
6 min: 100/0; b confidence: 2 = without any doubt, 1 = likely, 0 = unlikely; c a C18 column (40 °C) was used with an 
ammonium acetate buffer [50 mM; pH 7.4] + 5 % (v/v) MeCN as solvent (solvent B) under the following gradient 
conditions: solvent B/MeCN: 0 min: 100/0, 3 min: 0/100, 4 min: 0/100, 4.2 min: 100/0, 6 min: 100/0; d IAM column 
at 40 °C with the following gradient: solvent B/MeCN: 0 min: 100/0, 5 min: 0/100, 5.5 min: 0/100, 6.5 min: 100/0, 
8.2 min: 100/0. 
 
In general, the investigated compounds 5.22, 5.25 and 5.60 show high plasma protein 
binding (> 99 %). However, with regard to the lipophilicity and membrane binding, the three 
substances differ considerably, showing CHI values between 2.85 and 82.28 and CHI IAM 
values between 2.07 and 53.50. Compound 5.60 bears two carboxylic residues, which cause 
the low CHI and CHI IAM values compared to the other two compounds.  
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To conclude, due to the high protein binding of the tested compounds, the free (non-protein-
bound) compound concentration is too low to observe inhibitory activity on the snake venom 
hyaluronidases from Bitis arietans and Naja siamensis. The inhibition cannot be determined 
when applying the raw freeze-dried snake venom solutions. In order to find out whether the 
compounds show inhibitory effects on the snake venom hyaluronidases, the hyaluronidases 
need to be isolated from the venom and tested again. 
 
7.4 Summary and conclusion 
With regard to hyaluronidase activity, the venoms from two different snake species, 
Bitis arietans and Naja siamensis, were characterized. The Bradford assay, which was used 
to determine the total protein content of the lyophilized raw snake venom, revealed that the 
venoms contained between 55 % and 62 % protein. In accordance with previous results from 
our laboratories, the viper venom from Bitis arietans contained more protein than the cobra 
venom from Naja siamensis.17  
 
Electrophoretic and zymographic experiments provided information about the molecular 
weight and activity of the snake venom hyaluronidases. The investigated hyaluronidases had 
a molecular weight between 45 and 65 kDa, which was in the same range as the molecular 
weights of hyaluronidases in venoms from other snakes, spiders, or scorpions (33-70 kDa). 
Additionally, in the venom from Bitis arietans hyaluronidase isoforms were found. Generally, 
the hyaluronidases have their maximum activity in the pH range between pH 4 and 7, as 
verified in both assays. However, in the colorimetric assay, both hyaluronidases show 
highest activity at only one pH value (pH 5.0).  
 
The four compounds 5.22, 5.25, 5.60, and diflunisal were tested in the turbidimetric assay for 
inhibition of the hyaluronidases in the venoms from Bitis arietans and Naja siamensis. 
Unfortunately, no inhibitory activity was detected for the hyaluronidase from Bitis arietans. 
Compounds 5.22, 5.60 and diflunisal showed poor inhibition of the hyaluronidase from Naja 
siamensis. The poor results may be caused by high protein binding of the tested compounds, 
since the unpurified raw snake venoms were used in the turbidimetric assay. The plasma 
protein binding of the investigated compounds, determined with the help of an HPLC based 
method (cooperation with Origenis GmbH, Martinsried, Germany), was >99 %. Due to the 
high protein binding of the investigated compounds it remains unclear whether these 
substances are lacking inhibitory activity on snake venom hyaluronidases or the free fraction 
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of inhibitor is too low to produce a relevant effect. Nevertheless, for the treatment of a snake 
bite it is important that the hyaluronidase in the raw snake venom is inhibited. Therefore, 
inhibitors of snake venom hyaluronidases with considerably lower protein binding are 
needed. 
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Hyaluronidases are enzymes that predominantly degrade hyaluronan, a major constituent of 
the extracellular matrix. They can be ubiquitously found throughout the animal kingdom and 
have been isolated from a large number of different organs and animal venoms. Additionally, 
hyaluronidases are produced by bacteria and fungi. In case of pathogenic bacteria and 
animal venoms, the hyaluronidases act as spreading factors. They cause local tissue 
damage to facilitate the diffusion of pathogens and toxins, respectively. Inhibitors of the 
hyaluronidases are required as pharmacological tools to further investigate their 
physiological and pathophysiological roles of these enzymes.  
 
Previously, we identified hyaluronidase inhibitors among lipophilic vitamin C, indole, and 
benzoxazole derivatives. Due to the lack of drug-like properties and high plasma protein 
binding, such substances are considered inappropriate for in vivo studies. The goal of this 
thesis was the design, synthesis, identification, and pharmacological characterization of 
novel low-molecular weight inhibitors of the bacterial hyaluronidase SagHyal4755 with 
improved drug-like properties. 
 
In a first attempt, several commercially available drugs, especially non-steroidal anti-
inflammatory drugs (NSAIDs), were investigated for inhibitory activity on the hyaluronate 
lyase SagHyal4755 and the bovine testis hyaluronidase (BTH). All tested substances were 
inactive or only weakly active on BTH, suggesting inactivity of these compounds at the 
corresponding human enzyme, the PH-20 hyaluronidase. In contrast to the mammalian 
enzyme, the bacterial hyaluronidase was inhibited by several compounds. The salicylate 
diflunisal (IC50 (SagHyal4755) = 195 µM) was identified as a putative lead compound for the 
design and synthesis of chemically related inhibitors of SagHyal4755 with improved drug-like 
properties. 
 
The scaffold of diflunisal was modified by introduction of a variously substituted aryl rings via 
Suzuki-Miyaura coupling led to potent inhibitors, for example 1,1’:3’,1’’-terphenyl-4-carboxylic 
acid and 4-hydroxy-1,1’:4’,1’’-terphenyl-3-carboxylic acid which revealed IC50 values of about 
30 µM on SagHyal4755 corresponding to a 6-fold increased potency compared to the lead 
diflunisal. However, inhibitors for the second bacterial hyaluronidase, SpnHyl, were not found 
among the diflunisal analogs, indicating differences between the binding pockets of these 
related enzymes.  
 
In a second synthetic approach, analogs of 6,7-dichloro-1H-indoles and 5-hydroxy-1H-
indoles were synthesized. Whereas the investigated compounds showed only weak or no 
inhibition on both the bovine testicular hyaluronidase (BTH) and the bacterial hyaluronidase 
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SpnHyl, IC50 values in the two-digit micromolar range were determined on SagHyal4755. 
6,7-Dichloro-1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carboxylic acid was the most potent 
inhibitor from the series (IC50 = 16 µM). 
 
In general, the potency of both, diflunisal- and indole-type hyaluronidase inhibitors, is 
strongly dependent on the presence of a negatively charged carboxylic group and chloro 
substituents as well as the overall lipophilicity of the compounds. The combination of these 
structural features resulted in inhibitory activity on SagHyal4755 in the lower two-digit 
micromolar range.  
 
In search of bioisosteric replacements of the indole scaffold, a small series of eight 
2-phenylindolizine derivatives, with and without carboxylic acid moieties, was synthesized. 
Except for 4-(6-cyanoindolizin-2-yl)benzoic acid (IC50 = 56 µM), these compounds showed 
very weak or no inhibition of the streptococcal hyaluronidase SagHyal4755. All synthesized 
compounds were devoid of inhibitory activity on BTH. 
 
A subproject of this thesis focused upon the characterization of venoms from two different 
snake species, Bitis arietans (viper) and Naja siamensis (cobra), with regard to their 
hyaluronidase activity. Both venoms contain hyaluronidases with a molecular weight between 
45 kDa and 65 kDa, which showed their maximum activity at acidic pH values (pH 4-7). The 
investigation of four selected compounds for inhibition of the two snake venom 
hyaluronidases revealed very weak or no inhibition. Since the pure reptile hyaluronidases 
were not available for more detailed investigations, lack of activity at these reptile enzymes 
cannot be ruled out. However, the high protein content in the raw venoms has to be taken 
into account as well. This assumption is supported by the high plasma protein binding of the 
tested compounds, as determined by an HPLC based method. 
 
Taken together, substances derived from three different scaffolds were identified as two-digit 
micromolar inhibitors of the hyaluronate lyase SagHyal4755, but not of the bacterial 
hyaluronidase SpnHyl, the bovine testis hyaluronidase (BTH), and the snake venom 
hyaluronidases. 
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9.1 Abbreviations 
abs absolute 
Anal. Analysis 
aq aqueous 
Ar aromatic 
atm standard atmosphere 
AU absorption units 
Bn Benzyl 
BSA bovine serum albumin 
BTH bovine testicular hyaluronidase 
c concentration 
calcd. calculated 
cat. catalytic amounts 
CD44 cluster of differentiation 44 
conc. concentrated 
COSY correlated spectroscopy 
cpd compound 
Cquat quarternary carbon atom 
CTAB cetrimonium bromide, cetyltrimethylammonium bromide 
CV column volume 
d day(s) or doublet 
δ chemical shift 
Da Dalton 
DCM dichloromethane 
DEPT distortionless enhancement by polarization transfer 
DMAB p-(dimethylamino)benzaldehyde 
DMF N,N-dimethylformamide 
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DMSO dimethylsulfoxide 
DMSO-d6 per-deuterated DMSO 
dppf diphenylphosphino-ferrocene 
DSCG disodium cromoglycate 
EC enzyme commission number 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EI electron impact ionization 
ELISA enzyme-linked immunosorbent assay 
eq equivalent(s) 
ESI electrospray ionization 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
f. c. final concentration 
FCS fetal calf serum 
GAG glycosaminoglycan 
GBS Group B streptococcus 
GlcNAc N-acetyl-D-glucosamine 
GlcUA D-glucuronic acid 
h hour(s) 
H2O water 
H2SO4 sulfuric acid 
HA hyaluronic acid, hyaluronan 
HAS hyaluronan synthase 
HCl hydrochloric acid 
HCOOH formic acid 
HMBC heteronuclear multiple bond correlation 
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HN hyaluronectin 
H2N4 hydrazine hydrate 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectroscopy 
HSA human serum albumine 
HSQC heteronuclear single quantum correlation 
Hyal-1 (human) hyaluronidase 1 
IC50 concentration of an inhibitor required to give 50 % inhibition of enzymatic activity 
IU international units 
J coupling constant 
LiOH lithium hydroxide 
m mili or multiplet 
M molar 
M mass 
Mr molecular mass 
Me methyl 
MeCN acetonitrile 
MeOH methanol 
min minute(s) 
mp melting point 
MS mass spectral or mass spectrum 
MTP microtiter plate 
mw molecular weight 
m/z mass-to-charge ratio 
N number of experiments 
NaBF4 sodium tetrafluoroborate 
Na2CO3 sodium carbonate 
NaH sodium hydride 
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NaNO2 sodium nitrite 
NMR nuclear magnetic response 
NP normal phase 
NSAID non-steroidal anti-inflammatory drug 
OAc acetate 
OD  optical density 
O-sulfated oxygen sulfated 
PAD proton acceptance and donation 
PAGE polyacrylamide gel electrophoresis 
Pd/C palladium on activated charcoal 
PE petroleum ether 
pH negative logarithm of the hydrogen ion concentration 
Ph phenyl 
pKa negative logarithm of the acid dissociation constant (Ka) 
POCl3 phosphoryl chloride 
PPB plasma protein binding 
ppm part per million 
q quartet 
RHAMM receptor for hyaluronate-mediated motility 
RP reversed phase 
rpm revolutions per minute 
rt room temperature 
s singulet 
SagHyal4755 hyaluronate lyase from Streptococcus agalactiae strain 4755 
sat. saturated 
SDS sodium dodecylsulfate 
SEM standard error of the mean 
SPAM1 spam adhesion molecule 1 (also termed PH-20) 
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SpnHyl hyaluronate lyase from Streptococcus pneumoniae  
t triplet 
t0 dead time 
tR retention time 
TBTA tert-butyl-2,2,2-trichloroacetimidate 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TIC total ion count 
TLC thin layer chromatography 
tris tris(hydroxymethyl)aminomethane 
(r)TRU (relative) turbidity reducing unit 
U unit(s) 
UV ultraviolet 
v/v volume concentration in % 
Vcpal Vitamin C palmitate 
w/v mass concentration in % 
X-ray X-radiation, form of electromagnetic radiation 
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